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    Cannabinoid receptors (CB1 and CB2) are GPCRs that belong to the rhodopsin-like family. 
Recent studies have demonstrated a role for CB2 in attenuating bone cancer-induced pain, 
reducing microglial activation in Alzheimer’s disease, and regulating bone mass in osteoporosis. 
As such, there is an urgent need for the development of new therapeutic agents targeting CB2. 
However, structure- or fragment-based in silico drug design is hampered by the absence of 3D 
structural information on CB2, because of its inherent structural complexity. 
  Recently, it has been shown that specific residues of CB2 (in transmembrane helices III, V, VII 
and extracellular loop 2) play crucial roles in the binding of the vast majority of cannabinoid 
ligands. In this report, we performed computer modeling along with site-directed mutagenesis 
studies and the results suggest that four residues that lie within these regions have a novel 
importance for receptor recognition of compound XIE95-26, a discovered CB2 inverse agonist in 
our lab, and known cannabinoid ligands CP-55940 (agonist) and SR144528 (inverse agonist). 
These mutant CB2 receptors were characterized by western blot, and ligand binding studies. 
Moreover, functional assays were performed for some mutant CB2 receptor to illustrate the role 
of altered residues in downstream signaling. Next, we’ve taken further steps to provide a 
genetically modified functional CB2 for biophysical and biochemical studies with the goal of 
improving the current purification methodology for the production of chimeric CB2 fusion 
proteins from the baculovirus system. By introducing a fusion protein and rational modifications 
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 v 
to the chimeric receptor, investigators endeavoring to purify other GPCRs have overcome the 
challenge of obtaining sufficient stable protein for structural studies. Thus, different generations 
of truncated CB2 receptor were obtained to assess any improvements in receptor expression. 
Receptor expression and ligand binding capacity were assessed as criteria for pilot scale 
purification and for detergent selection. The best constructs were subjected to the optimal 
purification scheme using immobilized metal affinity, anti-M2 affinity, and size exclusion 
chromatography steps. 
    Collectively, results from this study will provide insights into the structure and functional 
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1.1 INSIGHTS INTO STRUCTURE OF GPCRs 
    G protein-coupled receptors (GPCRs) comprise a large family of integral membrane, cell-
surface receptor proteins characterized by seven hydrophobic transmembrane helices that are 
connected by three intracellular and extracellular loops [1]. Although they share a common feature 
(i.e.α-helical transmembrane helices), the N-terminal is considered a highly diverse region among 
GPCR superfamilies [2]. GPCRs are expressed in all types of tissue throughout the human body 
and are involved in different physiological and pathological functions. They act as mediators 
responding to a huge array of stimuli, from protons to polypeptides, including extracellular and 
intracellular ligands, proteins, hormones and lipid derivatives. Upon receptor stimulation, serial 
ligand-receptor conformational changes occur, causing the receptor to change and initiate signal-
transduction activities. 
    The GPCR superfamily accounts for nearly 800 different human genes, or approximately 4% of 
the entire protein-coding genome [3]. The specificity and diversity of these receptors in diseases 
has made GPCRs some of the most popular therapeutic targets, accounting for more than 40% of 
marketed drugs, nearly 200 [4]. With mapping of the human genome, most of the non-olfactory 
GPCRs have been cloned to date, some of which are named because they involved in heterodimeric 
G proteins coupling like other known GPCRs. Others are only recognized by their α-helical 




1.1.1 GPCR superfamilies 
    Despite the diversity of GPCR functions in the human body, most classes of GPCRs share a 
high degree of homology in their seven transmembrane α-helical structures [6]. The receptors 
consist of three regions. The extracellular region includes extracellular loops responsible for ligand 
recognition/binding and the N-terminal, intracellular regains, relatively short unstructured regions 
involved in protein-protein interactions [5, 6]. The third region is the transmembrane region, which 
is divided into two parts. The upper part, usually the location of the ligand-binding pocket, is 
considered the most structurally diverse among GPCRs. The lower part of the transmembrane 
region is responsible for downstream signaling and has the most conserved residues involved in 


















Figure 1-1. General structure of GPCRs. 
Extracellular (EC) and transmembrane-extracellular (TM-EC) regions are responsible for ligand-
binding and show higher diversity regions among GPCRs and less conformational changes. 
Whereas, intracellular (IC) and transmembrane-intracellular (TM-IC) regions are responsible for 







   Several GPCR phylogenetic classification methods have been used to differentiate between the 
superfamilies [8]. One classification is based on common structural features of the seven 
transmembrane helices, such as sequence homology and functional similarity. Other classifications 
are based on ligand binding. The mostly frequently system is annotated by A (rhodopsin-like 
receptors), B (secretin/adhesion), C (metabotropic glutamate), D (fungal mating pheromone 
receptors), E (cAMP receptors), and F (frizzled/smoothened receptors), plus a Roman numeral for 
the sub-class [9]. However, because some of these classes are not found in vertebral GPCRs, 
particularly in the human genome, overall GPCRs are divided into four classes, all of which bind 
to G proteins; rhodopsin (family A), secretin and adhesion (family B), glutamate (family C), and 
frizzled/taste2 (family C).  Figure 1-2 represents the prototypical GPCR subfamilies (class A, B, 
and C) [9]. 
     Family A, or rhodopsin, is considered large and diverse within the 7-TM regions. However, the 
members share a high percentage of amino acid sequences and conserved motifs. More than 85% 
of identified GPCRs are Class A/rhodopsin-like receptors, approximately 670 full-length human 
receptors [10]. The rhodopsin family is divided into subgroups: α, β, γ, and δ.  
 The Rhodopsin family α-group represents the highly targeted druggable group 
(approximately 18 targets) among this class. Nevertheless, major cardiovascular 
side effects are noted for amine receptors, which is less frequently found in other 
members of α-group.  
 The rhodopsin family β-group is the second drug target subgroup. It mainly 
comprises the peptide ligands. Like the α-group, the ligand binding of β-group is 
within the 7TM pocket but also involves the N-terminus and extracellular loops.  
6 
 
 The rhodopsin γ-group contains both peptides and lipid-like compounds. Targeting 
this group with drugs has shown potential for treating drug abuse for opioids and 
alcohol and for treatment of acute and chronic pain, inflammation, and 
hypertension. One of the best examples of marketed drugs for this group is 
maraviroc (CCR5 receptor antagonist). It is approved as an antiretroviral drug for 
treatment of HIV infection.  
 The δ group is targeted by peptides. It is mainly composed of glycoprotein-binding 
receptors, PARs, and olfactory receptors, P2Y12, and leukotriene receptor 1. 
     A common feature of the class A GPCR is a relatively short N-terminus and the ligand binding 
pocket site for the endogenous ligand (or orthosteric binding site) which  is located within the 
seven transmembrane domains (TM 1-7). This family includes the most targeted receptors among 
all other families. This class also contains conserved residues that are essential for structural, 
conformational, and signaling transduction: 1- DRY (lower part of third helix and intracellular 
loop), 2- CWxP (at sixth transmembrane), and 3- NPxxY (at the seventh transmembrane). 
Examples of class A receptors include purinergic, adrenergic, 5-hydroxytryptamine, neuropeptide, 
muscarinic acetylcholine, dopamine, galanin, eicosanoid, cannabinoid, chemokine, kinin, 
endothelin, histamine, melanocortin, lysophospholipid, vasopressin, GPR30, somatostatin, and 
olfactory GPCRs. 
       Family B GPCRs contains two subgroups, secretin and adhesion receptors. Secretin GPCRs 
have similar topology features to the rhodopsin family without significant sequence homology 
[11]. In addition, they contain large extracellular and N-terminal domains, which have the ability 
to bind large molecules such as peptides and hormones due to the presence of disulphide bonds. 
Moreover, the N-terminal has conserved residues such as rxCxxxGxw.  
7 
 
    Adhesion receptors make up the other subgroup of family B. Adhesion receptors are known for 
their structural  and genomic complexity compared to other families [12]. The adhesion GPCRs 
account for more than 30 of the receptors in vertebral genomes available in the GPCR data bank. 
Like secretin receptors, adhesion receptors are connected to large N-terminal domains. Moreover, 
they undergo proteolytic cleavage processes at site (CPS) motifs to separate the non-covalently 
attached complexes between transmembrane and N-terminals. These processes are responsible for 
the constitutively active receptors which drive signaling [13]. The binding pocket of class B 
receptors is located in the juxtamembrane region of the N-terminal and the extracellular loops 
together with TM6. The challenge among these groups is that only a few ligands have been 
identified due to the morphological complexity of these receptors. Examples of family B GPCRs 
class are Cadherin EGF LAG (CELS), calcitonin, corticotropin-releasing hormone, glucagon, 
latrophilin, brain-specific angiogenesis EGF-like module-containing mucin-like, and vasoactive 
intestinal polypeptide receptors. 
    Metabotropic glutamate receptors (Family C) act as modulators for synaptic and central nervous 
system transition [14]. Unlike family A, family C is recognized by the massive extracellular N-
terminal domain that have a clamshell-like morphology, and the Venus flytrap module (VFM) 
which contains the endogenous ligand-binding site [15]. Similar to family B, the N-terminal 
demines of family C contain a cysteine-rich domain (CRD) and VFM domains consisting of two 
lobes dimerized together, that mediate binding to small ligands such as glutamate or Ca2+. Upon 
ligand-VFM binding, a series of conformational changes at the cysteine-rich domains leads to the 
heptahelical domain C-terminal. Like other GPCRs, the C-terminal of glutamate receptors are also 
important in G-protein receptor coupling, which is subjected to splicing and phosphorylation [14]. 
Family C is sub-classified into three subgroups, all of which are expressed mainly in the CNS. The 
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first group includes Metabotropic glutamate receptor (mGluRs 1) (a,b,c,d,e and f) and 5. The 
second group includes mGluRs 2 and 3, and the third group includes mGluRs, 4, 6, 7, and 8.  
     The last family of GPCRs is the frizzled (FZD) and smoothened (SMO) receptor family [16]. 
They are known to be involved in embryonic development, cancer, and central nervous and 
cardiovascular system diseases treatment due to their ability to modulate cell proliferation and 
tissue homeostasis. Smoothened receptors have also shown to play a major role in embryogenesis 
through the canonical hedgehog-signaling pathway [16]. Both FZD and SMO receptors share high 
sequence homology and are involved in the WNT signaling pathway leading to activation of 
proteins in the cytosol [16]. Like family C, FZD GPCRs contains large N-terminals with a 
cysteine-rich domain that is involved in ligand binding [17]. Examples of ligands for FZD are 
WNTs, Norrins, FRPs, R-spondin, and CTGF [17]. 
     Due to the important role of GPCRs acting as responders to signals, it has been observed that 
GPCRs are expressed in almost all organs and are responsible for different physiological processes 
such as vision, smell, taste, mood, behavior, immune modulation, and maintenance of other 
homeostatic processes [13, 14]. Moreover, targeting GPCRs with small molecule drugs has 
revealed therapeutic potential for treating pain, inflammation, cardiovascular, and metabolic 





Figure 1-2. Schematic view of the 7TM model of GPCRs superfamily. 
Three major class of GPCRs based on sequential similarities, ligands, and function of the receptor. 
Class A is the large, well-known class. The ligand binding pocket is located within 7-TM for both 
orthosteric and allosteric ligands. The N-terminal of family B and C contain conserved cysteine-
rich domains (CRD) that form three cysteine bridges, which are important for orthosteric ligand 
interactions. In addition, family C has a Venus flytrap module (VFM) which contains a ligand-





1.1.2 GPCRs activation and signaling 
      Despite the diversity in the biophysical and biochemical structures of GPCRs, they are mostly 
represented by active (R*) and inactive (R) states that are in a dynamic equilibration. Upon the 
ligands-receptor binding, different helical conformation and conserved residuals interactions 
disruption are obtained to shift the receptor towards one of these states. In addition, ligand 
involvement has shown to be part of this equation. For example, agonist binding to the receptor 
causes the receptor to strongly shift to the active state (R*) while a partial agonist will lead to a 
less effective active state characterized by huge receptor conformational changes [21]. On the other 
hand, the inverse agonist preferentially stabilizes and shifts the receptor to the inactive state (R) 
and reduces basal activity [21].  
    Solving rhodopsin, A2A adenosine receptor and β adrenergic receptor co-crystal structures, 
molecular modeling and dynamic simulations of GPCRs have provided preliminary data for 
understanding the activation and signaling of GPCRs [22, 23]. Typically, the receptor undergoes 
different rearrangements of its transmembrane core as well as extra- and intracellular loops.  
Binding of agonists will initiate these changes starting from the binding pocket to transmembrane 
cores. The kink-forming residue (Pro at 5.5) in TM5 undergoes a small change that leads to 
distortion and rotation of this helix. TM3 and 7 are then moved and rearranged. Ultimately changes 
these cause the extracellular side of the receptor to pull out, offering space for the G protein to 
bind. In addition, the hydrophobic conserved residues clustering at the bottom of the pocket will 
rearrange, leading to contact between TM3, TM5, and TM6 interface [24].  
       Studies have found that ligand induced receptor activation and signal transduction takes place 
by the disruption of non-covalent, intermolecular interactions which stabilize the receptor in its 
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inactive state (R) [25]. Family A GPCRs are held in their inactive state by a couple of slat-bridge 
interactions that stabilize the receptor transmembrane (TM) domains in a specific basal 
arrangement [26]. The transmembrane helices have a more significant role in stabilizing the 
receptor than the extra- and intracellular loops [27]. For example, in rhodopsin, the receptor is 
stabilized by interaction between Glu 134, Arg 135 in TM3, and Glu 247 and Thr 251 in the 
cytoplasmic end of TM6 [27]. These interactions between the cytoplasmic end of TM3 and TM6 
are known as the “ionic lock” as shown in (Figure 1-3). Disruption of the ionic lock, referred to 
as Ionic Lock Disruption (ILD), leads to receptor activation [25]. Amino acids, which constitute 
the ionic lock, are highly conserved throughout rhodopsin Family A. Mutation of these key amino 
acid residues, which stabilize the receptor in the inactive state, results in the generation of 
Constitutively Active Mutants (CAMs). The best characterized are mutations of the highly 
conserved (D/E)R(Y/W) motif the members of the rhodopsin GPCR family. This has also been 
demonstrated in the beta-2-adrenergic receptor (β2 AR), adenosine A2A receptor (A2 AR [24], 
cannabinoid receptor 1 [28], histamine receptor [29], and D3 dopamine receptor [30] .  
    Rotamer Toggle Switch (RTS) is another molecular switch commonly found in the activation 
of amine and opsin family GPCRs [31, 32]. This activation process was initially reported for 
rhodopsin [20]. This is mediated around the conserved proline residue in TM6 of these receptors. 
For example, the β2 AR mutation of Leu 272 to alanine at the cytoplasmic end of TM6 results in 
a marked increase in receptor basal activity and instability [33]. Monte Carlo simulation studies 
have suggested that the β2 AR amino acid residues Cys 285, Trp 286, and Phe 290 constitute the 
aromatic triad, and ligand interaction in this region can couple to and modulate the bend angle kink 
at Pro 288, leading to receptor activation [34]. Rotational toggle of conserved residues have also 
been reported to initiate agonist activation in the histamine H1 receptor [35], D2 dopamine receptor 
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[36], and the Trace Amine Associated Receptor [37]. In a recent and very elegant study with the 
CB1 receptor, Monte Carlo simulations were used to determine the ligand induced structural 
changes around the “aromatic microdomain” of CB1, which refers to the microdomain composed 
of aromatic residues from TM 3-4-5-6 [38]. Residues Phe 201 and Trp 357 act as the toggle pair 
switch to maintain the receptor in the inactive state [39]. Results from this and related studies 
indicate that the F201/W357 interaction leads to receptor stability and can be disrupted by several 
subclasses of ligands leading to CB1 receptor activation. Such detailed molecular dynamic 
simulation studies have also been performed with CB2[26]. Comparing the conformational 
changes for the cannabinoid receptor 2 helices during receptor activation by CP55940 (full agonist) 
revealed that CB2 endures larger conformational changes. TM3, extracellular loop (ECL2), TM6, 
and TM7 are all subject to a deviation of approximately 4.5 Å compared to the inactive state of 
the CB2 receptor. Second, the ionic lock residues of CB2 (Arg3.5, E/DRY, and Glu/Asp6.30) are 
more stable during binding to the inverse agonist (SR144528) compared to binding with CP55940 
[40, 41]. Similarly, Trp258, which is part of the CPxY motif at TM6, showed a significant role in 
CB2 function [26]. The space between CPxY and the agonist is significantly smaller when 
compared to the inverse agonist. Upon activation of the receptor, cysteine and proline residues 
moved toward the intracellular side. On the other hand, Trp258 moved towards the extracellular 
side leaving space around 5 Å from when bounded to SR144528. Try299 of the NPxxY motif also 
showed subtle changes when engaged into movement at TM7 by the activation [40].              
    The classical model of “an activated G protein-coupled receptor” consists of 1) receptor, 2) 
heterotrimeric G proteins made up of Gα and Gβγ complex domains, and 3) effectors such as 
transporters, ion channels, and other enzymes [19]. G proteins are heterotrimeric non-
transmembrane proteins attached to the cytoplasmic side of membranes by one or two lipid 
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moieties. The Gα subunit contains the region for GTP-GDP exchange. Additionally, there are four 
main sub-families of Gα: Gs, Gi/o, G12, and Gq. The subsequent role of the individual Gα subunit 
depends on the cognate GPCR, which also determines the downstream signaling pathway. The 
basal activity of the receptor includes Gα binding to GDP, and the whole heterotrimeric G is 
formed. Upon receptor activation by external ligands, endogenous molecules, or other proteins, 
Gα recruits GTP and exchanges it for GDP triggering dissociation of the Gα and the Gβγ subunits. 
These subunits are responsible for independent downstream signaling events (Figure 1-3).  
     The second messenger can be initiated by many elements such as ion channels (calcium and 
potassium), guanylyl cyclases (cGMP), adenylyl cyclase (AC) and phospholipase C [42]. Gαi 
inhibits adenylate cyclase and leads to decreases in cyclic Adenosine Monophosphate (cAMP) 
levels while Gαs leads to the stimulation of adenylase cyclase activity causing increased cAMP 
levels in the cell which then activates protein kinase A (PKA) and phosphodiesterase proteins 
(PDEs) [43, 44]. In addition, receptor activation leads to phosphorylation of the C-terminal and 
intracellular loops by G protein-coupled receptor kinase (GRK), which can then couple to arrestin. 
Arrestin is a regulatory and signaling protein that is involved in extracellular signal-regulated 
kinase (ERK) pathways, which prevent the coupling of the G protein and regulates desensitization 
and internalization of the phosphorylated receptor via clathrin-mediated endocytosis [33].   
     Recently, the concept of GPCR activation and signaling has changed [25]. Structurally 
dissimilar ligands are believed to disrupt different structural motifs of the GPCRs resulting in 
disruption of distinct molecular stabilization motifs, which eventually leads to activation of 
different signal transduction events (biased ligands) [25]. New ligands that bind to β2 AR are 
grouped into several subclasses based on their functionality, which can be correlated to their 
structure. For example, the agonist, salbutamol (a catecholamine ligand), can lead to quenching of 
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the fluorescent probe of monobromobimane (MBB) fluorophore, whereas catechol cannot [45, 
46]. Utilizing mutations at the site of activation and increased fluorescence quenching at this site 
will indicate disruption of ionic lock or other activation mechanisms in response to ligand binding. 
However, catechol does have detectable effects on the fluorescent change in fluorophore and 
tetramethylrhodamine methylester (TMRM) when placed at IL3. More potent (full agonist/strong 
partial agonist) β2 AR ligands can activate the receptor by disruption of both ionic lock disruption 
(ILD) and rotamer toggle switch (RTS) stabilizing interactions. However, ligands with lesser 
potency (partial agonist) would selectively activate the receptor by disruption of only either one of 
the molecular switches. Computational simulation studies involving Monte Carlo simulations 
suggest that the aromatic catechol ring is able to interact with the aromatic stacking present 
between Trp 286 and Phe 290, leading to receptor activation by rotational toggle switch, which is 
concerned with the movement of the Pro 288 and leads to the movement of TM6. However, the 
addition of the aliphatic chain bearing an amine group would allow it to access the ionic lock and 
thereby increase ligand potency, as was observed for catecholamines, e.g. isopreterenol, 
epinephrine, and norepinephrine [45, 46]. These seminal studies have indicated that ligands with 





Figure 1-3. G-protein-coupled receptors and classical signal transduction.  
Topological illustration of GPCRs showing different conserved motifs and molecular switches 
(DRY, NPXXY motifs, ionic lock, and toggle switches). Upon binding of the internal and external 
molecule, the receptor is subjected to helical conformational changes, which are required for 
activation, coupling with either the G protein or the arrestin protein. Different instigators, such as 
adenylate cyclase, channels, or other enzymes, are activated and produce a second messenger, such 




1.1.3 Significance, challenges for stabilization and crystallization of G protein-
coupled receptors 
    In recent years, significant progress has been made in the study of the structure of GPCRs. For 
example, the past decade has witnessed remarkable progress in the study of the in the molecular 
biology of GPCRs after the first three dimensional (3D) crystal structure of rhodopsin was reported 
in 2000 [27]. Twenty-nine GPCR crystal structures have been solved, nine of which were in 2012 
alone [47]. Scientists were able to gain insight into the general topology of the GPCRs for the first 
time. Moreover, high-resolution 3D structures of GPCRs have provided a detailed understanding 
of ligand binding sites, receptor-ligand interactions, and receptor conformations and functions. 
Despite the significant success in GPCR crystallization, heterologous GPCR production is still 
challenging due to difficulties in functional expression, purification, and inherent structural 
instability. Moreover, structural information for GPCRs remains elusive is part due to their 
dynamic character and versatile functionality. GPCRs bind a variety of different ligands, resulting 
in varying modes and degrees of signal transduction. Obtaining high quality diffraction of GPCRs 
is also difficult due to the presence of detergents, inherent receptor flexibility, and a lack of 
hydrophilic regions that can form crystal lattice contacts [48-50]. Therefore, creative efforts are 
necessary to design modified receptors or receptor complexes with an enhanced ability to sustain 
lattice-forming interactions. These include building chimeric receptors with high expression and 
stability levels and fewer post-translational modifications [51]. For example, the unstructured, 
flexible regions of the N- and/or C-terminals can be truncated to remove the N-glycosylation 
region and eradicate the proteolysis frequently observed in N-terminals [52]. In addition, site-
directed mutagenesis can be implemented to stabilize the receptor, improve protein expression 
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levels, and increase the melting temperature of the receptor [52]. Different strategies have been 
proposed recently to overcome the lack of polar regions and receptor flexibility [51]. The GPCR’s 
third intracellular loop, (IL3/ICL3) which links the cytoplasmic ends of TM 5 and 6, is highly 
flexible and plays an active role in receptor G protein interaction, activation, and signal 
transduction [53]. In rhodopsin family GPCRs, the IL3 residue(s) interact within the conserved 
DRY (Asp-Arg-Tyr) motif and comprise the ionic lock which generates the active and inactive 
conformations of the receptor [25], [54, 55]. The dynamic IL3 region contributes to a 
heterogeneous population of GPCRs with varying conformations and the structural flexibility of 
the protein, that prevent the growth and formation of diffraction quality crystals [43, 53]. It is now 
understood that structural modification of IL3 can be done to arrest receptorconformational 
flexibility and provide greater polar surface area (Figure 1-4) [56]. Increased polar surface area 
allows the formation of crystal lattice contacts [56]. Most of the high resolution GPCR structures 
solved so far require the GPCR to be locked in one of the conformational states, preferentially the 
inactive state [57, 58]. The inactive state is characterized by reduced conformational flexibility 
and has been achieved by co-crystallizing the receptor with saturating amounts of inverse agonist 
ligands (high affinity and low off-rate) [59]. Inverse agonists at saturating concentrations reduce 
the conformational heterogeneity of the receptor population by driving most of the receptor to the 
inactive conformation. Recently, however, the active form structure of the β2 AR was solved by 
co-crystallizing the receptor with saturating amounts of agonist and structural stabilization with a 
camelid antibody [60]. Previously, two methods have been used to stabilize this region. In one 
method, TM 5 and 6 regions were stabilized through binding to a Fab5 antibody, and the antibody-
protein complex was used to generate a structurally stabilized receptor [61]. However, crystal 
structure resolution was low due to the size of the protein packing at extracellular domains [62].       
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In order to improve crystal structure resolution, different soluble fusion proteins can be used to 
replace the third intracellular loop in addition to C-terminal truncations [51]. Different criteria are 
used to choose the best fusion partners for insertion [51]. For example, the distance between the 
N- and C-terminals of the fusion protein needs to be optimized to be similar to the distance between 
helices 5 and 6 of the receptor. In addition, the molecular weight of the fusion protein must not 
exceed 20 kDa to avoid disruption of the overall integrity of the receptor. Additionally, the overall 
charge and origin of the protein should be considered as a factor for choosing the fusion protein. 
Ultimately, among hundreds of fusion proteins present in the protein data bank (PDB), only five 
have been previously selected: T4 lysozyme (T4L), apocytochrome b562RIL (BRIL), xylanase, 
rubredoxin, and flavodoxin [51]. The success of the TM5-(T4L)-TM6 fusion method has allowed 
for the determination of more than sixteen GPCR structures, including human β2-adrenergic 
receptor (β2AR) [63], adenosine A2A receptor [58], histamine receptor 1 [64], sphingosine 1-
phosphate receptor 1 [65], D(3)-dopamine receptor [30], chemokine receptor type 4 (CXCR4) 
[57], muscarinic acetylcholine receptor M2 [66], delta-type opioid receptor [67], neurotensin 
receptor [68], human protease-activated receptor 1 [69], corticotropin-releasing factor receptor 1 
[70], M3 muscarinic, acetylcholine receptor [71], μ-opioid receptor [72], and serotonin receptors  
[73]. In addition, the insertion of another fusion protein, such as apocytochrome b or rubredoxin 
to the third intracellular loop, led to the identification of GPCRs structures such as the human 
P2Y12 receptor [61, 62] and the CCR5 chemokine receptor [74], respectively. The insertion of 
fusion protein into the N-terminal of GPCRs led to successful crystal structure for δ-opioid 
receptor [75], nociceptin/orphanin FQ (N/OFQ) peptide receptor [76], and glutamate receptor 1 
[77]. Additionally, antibodies that recognized one state of the receptor conformation were also 
used for obtaining GPCR co-crystal structures in the case of the β2 adrenoceptor [48, 67] and 
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muscarinic acetylcholine receptor [78]. Finally, the GPCR crystal structures with no chimeric 
modifications were obtained via point mutations to increase the thermostability or by deletions of 
the unnecessary parts of the receptor that hamper crystallization, such as in the case of the 


































Figure 1-4. General requirements for co-crystal studies of GPCRs. 
Different pre-structure/function studies on GPCRs are required to obtain crystal structure:  
1. Stabilization of the third intracellular loop is required using fusion proteins or monoclonal 
antibodies; T4 lysozyme and apocytochrome b526 are the most used fusion proteins for co-
crystallization of GPCRs; 2. N- And/or C-terminal truncation to remove N-linked glycosylation 
and proteolysis (indicated by red circles); and 3. Point mutations to increase thermal stability and 
functional expression and the presence of high affinity/low of rate ligands. Adapted from [43]. 
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1.2 CURRENT METHODS FOR RECOMBINANT GPCR EXPRESSION AND 
PURIFICATION 
      Despite the recent progress in the structural and molecular determination of GPCRs over the 
last decade, the overexpression of membrane proteins for structural and biophysical studies 
remains challenging. Due to the intrinsic lipophilic properties of the seven transmembrane helices, 
which often results in low protein yields due to the toxic effect of overproduction of foreign 
transmembrane proteins, and the ineffectiveness of conventional protein purification techniques, 
solving the crystal structures of most GPCR structures remains a daunting task. 
     Purified GPCRs can be utilized for a variety of applications in drug design and development. 
For example, purified GPCRs protein can be used in the high throughput screening of chemical 
libraries in binding assays to find hits and improve the affinity and selectivity of compounds. 
Moreover, purified GPCRs protein can be used in used in biochemical and biophysical studies, 
such as nuclear magnetic resonance and mass spectrometry, X-ray crystallography, or in studies 
of downstream signaling using florescent probes [35, 37]. A large number of potential expression 
systems have been utilized and/or evaluated for producing GPCRs. The choice of expression 
system depends on the specific requirements for the different GPCRs and investigative purposes. 
Several hosts have been used previously, such as Escherichia coli lysates (cell-free translation), 
bacteria H. salinarium, L and lactis systems, yeasts species such as of S. cerevesiae and S. pombe, 
and eukaryotic expression in insects (like Sf9, Sf21, and Hi5) and mammalian cells, are illustrated 
in (Figure 1-5). The use of different expression systems not only provided tools for studying 
GPCR structure, but also provided solid knowledge for expression strategies in general, as shown 
in Table 1. 
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1.2.1 Yeast  
          Saccharomyces cerevisiae (baker’s yeast) and P. pastoris are the most widely used yeast 
heterologous protein expression systems [82]. They also have the first completed genomic 
sequence of a eukaryotic organism. Unlike most expensive and intractable higher eukaryotic 
microorganisms, yeast represents a unicellular microorganism that is an alternative for high-level 
expression of recombinant protein for both commercial and research purposes [83]. The yeast 
system has the advantage over the mammalian system for isotopic labeling with most of the protein 
folding capabilities. However, mammalian GPCRs often been proven to be toxic to yeast host cells 
[84]. Thus, their expression is usually controlled with an inducible promoter to maximize cell 
health. Saccharomyces cerevisiae (baker’s yeast) is commonly regulated by the GAL promoter 
upon galactose induction. In addition, this yeast has been used for the expression and determination 
of transmembrane proteins and GPCR structures, including crystal structures of the human H1 
histamine receptor [85] and human adenosine A2 receptor [61]. Alpha factor Ste2p was expressed 
and purified previously using the C-terminal Flag and His6 tags with yields up to 1 mg [86]. The 
human dopamine D1A receptor, mouse serotonin 5HT5A receptor, and human β2 AR are other 
examples of successful expression and purification of GPCRs using Saccharomyces cerevisiae 
yeast as a host system for expression and utilization [87].  
     Schizosaccharomyces pombe is a yeast representing another strain that was recruited for 
recombinant protein expression [88]. These strains are less commonly used compared to other 
yeast strains. Nevertheless, it has been utilized for expressing highly complex proteins. Moreover, 
it is different from Saccharomyces cerevisiae in the glycosylation process where the vector is 
designed for both stable and transient expression. This strain has been previously used to produce 
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a mammalian-like signal transduction system for human dopamine D2 receptor overexpressed in 
the plasma membrane [89].  
      Marked success was achieved for investigating the pharmacological functions of about 100 
GPCRs utilizing another strain of methylotrophic yeast, Pichia pastoris [89]. Since P. pastoris is 
capable of maintaining most of the post-translational modifications such as glycosylation, 
proteolytic and disulfide bond processing, and is easily used and cultured in bioreactors, it has 
become one of the most attractive systems for studying GPCR pharmacological function. 
Recombinant protein expression in P. pastoris is controlled by the alcohol (methanol-regulated) 
oxidase promoter I (AOX1) in the presence of glucose or glycerol. A DNA vector integrates with 
the host genome. Although the overall total yields of GPCRs expressed in yeast are not high in 
some cases, functional proteins were obtained, including the human dopamine D2 and mouse 
OPRK receptors [89]. Cannabinoid receptors have also been expressed and characterized using P. 
pastoris [90]. Cannabinoid receptor CB1 and CB2 gene expression was engineered through a c-
myc epitope and a hexa-histidine tag at the C-terminal of the receptors. The results showed that 
the functionality and pharmacological profiles were similar to those obtained from mammalian 
systems [91, 92]. Other low-producing GPCR yeast strains, namely, Hansenula polymorpha, were 
also utilized for evaluating GPCRs, such as CCR5 and CXCR4 expression [89]. 
     Yeast systems have also been used as a tool for screening and for the optimization of functional 
GPCR fusion proteins for crystallography (T4 Lysozyme) [93]. A library of variant receptor forms 
was created in which T4L was inserted into different positions of the third intracellular (IC3) loop 
by replacing a number of amino acid residues in the loop [93]. By expressing receptors in 
Saccharomyces cerevisiae yeast, different criteria were taken into consideration for choosing the 
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best initial construct for scaling up, such as overall expression levels at the cell surface analyzed 
by green fluorescent protein (GFP), agonist binding and signal transduction via G protein [93]. 
1.2.2  Cell-free expression 
      Cell-free translation expression systems are another powerful technique that have been applied 
to producing many soluble recombinant proteins in relatively ample quantities in the presence of 
detergents or membrane mimetics [94]. This system is based on crude lysates of prokaryotic 
(mainly, E. coli) or eukaryotic cells (wheat germ embryos or rabbit reticulocytes) which contain 
all the necessary ingredients, such as amino acids and nucleotides, all of which are essential 
components for transcription, translation, protein folding, and energy metabolism [94]. Cell-free 
expression can provide isotopically labeled proteins for nuclear magnetic resonance (NMR) and 
X-ray crystallography. Much attention has been devoted to using this system after the NMR 
structure of the bacteria proteorhodopsin [95] and the X-ray crystal structure of eukaryotic 
Acetabularia rhodopsin II from marine alga was discovered [96]. Nevertheless, there are no NMR 
or X-ray crystal structure available for GPCRs using this method to date.  
1.2.3 Mammalian Cells 
      The expression of GPCRs in mammalian cells has several advantages over other expression 
systems. It produces native refolding and maintains modified GPCRs during expression, enabling 
G protein downstream signaling [97]. The mammalian expression system is also the best way to 
examine the effects of modification on the receptor, such as site-directed mutagenesis and 
screening various compounds for a specific receptor [98]. Although there are high costs for 
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handling and producing GPCRs using this system, the receptor can be processed and maintained 
for a long time under selective conditions. Usage of mammalian cells is always advisable and 
recommended over insect cells in cases where low-yield functional protein and/or large quantities 
of misfolded protein are produced. There are two main expression processes of the membrane 
protein using mammalian cells, including the transient and stable expression process shown in 
(Figure 1-5). Transient expression systems allow the membrane protein to be expressed in the 
presence of cationic lipids or recombinant non-replicative viruses for a short time compared to a 
stable system. In both systems, either an inducible promoter or a constitutive promoter is required 
to produce the protein. For non-replicative viruses used only for gene therapy and cell biological 
studies–the Semliki Forest Virus (SFV) expression system has been used extensively for 
expression of 101 G protein-coupled receptors in three mammalian cell lines [90, 91]. Although, 
the SFV system is successful at expression GPCRs, a high proportion of the receptors were 
misfolded, as indicated by their loss of functionality, e.g. bradykinin B2 receptor [99], alpha 2B 
adrenergic receptor [100], and angiotensin II receptor [101]. The disadvantage of SFV is the high 
cost and technical challenges for scaling up due to biosafety and handling restrictions. Other 
methods for the transient expression for incorporate DNA into the host cell though the use of 
chemical agents like cationic lipid compounds or electroporation. These methods are also not 
feasible for large scale production due to the high cost and requirement for optimization 
requirements, such as plasmid specification, amount of plasmids and reagents, and the optimum 
time for expression. Bovine rhodopsin (Opsin A) is an example of the first GPCR crystal structure 
solved using transient transfection of monkey kidney fibroblast cells, COS-1.The recombinant 
protein was  mutated and designed to be more thermally stable through the generation of a disulfide 
bond between the N-terminal and loop E3. This mutant receptor was expressed in Cos cells. 
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Utilizing  a constitutive adenovirus promoter and DEAE dextran, about 2.5 mg of purified protein 
was produced, and the structure of the receptor was determined (3.4 Å) [102].  
     On the other hand, stable transfections are able to integrate the gene of interest into the host 
cellular genome. Thus, the GPCR gene of interest contains an antibiotic resistance site for stable 
cell line selection. Moreover, the inducible promoter is preferable for reducing cell toxicity [103]. 
The advantage of using stable over transient transfection is the ability to produce the recombinant 
protein without needing to re-transfect the gene. Among different stable cell lines available on the 
market, Chinese hamster ovary cells (CHO), baby hamster kidney cells (BHK-21), and human 
embryonic kidney cells are the most predominantly used cells for generation of GPCR stable 
expression [89]. In addition, to the tetracycline inducible system ,the crystal structure for the 
constitutively active rhodopsin mutant Glu113Gln in complex with a peptide was also obtained by 
stable transfection of HEK 293S (TetR)GnTI at a resolution of 3Å [104]. Another crystal structure 
of the constitutively active rhodopsin mutant at M 257Y6.40 in complex with the C-terminal end 
of the G protein α-subunit was submitted by Standfuss and his colleagues [105]. Activation and 
binding was assayed with the amount of radioactivity and GTP γ35S bound to G protein 
transductions. Finally, the crystal structures of constitutively activated G90D rhodopsin were also 
obtained and utilized for their desensitization capabilities [106].  
1.2.4 Escherichia coli (E.coli) expression 
     Both E. coli and yeast cells have provided minor advantages over other heterologous expression 
systems. Due to low cost, the capacity for scaling up, short doubling time, and easy handling in 
the laboratory, the bacterial system is usually the first choice among expression systems [59, 84]. 
In addition, both cell-free translation and E. coli’s purified protein are eligible for NMR and 
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crystallography studies. However, the lack of post-translational modifications, absence of 
necessary interacting proteins for the production of fully functional receptors such as G-proteins, 
and the inability to translocate proteins to their subcellular destinations (for example, the transport 
of membrane proteins to the plasma membrane) are considered drawbacks of this system. It has 
been shown previously that some GPCR cases such as rhodopsin, somatostatin, follicle-
stimulating hormone receptors, and β2 adrenergic receptors require this post-translational 
modification not only to produce folded protein but also to preserve the receptor affinity to ligand 
binding and/or G-protein coupling as well as insertion into the plasma membrane [107-109]. Non-
relevant membrane environment for GPCR expression in bacterial systems is also very different 
from other eukaryotic cells. Missing are the reductive environment, required to form disulfide 
bonds and the lipid composition (mainly cholesterol) is another disadvantage of using E. coli. 
Nevertheless, successful examples of GPCR expression in the inner membrane of E. coli have 
been obtained, such as human β2-adrenergic receptor [108] and human CB2 receptor [110]. There 
are two different site used to date of recombinant GPCR expression, the plasma membrane or in 
bacterial inclusion bodies (IBs). Each of these approaches is subject to many requirements for 
success. Fusing a signaling  peptide protein to the N-terminal sequence of GPCRs, like β-
galactosidase or maltose binding protein (MBP), and inducing the expression with isopropyl-β-D-
thiogalactoside (IPTG) in the presence of a weaker promoter has produced many functional 
GPCRs in the inner membrane of the bacteria, including β2-adrenergic receptors [111],  A2a  
adenosine receptor [112], rat neurotensin NTS1 receptor [48, 113], human serotonin 5-HT1A 
[114], and M1/M2 muscarinic acetylcholine receptor [115, 116]. Mistic, is another integral 
membrane protein enhancer that can be fused to the N-terminal sequence for expression of GPCRs. 
It has been used in combination with the TarCF transducer to facilitate expression and produce 
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purified human CB2 receptor [110]. The purified CB2 protein exhibits functional binding activities 
comparable to the binding of membrane fractions.   
     In some cases, where the bacteria is incapable of handling and processing the expressed 
recombinant protein to the membrane, they are formed and localized in inclusion bodies as dis 
functional proteins. Thus, additional procedures are required to extract and refold the protein, to 
some extent, to the native condition. The advantages of inclusion bodies including: 1) less toxicity 
to the host compared to membrane expression, 2) the protein expressed levels is considerably 
higher than other approaches [117], and 3) inclusion bodies are resistant to proteolysis digestion 
and severe purification conditions [118]. In addition, the protein expressed in these inclusion 
bodies can be with or without fusion protein. The major drawback of using these inclusion bodies 
is the need for a refolding process, starting from IB enrichment from the cell preparations by 
centrifugation, and ending at reconstitution of the purified protein in a lipid mimetic environment 
and folded to its native state [119, 120]. Glutathione S-transferase (GST), ketosteroid isomerase, 
human α5 integrin (α5I), and thioredoxin (TRX) tag have been used previously to express GPCRs 
in inclusion bodies with different variations of protein yield. An example for using of (GST) for 
the purification and characterization olfactory receptors [121].The  ketosteroid isomerase also used 
for expressing the serotonin 5-HT4a receptor [122] and leukotriene BLT2 for expressing human 
α5 integrin (α5I) [123]. NusA, TRX, and GST tags were used extensively by Michalke et al. to 
screen IBS expression, purification conditions for 100 GPCRs in Escherichia coli [117]. However, 
among these GPCRs, human parathyroid hormone receptor 1 and mouse cannabinoid receptor 1 
were expressed without the need for fusion protein, and instead used an artificial, chaperone-
assisted, purification and refolding procedure [124]. In other studies, the TrpΔLE fusion protein 
was used for IB-directed expression. This fused polypeptide is derived from a leader sequence 
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TrpL, which is composed of 17 amino acids [125]. This fused polypeptide, TrpΔLE fusion was 
used in our laboratory previously for construction of the pMMHb-TrpΔLE-9His–Xa vector for 
studying expression of cannabinoid receptor CB2 transmembrane fragments [126-129].  
1.2.5  Insect cell / baculovirus 
    The baculovirus expression vector system (BEVS) is now widely used in GPCR research and 
scientific industrial communities [130]. This method of producing heterologous genes is attractive 
for many researchers due to the presence of a powerful polyhedrin promoter derived from the 
baculovirus Autographa californica’s multiple nuclear polyhedrosis virus (AcMNPV). BEVS is 
based on facilitating the introduction of a foreign gene into the viral replication genome by 
homologous recombination of a transfer vector (polyhedrin) containing the target gene and viral 
DNA. Recently, scientists developed different generations of BEVS that overcame the need for 
the plaque assay in previous systems. The Bac-to-Bac® (Invitrogen) baculovirus expression system 
has the advantages of the site-specific transposition properties of the Tn7 transposon. This system 
comprises a pFastBac™ vector harboring the expression gene and is controlled by the polyhedrin 
promoter in DH10Bac™ E. coli-competent cells. These competent cells contain a shuttle vector 
(bacmid) which has a mini-attTn7 replicon, antibiotics selection, and a helper plasmid. Insertion 
of the expression gene of interest into DH10Bac™ E. coli disrupts the lacZ sequence in the bacmid, 
which allows isolation of the recombinant bacmid by blue/white selection. Once the bacmid DNA 
is isolated, the recombinant bacmid DNA is used to infect insect cells. It is necessary to quantify 
the virus concentration before infecting the cell in order to know the measure of PFU (plaque-
forming units). The number of PFUs can be determined in either a plaque assay or by surface 
immune staining with gp64-PE antibody and flow cytometry analysis. After obtaining number of 
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(PFUs), this value is used to calculate the multiplicity of infection (MOI) using the following 
equation to get the correct amplification and expression of the recombinant protein:  
Inoculum required (ml) =  
(MOI X number of the cells) 
titer of viral stock (pfu/ml)
 
     The multiplicity of infection (MOI) usually ranges from 0.05 to 0.1 for producing the second 
virus titration (1 x 107 to 1 x 108) and from 1 to 5 for protein expression. Different cell lines can 
be substituted for insect cells such as Trichoplusia ni (High Five cells) and Spodoptera frugiperda 
(Sf9 and Sf21 cells). Both Sf9 and Sf21 cells are preferable over High Five cells in the production 
of baculovirus due to their high transfection efficiency. Table 1 summarizes the differences 
between all insect cell lines. The high levels of gene expression, solubility, post-translational 
modification, and safe handling procedures are features that make the BEVS attractive to use [131]. 
Protein expression is utilized throughout the unique characterization of the virus’ life cycle. In the 
first stage (10-24 hours, post-infection), the virus is replicated through budding of the cellular 
membrane, forming virus particles that infect the nearby cells. In this stage, the insect cell will 
increase in diameter and cell nuclei. It is unlikely that enough protein will be produced in this 
stage, so the cell needs to be maintained to for the next stage, which is the late stage (24-72 hours). 
The late of stage, enveloped nucleocapsids are occluded in the nucleus with polyhedrin. This is 
responsible for producing the protein and generates viral occlusion bodies. At this late stage, cell 
growth has stopped, and the cell develops a granular appearance. Due to the difference between 
mammalian and insect cell membrane composition, it might be required to add different membrane 
supporting materials into the media. For example, insect cells are known to lack phosphatidyl 
serine, cholesterol, and contain high phosphatidyl inositol content, which is required for the proper 
refolding of GPCRs in the membrane [94]. To mimic the expression conditions of the mammalian 
membrane, lipids can be added into growth media, such as in the case of the turkey β1-
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adrenoceptor [132] and human D3 receptor [30]. Moreover, addition of ligands to the growth 
media have been shown to increase expression levels of the protein.  
     To date, 119 GPCR structures, representing 22 different subtypes of GPCRs, from a total of 
826 GPCRs are listed in the GPCR network (http://zhanglab.ccmb.med.umich.edu/GPCR-EXP/). 
About 85% of the revealed structures have utilized the baculovirus system for protein expression. 
The majority of the GPCR structures determined used Spodoptera frugiperda (sf9) over other cell 
lines. Nevertheless, High Five TM cells have been used to determine some GPCR crystal structures 
such as β1-adrenoceptor [133, 134], A2A receptor [135], and rat neurotensin A [68], and human 
corticotropin-releasing factor B [70]. This also showed advantages for expression of the truncated 
receptor. Thus, cell-line production screening is required before large-scale production. 
       The cost of using this system is high due to the expensive growth medium. Special growth 
conditions at 27°C are also required for co-transfection agents. Moreover, it takes up to month to 
produce enough baculovirus for large-scale expression. On the other hand, using the insect 
cell/baculoviros system has major advantages over other systems. It can provide the desirable 
GPCR recombinant protein with correct folding, as well as form disulfide bonds and post-
translational modifications, which are required for many GPCR functions. However, some of the 
expressed proteins have non-homogeneous glycosylation, resulting in different forms of the 
protein, which can eventually affect the quality of the protein’s crystal form [136]. In addition, 
Spodoptera frugiperda (sf9) has been used to express Gα subunits such as Gsα, Goα, and Gqα, 






Table 1. Comparison of Baculovirus Expression Host Systems. 
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1.2.6 Other expression systems 
    Rhodobacter spheroids are examples of other prokaryotic systems which were previously used 
for GPCRs expression. Their success has remained limited as expression systems [59]. They have 
been used previously to functionally express human bradykinin B2 receptor (B2R), human 
adenosine A2a receptor (A2aR), and the human angiotensin AT1a receptor (AT1aR) [139]. In 
addition, Halobacterium salinarum has been used to express and identify bacteriorhodopsin.  
Haloferax volcanii and Lactococcus lactis, with other hosts, have shown their potential for 
expressing some GPCRs. However, there has been limited success with obtaining GPCRs crystal 
structures from these systems. 
    Utilizing the abundance of rhodopsin receptors in eye retina, rhodopsin was isolated from its 
natural source in a sufficient amount for crystal structure studies. Rhodopsin receptors were 
isolated in high amounts in 1998 from outer rod segment membranes using detergents [140]. This 
remarkable purification allowed for crystallization trials to take place. Two years later in 2000, the 
first GPCR structure solved by X-ray crystallography was bovine rhodopsin with a resolution of 
2.8 Å [27]. Similarly, squid rhodopsin’s crystal structure was defined and revealed [141, 142]. Due 
to the unique abundance and stability of the receptor, rhodopsin was extensively utilized for GPCR 
x-ray studies, leading to twenty-nine different crystal structures of with different resolution in the 
protein data bank.   
     Other eukaryotic systems have been utilized to produce GPCRs, such as transgenic animals. 
Caenorhabditis elegans is an example. Bovine and human adenosine A2A are expressed in 
neurons or muscles of this worm. They are able to produce native, functional GPCRs in milligram 
amounts. Moreover, the adenovirus encoding for CXCR1 was used to infect mice liver in vivo to 
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produce functional expression of recombinant GPCRs comparable to expressed protein in 
neutrophils [143]. An estimated 20 mice livers were enough to produce 1 mg of the functional 
protein, which is the same amount that can be produced from 5 L of cell culture media [144]. 
Retinal rod cells of transgenic Xenopus laevis have also been used to produce 20 homogeneously 
glycosylated GPCRs [145]. Ligand binding and functional assays of 5HT1A and EDG1 are 
performed to confirm that the function as well as the refolding of these receptors was preserved. 
The authors conclude that similar results could be universal and generalized to other GPCRs [145]. 
1.2.7 Comparisons of expression systems 
    There is no ideal expression system for GPCR production, taking into the account the cost, time 
consumed for vector production and protein expression, culturing difficulties, and scaling up as 
shown in (Figure 1-5). In addition, isotope labeling for NMR is also a major factor in choosing 
the system. The less attractive system is the cell-free expression system due to a poor expression 
levels compared with other systems. No crystal structures have been solved using this system. 
With simplicity and low cultivation costs, Escherichia coli is considered the most popular host for 
the overproduction of membrane proteins. The ability to scale up and NMR labeling are other 
advantages of using the E.coli system. However, the lack of glycosylation, limited post-
translational modifications for producing membrane protein, as well as the refolding process for 
some GPCRs expressed in inclusion bodies are considered major limitations of this system. The 
expression of recombinant GPCRs in mammalian and yeast cells is quite successful compared to 
cell-free translation due to the presence of post-translational modifications. However, 
glycosylation and hyper-glycosylation are different in yeast compared with mammalian cells. 
Also, the yeast cell membrane has a different lipid composition than that of mammalian cells. The 
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insect cell/baculovirus expression system is robust. It has mammalian-like post-translational 
modifications. The membrane compositions of the insect cell are different from those of 
mammalian cells. Insect membrane are composed of high phosphatidyl inositol content, low 
cholesterol content, and contain no phosphatidyl serine, indicating that additional lipid or 
cholesterol may need to be supplemented in the media [94]. Most of the co-crystal structures 













Figure 1-5. Comparison of GPCRs expression systems. 
Time and procedures required for cloning, expression, and purification of recombinant GPCRs in 




Table 2. Updated list of GPCR crystal structures subtypes released from different expression systems.  
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Neurotensin receptor 1 A 3ZEV 3.00 Å [79] 
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 Can be used for scaling up; 
easy to use  
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number of disulfide bonds 
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A 3VG9 2.7 Å [61] 
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(Natural)  
 Abundance in the receptor 
 Restricted to a few GPCRs 
 Expensive to use in the 
case of transgenic animals 
Rhodopsin (Bovine) A 1F88 2.8 Å [27] 
Rhodopsin (Squid) A 2Z73 2.5 Å [141] 
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 High cost and time- 
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 Expensive to culture same 
as insect/baculovirus 
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Rhodopsin (Bovine) A 2J4Y 3.4 Å [102] 
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 Toxic protein can be 
expressed 
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 Non suitable for large 
scale.  
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Insect cell  
 Performs more complex 
post-translational 
modifications and processes 
disulfide bonds properly   
 Relatively high expression 
levels 
 
 Work complexity 
 Producing virus and 
expressing protein is time 
consuming 
 High cost 
 Membrane composition 
different than mammalian 
cells 
Human β2- adrenoceptor A 2RH1 2.4 Å [63] 
Turkey β1 Adrenoceptors  A 2VT4 2.7 Å [147] 
Human Adenosine  A 3EML 2.6 Å [58] 
Human muscarinic (M2) A 3UON 3.0 Å [66] 
Human Dopamine (D3)  A 3PBL 2.89 Å [30] 
Human Chemokine (CXCR4) A 2K05 2.5 - 3.2 Å  [57] 
Human muscarinic (M3) A 4DAJ 3.4 Å [71] 
Human Lysophospholipid (S1P) A 
3V2W 
3V2Y 
3.35 Å [65] 








Human Chemokine (CCR5) A 3MBS  2.71 Å [74] 
Mouse δ and μ opioid receptor A 
4EJ4 
4DKL 
3.4 and 2.8 Å 
[67, 
72] 
Human κ and δ opioid receptor A 
4DJH 
4N6H 
1.8 and 2.9 Å 
[75, 
149] 
Human NOP opioid receptor  A 4EA3 3.01 Å [76] 
Human purinoceptor 12 receptor  A 4NTJ 2.62Å [150] 
Rat Neurotensin 1 receptor A 4GRV 2.8 Å [68] 
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B 4K5Y 2.98 Å [70] 
Human Free fatty acid 1 receptor A 4PHU 2.33 Å [152] 
Human Glucagon receptor B 4L6R 3.30 Å [153] 





2.8 and 2.6 Å 
[77, 
154] 










2.0  ENDOCANNABINOID SYSTEM 
    The endocannabinoid system is composed of cannabinoid receptors and endogenous ligands, as 
well as, lipids or enzymes that synthesize and degrade such ligands [156]. This system controls 
complex physiological processes that involve the endocrine and neurological systems, such as, 
mood regulation, immune modulation, pain, and memory and food intake [157, 158].  Currently, 
there are two known endogenous ligands, Anandamide also known as N-
arachidonoylethanolamine or (AEA), and 2-arachidonoylglycerol (2-AG). Additionally, there 
have been several mediators recognized for the endocannabinoid system, such as, N-arachidonoyl 
dopamine (NADA), N-palmitoylethanolamine (PEA) and 2-arachidonoyl glycerol ether (noladin 
ether). It is also widely known that enzymes of the endocannabinoid system include fatty acid 
amide hydrolase and the monoacylglecerol lipase. Also the selective anandamide reuptake 
transporter SART. 
    Anandamide was obtained from porcine brain extracts and consists of poly-carbon (20) fatty 
acids connected to ethanolamine by an amide linkage [159]. In addition, both AEA and 2-AG are 
derivatives of arachidonic acid that bind with different affinities to endocannabinoid receptors. 2-
AG exhibits a higher binding efficacy when compared to AEA. [160, 161].  When binding of endo- 
or exogenous cannabinoids to their cognate receptors (CB1 and CB2) occurs, adenylase cyclase is 
inhibited thereby triggering further intracellular downstream signaling. furthermore, the 
endocannabinoid system acts on other downstream signaling pathways which results in  activation 
of receptor kinase, mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinases (JNK) 
[158] [162].  
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    Cannabinoid ligands are often classified into three groups classical cannabinoids, such as [Δ9-
THC, Δ8- THC-dimethylheptyl (HU210)], non-classical cannabinoids, such as [CP55,940], 
eicosanoids derivatives [anandamide, 2-arachidonoylglycerol], carbimimetic indols [WIN 55,212-
2], and pyrazole derivatives [SR141716A, SR145528]. THC, one of the major active compounds 
of Cannabis sativa, has therapeutic uses including anti-inflammatory, immunosuppressant, 
analgesic [163] and anti-obesity effects [164]. However, it also produces major psychoactive 
effects such as catalepsia, hypothermic, and addiction [165, 166]. THC was isolated and 
structurally characterized in 1964 and cis considered to be a paradigm of synthesized analogs 
[167]. In 1971, the same researchers isolated multiple compounds of Cannabis sativa. These 




















Figure 2-1. Chemical structure, classes of cannabinoids and their examples. 
Different classes for both cannabinoid receptors CB1 and CB2 with examples. 
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2.1 CANNABINOID RECEPTORS 
2.1.1 Cannabinoid receptor CB1 
   The cannabinoid receptor 1 (CB1) was discovered and isolated from the cerebral cortex of the rat 
brain in 1990 by Matsuda and colleagues [168]. Extensive cloning studies later led to the discovery 
of CB1 receptors from human brain and testes [169]. Previously considered an orphan receptor until 
CP55,940 and Δ9-THC were shown to inhibit adenylyl cyclase as their mechanism of action. 
Cannabinoid receptors CB1 only share 44% overall amino acid identity with the receptor CB2. 
However, within the transmembrane domains, this percentage increases to 68% [170]. CB1 is 
predominantly expressed in the central nervous system, but can also be located in peripheral tissues 
such as the heart, lung, adrenal glands, tonsils, and spleen at low levels [170, 171]. The CB1 
receptor consists of 472 amino acids, with a molecular weight of approximately ~ 52.8 kDa. CB1 
receptors as a therapeutic target has been recently studied. Rimonabant, a CB1 inverse agonist 
drug for example, was a marketed in Europe drug for the treatment of obesity, smoking cessation, 
and associated metabolic disorders. However, due to potential psychiatric side-effects, such as 
severe depression and suicide, the drug was withdrawn from the European market in 2008 [172]. 
2.1.2 Cannabinoid receptor CB2 
    Cannabinoid receptor 2 (CB2) was cloned and isolated in 1993 using a PCR-based approach 
along with structural homology to other GPCRs [170]. Unlike CB1, which is primarily expressed 
in the central nervous system and it believed to be responsible for modulating N-type Ca2+ and K+ 
channels [173], the CB2 receptor is predominantly expressed in the spleen and other tissues with 
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immunological functions [170, 174-176]. CB2 does not exhibit ion channel effects [6]. CB2 
mediates cannabinoid signaling via multiple signaling pathways and has been implicated in 
inflammatory pain [137], autoimmune and immunological disorders such as, multiple sclerosis 
[177], and immune system related cancers [178]. Both CB1 and CB2 fall within the general 
structural pattern of Rhodopsin family GPCRs. Moreover, they are classified under family A which 
has a glycosylated N'-terminal external domains, seven transmembrane domains, and an 
intracellular C'-terminal tail [174]. The expression pattern for CB2 suggests the involvement of 
these receptors in many clinical manifestations and may serve as a platform for disease targets 
with limited CNS side effects [179]. 
    GPR55 has emerged as a novel orphan receptor that was identified and cloned as a GPCR   [180]. 
GPR55 couples through Gα13 subunit. It is a class-A, rhodopsin-like GPCR with low sequence 
similarity to CB1 (13.5%) and CB2 (14.4%) receptors [181]. It is mainly expressed in the CNS, 
similar to CB1. In addition, it has been shown to regulate osteoblasts and osteoclasts in bone 
remodeling [182]. Endocannabinoids such as AEA, and CB ligands such as virodhamine and 
CP55,940 bind and activate the GPR55 receptor. Due to the lack of the information regarding the 
role and mechanism of the receptor and its endogenous ligands, GPR55 remains an orphan receptor 
that is not classified as an endocannabinoid receptor. 
2.2 CANNABINOID RECEPTOR SIGNALING  
     CB1 and CB2, couple to the Gαi/o G-protein [183]. Activation of these receptors through agonist 
triggers replacement of GDP, which is bound to the Gα subunit, by GTP, then causing dissociation 
of the G protein. Gαi/o effectors inhibit adenylate cyclase causing cyclic adenosine 
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monophosphate (cAMP) reduction inside the cell. These effects on adenylate cyclase can be used 
to distinguish between antagonists/inverse agonists and agonists. Binding cannabinoid receptors 
to inverse agonist leads to stimulate the adenylyl cyclase and thus cause enhancement of the cAMP 
levels in the cells. Lastly, antagonist binding to CB receptor have no effect on inhibition or 
stimulation of the adenylyl cyclase. Therefore, no change on the cAMP levels will be observed 
[184]. The βγ dimer complex serves as a scaffold protein in the MAPK activation cascade. 
Moreover, the phosphatidylinositol-3-kinase (PI3K) inhibitors and subsequent recruitment of 
protein kinase B (PKB) are blocked, as illustrated in (Figure 2-2). 
      Cannabinoid receptors also can interact with different effectors (Ceramide) [185]. This lipid 
second messenger plays a critical role in cell cycle differentiation, proliferation, and programmed 
cell death [186]. In glioma and primary astrocytes, CB1 induces the hydrolysis of sphingomyelin 
by sphingomyelinases [187]. This increase in hydrolysis leads to an increase in the levels of 
ceramide which, in turn activates the ERK 1/2 pathway. Non-selective cannabinoid agonists, such 
as, Aanandamide, HU-210 and Δ9 –THC increase the metabolism and expenditure of glucose due 
to  a transient increase of ceramide levels in the cell [188]. In rat C6 glioma, both CB receptors 
have been linked to an increase  in levels of ceramide and  subsequent activation of the Raf-
1/MAPK cascade [189]. These increases in ceramide levels activate the MAPK pathway, which 
leads to apoptosis [189]. In rat primary neonatal microglia cells expressing CB2, 2-AG has been 
shown to activate the MAPK signaling pathway and promote cell proliferation [190]. Activation 
of MAPK can also induce the expression of genes such as, Krox 24 and Fos, which have been 
shown to be involved in growth, differentiation, and proliferation of cells [191, 192]. 
      Targeting the CB1 receptor has been shown to inhibit Ca2+ influx by ion channels [193]. CB1 
receptor agonists, including CP55,940 and anandamide, inhibit calcium channels causing a 
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decrease in Ca2+ levels via a cAMP-independent pathway [194]. Additionally, the CB1 agonist 
inhibited the Q-type Ca2+ currents in pertussis toxin (PTX) sensitive tumor for the cell [195]. In 
neuroblastoma-glioma hybrid and neuroblastoma cells expressing CB1 receptors, calcium 
concentration levels inside the cell were increased using CB1 agonists such as, 2-AG and 
WIN55212-2 [196, 197]. An alternative experiment using pulmonary endothelial cells 
demonstrated anandamide increased the intracellular calcium concentration due to the activation 
of phospholipase C [198]. 
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Figure 2-2. Cannabinoid receptor CB1 and CB2 signaling. 
The cannabinoid receptor couples to G proteins. The coupling leads to a decrease in cAMP, 
activates of  PKA , AKT and MPK, which all control the cell fate. Activation of the CB1 receptor 
leads also to produce of ceramide though sphingomyelin (SM) hydrolysis via 
sphingomyelinase (SMase) activation possibly through the adaptor protein FAN rectifying potassium 
currents. Adapted from [199, 200] and [201].
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2.3 PHYSIOLOGICAL ROLE AND THERAPEUTIC SIGNIFICANCE OF 
ENDOCANNABINOID RECEPTORS 
      Endocannabinoids have proven their involvement in multiple regulatory functions which 
include, energy metabolism, cardiovascular tone, immune system, and reproductive roles [188]. 
Throughout the past three decades, there have been many drugs on the market for the treatment of 
various disease states. For example, Δ9-THC (Marinol®), which has psychotropic effects, has been 
used as an anti-emetic drug for cancer patients as well as an appetite stimulant [202, 203]. 
Cesamet®, a synthetic analog for dronabinol, has been utilized by chemotherapeutic patients to 
treat nausea and vomiting. In Canada, Sativex® is used to treat pain management in multiple 
sclerosis patients. [204, 205]. The location of CB1 and CB2 determines the need for therapeutic 
uses.  For example, CB1 receptors are primarily expressed in the CNS allowing them to be a 
potential target by inverse agonists. This would be significant for appetite suppression and weight 
loss. CB2 is expressed in the peripheral tissue and modulates immunological activity and 
inflammatory responses in leukocytes [206]. Several studies have demonstrated a role for CB2 in 
bone mass regulation [207-210] and osteoporosis. CB2 knockout mice (CB2(-/-)) exhibit a dramatic 
reduction in bone nodule formation when compared to WT littermates [211]. Furthermore, CB2 
receptor modulation leads to various immune responses [212] which range from inflammation to 
neuroprotection[213]. Examples of these responses are proliferation, cell death and inhibition of 
antibodies that are mediated by T and B-lymphocytes. Cannabidiol, a natural constituent of 
Cannabis extract, [214] attenuates pathogenic T cells and reduces spinal microglial activation 
thereby, demonstrating improvement of multiple sclerosis symptoms in mice [215]. These studies 
provide compelling evidence to support that CB2 receptor agonists would be promising 
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therapeutics to treat neuropathies [216]. The CB2 agonist HU-910/30 has been demonstrated to 
reduce oxidative stress markers, inflammation and cell death following hepatic ischemia 
reperfusion injury in a mouse [217, 218]. Literature also supports the notion that CB2 has the 
potential to be a target for a myriad of other diseases such as, sepsis [219] chronic pain, anxiety, 
ataxia and catalepsy [220]. 
     There has been strong evidence to support that there is upregulation of cannabinoid receptors 
in bone, breast, prostate lung and blood related cancers when compared to normal tissues [221] , 
[222, 223]. Treatment with THC led to a significant reduction in lung adenocarcinoma [224] and 
blood related cancer [225]. Moreover, throughout the tumor progression, an upregulation of 
endocannabinoid-degrading enzymes has been documented. Attempts to diminish the enzyme 
levels resulted in tumor size suppression [226].  Speculatively, the mechanism of action is shown 
in (Figure 2-2). Briefly, cannabinoid receptors produce ceramides which leads to activated ERK 
and p38-MAPK signaling pathways, this in turn leads to considerable cell cycle arrest and 
apoptosis. Additionally, the inhibition of protein kinase A (PKA) caused by inhibition in cAMP 
leads to apoptosis [227, 228]. 
    Δ9-THC and endocannabinoid ligands have been proven to be potential inhibitors of cell 
proliferation, angiogenesis, and metastasis of breast cancer cell-lines [229]. In addition, selective 
CB2 agonists, such as JWH-133, inhibit cancer migration and angiogenesis in-vitro by triggering 
caspase activation leading to apoptosis. Prostate cancer cell-lines along with human prostate cancer 
tissues, were previously evaluated for overexpression of cannabinoid receptors [230-233].        
Furthermore, in-vivo studies have indicated that Methanandamide and JWH-015, both selective 
agonists to CB2, have anti-proliferative and pro-apoptotic effects that reduce tumor growth in 
athymic mice injected with PC-3 cells [234]. 
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    The presence of CB2 receptors in brain microglia suggests possible therapeutic targets in 
treating CNS-related diseases. In recent studies on Alzheimer’s disease JWH 015 activated the 
CB2 receptor, which in turn led to the removal of β-amyloid plaques by stimulation of 
macrophages [235]. This proof-of-concept was confirmed by treating with SR144528, a selective 
CB2 antagonist, to prevent JWH-015 from inducing plaque removal in situ. Cell cultures treated 
with CB2 ligand,  AEA, 2-AG, and noladin led to increased viability of neurons after exposure to 
different Aβ species toxins [236].  
     However, the most significant therapeutic target endocannabinoid receptors is for bone 
remodeling and homeostasis [208]. It has been demonstrated that osteoclasts, osteoblasts, stromal 
cells and osteocytes express large amounts of endocannabinoid metabolizing enzymes, NAPE-
phospholipase D, FAAH, and DAGLs α and β. Studies have shown that Estrogen-deficiency mice 
are associated with osteoclastogenesis and both CB1 and CB2 are highly expressed in bone-
marrow precursor cells. Inhibition of both CB receptors by selective inverse agonists led to a 
downregulating in osteoclast formation [237]. In contrast, other studies have shown that 
cannabinoid receptor agonists such as HU308, JWH133 and CP55,940 increased osteoclast size, 
number, and stimulated bone resorption [207, 209, 237].  
      Therapeutic interventions targeted at CB2 receptors displays immense potential to patients 
suffering from neuropathic, inflammation and pain, bone related disease and cancers. 
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2.4 OVERALL GOALS AND APPROACHES TO THE STUDY OF CB2 RECEPTOR 
STRUCTURE AND FUNCTION OF CB2 RECEPTOR 
      Design and synthesis of CB2 selective ligands is necessary to attain pharmacological end-
points [238, 239]. To design selective ligand structures, the activity of known ligands must be 
studied to further enhance potency and selectivity [239-241]. High resolution, three-dimensional 
structures of CB2 have provided a detailed understanding of form and function of the proteins and 
provided knowledge of ligand binding sites and receptor ligand interactions [58, 62, 63, 242]. 
These structures open doors to a large number of drug discovery techniques. [243]. These 
techniques include, but are not limited to structure-based drug design, virtual and fragment 
screening [244-246]. Solving the high-resolution 3D crystal structure of the CB2 receptor will 
contribute largely to the CB2 structure and function studies. However, heterologous GPCR 
expression and production is problematic due to their inefficient transport and insertion into the 
plasma membrane, the potential to induce toxicity to host cells, and inherent structural instability 
of the receptors [62]. Detergents used in the purification process negatively impact GPCR stability 
and yield. Crystallization of purified GPCRs are troublesome due to the presence of detergents, 
inherent receptors flexibility, and small hydrophilic regions [48-50]. Many technical barriers, 
therefore, need to be overcome in order to generate diffraction quality crystals of GPCRs. 
       Our goals for studying the structure of the CB2 receptor in this project are two-fold. Firstly, 
we utilized homology models and site directed mutagenesis to gain insight into the effects of the 
amino acid substitution on the binding and function of the receptors. It has been shown that some 
amino acid mutations aid in the purification of the receptor due to an increase in the thermal 
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stability of the protein [247]. The end goal would be a highly selective CB2 modulator with 
diminished unwanted effects. 
     Secondly, we will attempt to purify the functional CB2 receptor. Our goal is to develop a 
method for producing purified and functionally active CB2 receptor using detergents.  To achieve 
this we selected an insect cell expression system. This system is advantages because it can produce 
functional receptors without the need for refolding. To stabilize the receptor during the 
purification, a fusion protein was inserted at the third intracellular loop of the receptor. This protein 
will be able to analyzed using X-ray crystallography methods to study the CB2 structure and 
dynamics with or without ligand activation. To accomplish this goal, we plan to carry out CB2 
receptor expression, and purification studies using different fusion protein, structurally distinct 
ligands and different detergents. Ligand binding and western blot analysis will be used to identify 
the best construct for CB2 expression that also preserves the structure integrity of the CB2 




3.0  IMPORTANT BINDING RESIDUES OF CB2 RECEPTOR DETERMINED BY IN 
SILICO MODELING, MOLECULAR DYNAMIC SIMULATION, AND SITE-
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3.1  INTRODUCTON  
      Cannabinoid receptors are in the rhodopsin-like family of G protein-coupled receptors 
(GPCRs) with seven characteristic hydrophobic transmembrane helices attached by three 
intracellular and three extracellular loops [248]. Two types of cannabinoid receptors, CB1 and 
CB2, were characterized and cloned in 1990 and 1993, respectively [249, 250]. Differentiation 
between cannabinoid receptors can be based on the variations of amino acids making up the 
receptor, tissue abundance, selectivity and specificity to some ligands, signaling mechanisms, and 
phosphorylation pathways [251]. The CB1 receptor, for example, is expressed in the central 
nervous system (CNS) and is less predominant in peripheral organs and tissues such as the heart, 
lung, adrenal gland, tonsils, and spleen [171]. Unlike the CB1 receptor, the CB2 receptor is 
predominantly expressed in the peripheral immune system, such as the spleen and lymph nodes, 
where it is expressed in low amounts [250]. The distribution patterns of the CB2 receptor in 
peripheral organs suggest that the CB2 receptor may plays a crucial role in the regulation of the 
immune response [252]. Therefore, CB2-selective ligands may likely hold promise for the 
treatment of diseases with an immune origin, e.g. chronic pain [253], osteoporosis [254], and 
various cancers such as lung, bladder [255], pancreas [256], breast [257], and prostate [230] 
without CNS-mediated psychoactive effects. Cannabinoid binding induces a series of 
conformational changes among the transmembrane helices that shift the equilibrium toward the 
active receptor state [258]. Consequently, Gαi, a family of G proteins, binds to the third 
intracellular loop and C-terminus of CB2 to inhibit forskolin-stimulated adenylyl cyclase (causing 
a reduction in cAMP levels), activating the mitogen-activated protein kinase (MAPK) cascade and 
regulates protein kinase A (PKA) phosphorylation, all of which are important in maintaining cell 
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functional integrity [259]. Moreover, activation of the CB2 receptor results in a transient elevation 
of Ca2+ signaling in endothelial cells exposed to the endocannabinoid anandamide [198]. Due to 
the difficulties in GPCR functional expression and purification, as well as their inherent flexibility, 
only a limited number of GPCR crystal structures have been elucidated to date [53]. Given the 
scarcity of GPCR crystal structures, generating 3D models derived from previously reported 
GPCR structures and complementary site-directed mutagenesis experiments are considered to be 
a feasible alternative for studying ligand binding and receptor activation [260]. Different amino 
acids present in the binding pocket have been confirmed for their importance in both agonist and 
antagonist binding [261-268]. 
     In this chapter, we will provide a literature review as well as case studies for the residues that 
have shown important roles in both structure and function of the cannabinoid receptor CB2. 
Molecular modeling, docking, and site-directed mutagenesis studies, suggest that some residues 
of TM3, ECL2, TM 5, TM6, and TM7 are responsible for the large conformational changes 
observed during ligand binding. The results also imply important roles of these residues in ligand 
binding and downstream signal transduction of the CB2 receptor. We investigated the possible 
roles of V113 of TM3 (position 3.32) and L192 of TM5 (position 5.41) in binding with three 
structurally diverse CB2 ligands: CP-55,940, a non-classical cannabinoid agonist; SR144528, a 
diarylpyrazole inverse agonist; and XIE95-26, a biamide derivative inverse agonist [269]. We also 
illustrated the role of aromatic amino acids (Phe183) in the second extracellular loop and (P281) 
in the seventh transmembrane helix domain in ligand-biding recognition. These aromatic amino 






3.1.1  Understanding the role of binding in functional residues of the cannabinoid 
CB2 receptor by mutational studies  
     Solving the GPCR co-crystal structure for rhodopsin in 2000 expanded the horizons for 
understanding the activation mechanism of the receptors and differentiating the role of amino acids 
in both ligand binding and signaling transduction. The lower part of the receptor is known for high 
conformational changes and G protein coupling. The upper part of GPCR is responsible for ligand 
recognition by the receptor and triggering the related signaling transduction. Site-directed are 
applied to understand the effect of changing or removing one or more amino acids on ligand 
binding and receptor stabilization by thermostabilizing mutations. Thermostabilizing mutations 
are considered one of the most effective strategies for increasing the thermal melting point of the 
receptor. Different methods of thermostabilizing the mutation in the transmembrane regions have 
been used previously, such as creating disulfide bonds (i.e. cysteine mutation) between helix 1 and 
the C-terminal of the receptor to reduce their potential movement. Engineering a Zn2+ bridge by 
replacing amino acids at the end of the cytoplasmic region with histidine that can binding to Zn2+ 
to reduces conformational changes and consequently locks the receptor in the inactive state (R) 
[270]. On the other hand, mutations to the residues in the extracellular domains have shown some 
advantage over mutation in transmembrane regions by forming a salt bridge through linking 
extracellular loop 2 to the upper part of helix 7 (hydrogen bonding and electrostatic interactions) 
and by alanine or leucine scanning mutagenesis [270]. 
     Several amino acids present in the binding pocket have been validated for their importance in 
agonist and antagonist binding, such as S112, W172, Y190, W194, F197, W258, and S285 [261-
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268]. Moreover, the third and fifth transmembrane regions of the CB2 receptors play critical roles 
in the binding of the vast majority of cannabinoid ligands and subsequent signal transduction [261, 
271]. The following mutation data describes the current state of knowledge about amino acid 
residues, including the most important findings prior to 2008, which were reviewed previously 
[272, 273]. Figure 3-1 shows all mutation conducted for the CB2 receptor also in Table 3. 
 
Residues in the second helix: 
    Aspartate 163 in CB1 and aspartate 80 in CB2 were each mutated to asparagine or Glutamate. 
There was no disruption in the high affinity agonist binding (CP-55,940, THC, anandamide) [266]. 
However, the affinity of WIN-55,212–2 was changed significantly in CB1 mutant but not in CB2. 
In the case of the inverse agonist (SR141716A), mutant Aspartate 163 have been tested for the 
CB1 and the results show that there is no significant reduction in binding compared to wild type. 
Interestingly, the Aspartate-to-asparagine mutation abolished signaling responses to WIN 55,212–
2, or CP-55,940, whereas the Aspartate-to-Glutamate mutants showed significant reduction in 
coupling [266]. 
     Mutations in the second transmembrane domain of CB2, cysteine (89) was performed by 
substituted cysteine accessibility method (SCAM) [274]. This assay based on the mutation the 
cysteine residues in the receptor that are not responsible for ligand binding to serine. While the 
residues that are responsible for ligand binding (in the binding pocket) mutated to cysteine 
.Therefore, the sulfhydryl groups of the mutant cysteine residue were reacted with 
methanethiosulfonate reagents (MTS) and then the mutated receptor was tested. The study 
revealed that cysteine (89) is located in the boundary binding cavity of the water accessible surface 
[274]. The mutation showed that cysteine (89) was required for binding pocket of CB2.  
Residues in the third helix: 
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      In a chimeric receptor studies of the third transmembrane domains of CB1 and CB2, the third 
helix of CB1 was replaced by the third helix of CB2 in order to elucidate the role of the 
corresponding region to receptor binding for several types of ligands. There was a notable 
enhancement in the binding of amino alkylindoles AAI such as WIN 55,212-2, JWH 015, and 
JWH 018 to chimeric CB1 receptors compared to wild type CB1 receptors. Moreover, the data 
illustrated that amino acids in TM3 is important for the selectivity of several compounds to both 
CB1 and CB2. They concluded that after mutating glycine 195 in CB1 to the corresponding serine 
in CB2, both amino acids play a critical role in the binding to the mutant receptor to AAI [275]. 
      The lysine 192 residue in the TM3 domain of the CB2 receptor is conserved between the CB1 
and CB2 receptor. In CB1, lysine 192 is considered to be an important residue for the binding 
recognition of several agonists except WIN 55,212-2 [276]. However, a single mutation of the 
corresponding to lysine 109 in CB2 for alanine or arginine shows no significant effect on the 
binding of CP55,940, WIN 55,212-2, or THC. In contrast, JWH-015, exhibited a 10-fold reduction 
in binding [261]. The agonists exhibited comparable functional coupling to G proteins. Based on 
modeling studies, serine 112 provides a critical hydrogen bonding interactions in the K109A 
mutant. The CB2 double mutant of K109A/S112G lost the ability to bind to CP55940, 9-THC, 
and anandamide, but retained affinity for Win55,212-2 and JWH015. The receptor function was 
abrogated for CP55,940 and drastically reduced with Win55,212-2 [261]. In a different study of 
aromatic CB2’s micro-domain, by mutating the phenylalanine at 3.36 to alanine or tryptophan had 
no effect on the binding affinity for CP55,940, HU210, WIN55,212-2, anandamide, or SR144528. 
The F117A was an exception and produced increases in the affinity for SR144528 [277]. 
   DRY motif (Asp-Arg-Try) at the end of TM3 is a highly conserved residue among GPCR family 
A. On other member of GPCRs receptors of this class, glutamic acid is found instead of aspartic 
60 
 
acid. This motif is the connection between the third transmembrane helix and  the intracellular 
loop [41]. It is believed that the DRY motif is responsible for receptor activation of class A GPCRs 
and play a crucial role in keeping GPCRs in an inactive conformation [243], ligand binding, and 
downstream signaling [41]. Rhee et al. carried out a mutation study for all amino acids of the DRY 
motif (DRY130-132AAA) and D130A. Their data indicated that DRY130-132AAA and D130A 
markedly reduced  the binding of cannabinoid agonist [3H] HU-243 compared to wild type CB2 
receptors, whereas R131 and Y132 were not involved in the binding function. Moreover, the effect 
of the R131A mutant for inhibiting cAMP was weak using HU-210 and WIN55,212-2. On the 
other hand, the Y132A mutant showed partial but not complete reduction of downstream signaling. 
     Song et al. [278] tested the role of R131 in single transduction of CB2 receptor .They elucidated 
the importance  of  D130 in the DRY motif, together with A244 in TM 6  to maintain  the receptor  
in an inactive conformation (R form). Their data was comparable to previously reported data for 
effect of the R3.50A mutation on receptor binding affinity for HU-210, WIN55212-2, and 
anandamide. In contrast, the R131A mutation resulted in the abrogated functioning of G-protein 
signaling. In addition, the D130A and A244E mutations led to the complete loss of ligand binding, 
which may be due to changing of receptor conformations. Additionally, the results also indicated 
that both mutants abolished G-protein signaling by HU210, WIN55212-2, and AEA, and led to 
the loss of the constitutive activity. The data demonstrated that the D130A and A244E mutations 
had nothing to do with restraining the receptor in an inactive form which is contrary to the current 
hypothesis  [278].  
Mutations of fourth helix, second extracellular loop, and fifth helixes: 
  A series of chimeric studies between CB1 and CB2 were carried out to identify the domains that 
are responsible for binding SR141716A in CB1and SR144928 in CB2 [271, 279]. The studies 
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demonstrated that fourth and fifth helixes of CB1 are important for binding recognition of the 
antagonist. Furthermore, exchanges of the fourth transmembrane, second extracellular loop, and 
fifth transmembrane between both receptors led to the loss of binding of CP 55,940 for cells 
expressed in CB2 receptors but not CB1. The same regions of CB2 were shown responsibility for 
the binding affinity of SR144928 and WIN 55,212-2. In addition, having the entire second 
extracellular loop of CB1 placed by CB2 receptors caused elimination of binding of the agonist 
CP55940. Unlike CB1, mutations to cysteine 174 and cysteine 179 to serine in the E2 loop of CB2 
abolished the binding of CP55,940. The same mutations in CB1 prevent the receptor from being 
expressed at the cell surface [271, 279]. 
      GPCR studies of have shown that among the fourth transmembrane domains, tryptophan is a 
highly conserved residue [280-282]. Rhee et al. studied the effect of the mutations Trp at positions 
158 and 172 with several different side chains on binding and signal transduction. Different 
aromatic amino acids residues at TM4 in also had been subjected to the mutations including W172 
and W158. The study elucidated the importance of the aromatic side chain, with or without a 
hydroxyl group. They found that W158A and W158Y mutation receptors expressed in the COS-7 
cell line led to loss of binding activity for [3H] HU-243. Morover, both mutations showed subtle 
agonist-induced inhibition of cAMP by HU-210 or WIN55,212-2. On the other hand, W158F 
retained binding activity for HU-243 and the same signaling activity as wild type. In the case of 
mutating Trp172L, the mutant does not bind to [3H] HU-243, and in W172A mutants, slightly 
binds to [3H] HU-243, compared to the wild receptor. In addition, no inhibition of cAMP was 
observed for W172L, and little but insignificant for W172A, consistent with binding results. In 
contrast, W172F and W172Y mutants showed almost the same binding pattern and similar 




    In chimeric studies of CB1 and CB2, it has been proposed that TM5-2EL-TM5 are involved in 
agonist and inverse agonist binding. In addition, mutational and molecular modeling analysis 
carried out in these regions aim to discover the binding pocket of the inverse agonist, SR 144528 
[283]. Mutating S161 and S165 to alanine, and C175 to serine led to the elimination of SR144528 
binding activity. However, the binding activity of S161A and S165A mutants remains unaffected 
for CP 55,940 and WIN 55,212-2. The C175S mutation, on the other hand, did not alter the binding 
of CP55,940 but exhibited a significant reduction in binding affinity for WIN 55,212-2. The author 
suggests that S161 and S165 have direct hydrogen bonding with SR144528, and Cys175 may dip 
down toward the pocket to make direct π-π interactions with the inverse agonist. Other residue 
mutations have also been investigated in this study including V164I in 4TM, R177S in 2EL, and 
S193G in TM5. The results showed no significant effect on the binding affinity of agonists (CP 
55,940 or WIN 55,212-2) or inverse agonists (SR144528) [283].  
Residues in the fifth helix: 
   McAllister et al. performed mutation studies to test the role of conceived tyrosine residues in 
both CB1 and CB2. Using the Monte Carlo/Stochastic dynamics mixed methods that they 
concluded the presence of the aromatic ring at position 275 in CB1 and 190 in CB2 was crucial 
for maintain ligand affinity. Tyrosine was mutated to phenylalanine or isoleucine, resulting in 
comparable results for saturation binding to the Y190F mutants, but no specific binding of [3H] 
CP55,940 to the Y190F. Using different ligands, such as THC, anandamide, JWH 015, JWH 051, 
and WIN 55,212-2 revealed that mutant Y190F led to an approximate 24-fold reduction in binding 
affinity of anandamide to the CB2 receptor. Thus, reduction may be attributed to lose H-bonding 
interactions with the cannabinoid ligand. However, the same mutants did not significantly change 
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the binding affinity of other ligands nor do they impacted signaling transduction. In contrast to 
Y190F, mutating tyrosine 190 to isoleucine led to a loss of binding affinity and abolished 
functional activity [263]. 
     Based on computer modeling and mutagenesis studies, Zhang et al. postulate that both aromatic 
and hydrogen bond interactions of these residue to W194 are important for ligand binding of both 
WIN55212 and SR144528 as well as  for signal transduction. Therefore, W194 was substituted 
with tyrosine, phenylalanine, or alanine. The W194Y mutant retained of the binding affinity of 
CP55940, whereas it caused an eight-fold and five-fold reduction in binding capacity for both 
WIN55212-and the inverse agonist, SR144528, respectively. In addition, the W194Y mutation 
also caused a significant reduction in signal transduction i.e., agonist-induced inhibition of cAMP. 
Other mutations, namely the W194A and W194F mutations abolished the binding affinity for all 
ligands as well as disrupted of downstream signaling. Together these results suggest that W194 is 
crucial for activation of the CB2 receptor [284]. 
     It has been reported that WIN55212-2 has higher binding affinity to CB2 receptors than CB1 
[265, 285]. In the fifth transmembrane region, molecular modeling was carried out to clarify the 
potential interaction site between WIN55212-2 and resides at position 5.46 in both CB1 and CB2. 
Based on the amino acid numbering system[286] , the amino acid with aliphatic side chain, valine, 
that was replaced by phenylalanine in CB1, whereas CB2, aromatic residue phenylalanine was 
mutated to valine. Such a mutation will disrupt the aromatic stacking of CB2 with WIN55212-2. 
The CB2 F197V mutant caused a 14-fold decrease in WIN 55,212-2 binding affinity and it 
exhibited an approximate a 15-fold decrease in cAMP accumulation. In contrast, the CB1 the 
V282F mutation increased the affinity of WIN55212-2 by ~12-fold and a 13-fold enhancement of 
signal transduction. In both mutations, no change was observed in the binding affinities of HU-
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210, CP55940, or AEA [265]. 
      Unlike the vast majority of GPCRs, cannabinoid receptors have leucine at position 5.50 instead 
of Proline. Since conserved tyrosine 209 is located near the third transmembrane helix, which has 
been shown to have a potential role in downstream signaling, Song et al. speculated that this is 
important for the function and conformation of the receptor. Y209A mutant receptors show little 
reduction in binding affinity for WIN-55,212-2, HU-210, and anandamide, and that was attributed 
to a change in structure conformation. On the other hand, mutant L201P eliminated the binding of 
agonists. Moreover, both L201P and Y209A mutants led to a complete loss of the ability of 
cannabinoid agonists to inhibit forskolin-induced cAMP. The results suggest that 5TM, lacking 
proline and tyrosine 5.58, are important for CB2 function [287]. 
 Residues in the sixth helix: 
    Using the substituted-cysteine accessibility method (SCAM), Nebane et al. were able to identify 
key binding site residues in the sixth transmembrane domain [267]. SCAM is based on the 
interactions between ionized cysteine and methanethiosulfonate reagents. These reagents react 
more strongly with ionized cysteine in the water accessible regions than with un-ionized cysteine 
located in TM domains. Some mutant residues lost their ability to bind to CP55940. D630 (240)N 
and D630(240)C mutant CB2 receptor led to disruption of the interaction with R3.50(131) in the 
third helix, causing complete loss of the binding and functional activity of the receptor. Highly 
conserved tryptophan W6.48 (258) shows that it is crucial for receptor activation through the 
CWXP motif in rhodopsin-like GPCRs. Previously, this residue in CB1 was important for 
WIN55212-2 and SR141716A binding affinity [38]. Mutating this residue to alanine or 
phenylalanine leads to failure to bind to ligands and downstream signal elimination [277]. It is 
believed that P6.50 (260) is responsible for keeping the receptor shape. Mutation of this residue to 
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cysteine abolished of the ligand binding affinity and abrogated of signaling by changing helix 6 
topology. Given that serine 6.58(268) is involved in interacting with the third extracellular loop, 
the S6.58 (268) C mutant eliminated binding affinity. The study not only demonstrates the 
important residues in ligand binding and receptor functional activity but also identified the water 
accessible amino acids in the binding crevice. Among 34 consecutive residues in TMH6, V6.51 
(261), L6.52 (262), L6.54 (264), M6.55 (265), L6.59 (269), and T6.62 (272) mutant residues show 
significant reduction in binding affinity compared to C2.59(89)S, a background mutant that is not 
sensitive to the methanethiosulfonate ethylammonium reagent. [267]. 
      The same group also investigated the effect of mutating aspartic acid at position 6.30 on the 
binding affinity and signaling of both CB1 and CB2 receptor [288]. The study also speculated the 
participation of these residues in activation of the receptors through “ionic lock”. Neutralizing the 
negative charge by asparagine mutation D6.30 (240)N had  comparable binding affinity for 
CP55,940 to the wild type and also maintained the inhibition of cAMP accumulation.. This study 
concluded that D240 does not maintain a salt bridge and thus may not be critical for maintaining 
the receptor in the inactive form [288].  
    Another studies of the DRY motif and alanine at position of 244 demonstrated their importance 
to signal transduction and its possible involvement in maintenance of the receptor in the inactive 
phase. Feng and Song showed that the A244E mutant CB2 receptors lost the binding of [3H] HU-
243, [3H] WIN55212-2, or [3H] CP55940. Signaling was significantly reduced using WIN55212-
2 and HU-210 and eliminated for anandamide. These results suggest that D130A and A244E 
mutants are not involved in constitutive activation of the receptor [278]. 
Residues in the seventh helix: 
      Serine 285 and S292 at helix 7 had been tested for their ability to make H-bonds with a 
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hydroxyl group of the classical cannabinoid agonists, HU-210 and CP55940, in binding and 
signaling assays. The study conducted by Rhee et al. showed that mutation S285 and S292 to 
alanine caused about 12-fold reduction in the binding affinity of S285A and a 3-fold decrease in 
the binding affinity of S292A for [3H] Hu-243. The functional activity assay for the S285A mutant 
has similar inhibition of adenylyl cyclase activity as the wild type using HU-210 and CP55940 for 
agonist-induced inhibition of AC activity. However, this was not the case for S282A, where signal 
transduction was eliminated using HU-210 and revealed less affinity for the reduction in AC 
activity compared to wild type using CP55940. Interestingly, no changes have been reported in 




Figure 3-1. 2D diagram for mutations and receptor chimera studies of CB2. 
Previse literature CB2 amino acid mutations. Blue circles- single mutated amino acids of CB2 receptor. Red circles-chimeric CB2 
receptor, purpose of replacing TMH3 of CB2 receptor with THM3 of CB1 receptor [275]. Green circles, replacing TMH4-ECL2-TMH5 
of CB2 with that of CB1 [271, 279]. All mutation adapted from [272, 273]. The figure generated using: http://www.gpcrdb.org/ [289, 
290].    
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Table 3. Updated list for the mutations studies in CB2.  The list shows the important residues for their ligands binding, recognition, and signaling 
transduction.  



















CB2: No change (CP-55,940, ∆9-THC, 
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D80N mutation signaling abolished by WIN 
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K109A: No effect on binding to 9-THC, CP-
55,940, WIN 55,212-2, and anandamide. 
Reduction in binding affinity for JWH015 but no 
effect on signaling. 
K109R: No effect on binding or signaling. 
K109A/S112G: Loss of ability to bind to 
CP55940, 9-THC, and anandamide, but retained 
affinity for Win55212-2, JWH015. Signaling 
abrogated using CP55940 and drastically reduced 
in function using WIN 55,212-2. 
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V113E and V113L: Mutation led to loss of 
binding affinity and signal transduction.  
 
V113:  In this position, 
needs to be a 
hydrophobic side chain 

















F117A, Y: Binding remains unchanged for all 
ligands compared to wild type. However, F117A 
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DRY130-132AAA and D130A:  Binding is 
significantly decreased, and impairment of    
signaling function activation by HU-243 and 
WIN 55,212-2. 
R131A: No effect in binding to both HU-243 and 
WIN 55,212-2. Inhibition of adenyl cyclase was 
slightly affected more in the case of HU-210 and 
less for WIN 55,212-2.  
Y132A: No effect in agonist binding; signaling 
was notably affected.  
D130: Important for 
binding activity and 
signal transduction. 
 
R131: Slightly affected 
downstream signaling. 
 
















R131A: No change in binding to agonist 
compared to wild type; signaling abolished using 
same agonists. 
D130A and A244E: Loss of binding and 
signaling for agonists. Also does not contribute to 
activation of receptor. 
D130A, R131A, and A244E: Leads to lost signal 
transduction. In addition, does not restrain 
receptor to inactive state. 
R131: Plays role in 
signal transduction and 
constitutive activity.  
D130 and A244: 
Important for receptor 
conformation. Not 
involved in ligand– 
receptor interactions. 
D130, R131, A244: 
Important for 


























CB2/1(TM4-2EL-TM5) and CB2/1(2El): The 
exchange leads to loss of binding for CP55,940 
and change in ligand affinity for WIN 55,212-2, 
SR144928. 
 




























W158A/Y: Loss of binding to agonist (HU-210) 
and signaling was abolished using HU-210, 
WIN55,212-2. 
 
W158F: No effect on the binding and signal 




W158: Important for 











S161 and S165 
 
Agonists: 




S161A and S165A: Loss of binding activity of 
SR144528 and no effect on binding for CP 
55,940 and WIN 55,212-2. 
 
V164I: No effect on binding for CP 55,940, WIN 
55,212-2, and SR144528. 
 
 
S161 and S165: 
Important residues for 


















W172L/A: Lost binding for Leu mutant; 10% of 
the binding was eliminated in the case of Ala 
mutation signaling. 
 
W172F/Y: Same binding capacity as wild type 
and same adenyl cyclase inhibition using HU-
210, WIN55,212-2, or 2-arachidonoylglycerol. 
   
 
 
W172: Important for 

























C174S and C179S:  Failed to bind to WIN55212-
2, 9-THC, and anandamide. 
 
C175S: Loss of SR 144528 binding; no change in 
CP 55,940 binding and 8-fold reduced binding 
capacity of WIN 55,212-2. 
R177S: No effect on binding for CP 55,940, WIN 
55,212-2, and SR144528. 
 
C174 and C179: 
Important for agonist 
binding (CP55,940, 
WIN 55,212-2, 
anandamide,  ∆9-THC  
 























F183Q/V: Mutation led to loss of binding and 
signal transduction using cAMP assay.  
 
ECL aromatic ring 
























JWH 015, JWH 051 
 
Y190F: Leads to about 24-fold reduction in 
binding of anandamide whereas no change in 
binding to other ligands (CP 55,940, WIN 
55,212-2 ∆9-THC, anandamide, JWH 015, JWH 
051) and no effect on signals.  
 
Y190I:  Lost binding for ligands and signaling 
was eliminated. 
 
Y190:   Important for 
anandamide binding 
through H-bond.  
 
Y190: Aromatic residue 
in this position is 

















L192A and L192S: mutation to polar side chain 
led to loss the receptor binding and function 
ability. Whereas hydrophobic side chain mutation 
retained the receptor binding and functionality. 
L192 : At this position 
need to hydrophobic 
side chain to recognize 












S193G: No effect on binding for CP 55,940, WIN 






















W194Y: No effect on CP 55,940 binding affinity; 
8-fold reduction in WIN 55,212-2 and 5-fold 
reduction in SR144528 binding affinity. 
Signaling is reduced using agonists. 
 
W194F and W194A:  Binding not detected for all 
ligands. Complete elimination of signaling.  
 
W194: plays role in 
















CP 55,940, HU-210, 
WIN 55,212-2, 
anandamide 
F197V: No change in the binding affinities of 
HU-210, CP55940, and AEA; decreased affinity 
of WIN55212-2 for CB2 by 15-fold and 15-fold 
decrease in signaling. 
 
F197: Important for 













WIN 55,212-2,  
anandamide 
L201P: Binding affinity was lost for ligands and 
signaling was eliminated.  
 
Y209A: Little effect on binding affinity for HU-
210, WIN 55,212-2, anandamide; the signaling 
was abolished.  
L201: Important for 
receptor functions. 
Y209: Mutation Y209 
causes conformational 
change leading to 


























D240N: Neutralizing the charge shows neither 
reduction in binding affinity or alteration of 
signaling. However, it is important for activation 
of the receptor. 
 
D240C: Disrupts the interaction with R131 in 
third helix causing complete loss of binding and 
function of the receptor. 
 
D240: Importent for 
receptor activation. 
Mutation of this residue 
causes conformational 




D240: Mutation to Cyc 
leads to loss of H-bond 




















A244E: Loss of binding affinity for HU-243, 
WIN55212-2, or CP55940; significant reduction 
in signal transduction using WIN55212-2 and 
HU-210 and completely abolished signaling 
using anandamide. 
 













W258C, F, A:  All mutations led to lost binding 
affinity. These indicate that the aromaticity at 
position 5.43 is critical for ligand binding. 
 
Trp258 is part of 
CWXP motif which is 


















P260C:  Loss of binding due to change in 6TMH 
structure. 
  
S268C: Loss of binding due to destabilization of 
receptor.  
P260: Produces kink in 
the helix; mutation will 
make change in the 
helix geometry. 
S268: Making H-bond 
with ECL3 to stabilize 
















V261C, L262C, L264C, M265C, L269C, and 
T272C: Using substituted-cysteine accessibility 
method leads to significant inhibition in binding 
affinity of CP-55,940. 
V261, L262, L264, 
M265, L269, and T272 
are on the water-
accessible surface of 




























F281K:  Mutation led to loss of binding and 
function of the receptor detected by cAMP assay.  
F281 making strong 
π−π interaction with 



















Single mutant C284A, C284S, C288A, and 
C288S shows significantly low binding of AM 
1336 and AM6720 compared to wild type 
binding.  
 
Double mutant (C284A.C 288A) or (C284S C 
C288S) will abolish covalent binding of AM 
1336 compared to wild type binding. 
Only C288A or C288s but not C284A or C284s 
show abrogated binding with AM6720. 
 
C284 and C288 
important for binding of 
AM1336 and function.  
 
C288 important for 















S285A: Important for binding of HU-243; 
mutation causes about 13-fold decrease in the 
binding affinity; not crucial residue for AC 
activity using HU-210, CP55940, and 
WIN55,212-2. 
 
S285:  Important for 














S292A:  Important for binding of HU-243; 
mutation causes about 3-fold decrease in the 
binding affinity; important for AC activity of 
classical cannabinoids (HU-210 and CP55940) 
but not WIN55,212-2. 
S292: Important for 
binding and signal 















Y7.53A:  loss of binding for HU-210, 
WIN55,212-2, AEA, and HU-243; loss of 
downstream signaling by HU-210 and 
WIN55,212-2. Reduced signaling using  
AEA. 
Y299: Part of Y299 
within the NP(X) Y 
motif motif, which is 
important for ligand 
binding and signaling. 
[293] 
 
C terminal  
 
C313 








C313A and C320A:  No effect on binding; 
significantly reduces signaling for WIN55,212-2 
and  HU-210. No signal transduction detection 
using AEA. 
C313 and C320 
mutations markedly 
reduce functional 






3.2 CASE STUDY: IN SILICO MODELING AND SITE-DIRECTED 
MUTAGENESIS VALIDATION FOR ROLE VALINE 3.32 (113), 
PHENYLALANINE 182, 281 AND LEUCINE (192) IN LIGAND RECOGNITION 
AND DOWNSTREAM SIGNALING ACTIVITIES 
    We performed molecular modeling and docking studies to predict a putative binding pocket and 
associated ligand-receptor interactions for human cannabinoid receptor 2 (CB2). Figure 3-2 shows 
a schematic flow diagram of the steps for testing the important residues from 3D models and ending 
with a study of the binding and function of the receptor CB2 receptor.  Our data demonstrated that 
two hydrophobic residues came in close contact with three structurally distinct CB2 ligands: CP-
55,940, SR144528 and XIE95-26 [291] (Figure 3-3). In addition, modeling and molecular 
dynamics simulation results predicted two new residues, Phe183 in extracellular loop 2 and 
Phe281 in the seventh transmembrane domain, that were important for SR144528 and CP55940 
binding to CB2 [40]. Site-directed mutagenesis experiments and subsequent functional assays 
further implicated the roles of these residues in the ligand binding and downstream signaling 
activities of the CB2 receptor [40, 291]. Seven different point mutations were introduced to the 
wild type CB2 receptor: V113E, V113L, F183Q, F183V, F281K L192S and L192A. Our results 
demonstrated that mutation of Val113 to a glutamic acid and Leu192 to a serine led to the complete 
loss of CB2 ligand binding as well as downstream signaling activities. Substitution of these 
residues with those that have similar hydrophobic side chains such as leucine (V113L) and alanine 
(L192A), however, allowed CB2 to retain both its ligand binding and signaling functions. 







Figure 3-2. Steps involved in the prediction and validation of the important CB2’s 
residues for the binding affinity and functionality of the receptor. 
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 properties for F183 in 2ECL using a polar amino acid such as glutamine at 281 in at the 7TM loop 
using valine and lysine, led to loss of binding affinity.  Our modeling results validated by 
competition binding and site-directed mutagenesis experiments also suggest that residues V113, 
F183, L192 and F281 play important roles in ligand binding and downstream signaling 
transduction of the CB2 receptor [40, 291]. 
 
3.2.1 Materials and Methods 
3.2.1.1 Molecular modeling using I-TASSER protein structure prediction server  
     A CB2 homology model was constructed from the antagonist-bound A2A receptor (3EML.pdb) 
[294], human dopamine D3 receptor (3PBL.pdb) [295], bovine rhodopsin (1L9H.pdb and 
1F88.pdb) [296, 297], human beta2-adrenergic receptor (2RH1.pdb) [63], and the turkey beta1-
adrenergic receptor (2Y00.pdb and 2VT4.pdb) [298, 299]  using the I-TASSER protein structure 
prediction server [300, 301]. Five models were obtained using the I-TASSER prediction server, 
Figure 3-3 .Structures of Cannabinoid ligands. 




and the model (model 1) with the highest confidence score (C-score) -0.96 was selected as the 
optimal model. It was further minimized using a conjugate gradient method with the AMBER 
force field (AMBER7 FF99) defined in the Tripos Sybyl software [302]. The minimization was 
run for 500 iterations and the maximum derivative of energy was set to 0.05 kcal · mol-1 · Å-1. 
Further molecular modeling studies were then carried out on the minimized CB2 homology model 
to predict a putative binding pocket and potential ligand-receptor interactions such as hydrophobic 
interactions, hydrogen-bonding and pi-pi interactions via a flexible docking protocol previously 
reported [264, 303]. Briefly, in order to predict a putative binding pocket, MOLCAD analysis 
[302] was performed on the 3D homology model to find a solvent-accessible cavity around 
important binding residues including SER112, TRP172, TYR190, TRP194, PHE197, TRP258, 
and SER285 reported in the literature [261-268]. Once a pocket was defined, flexible docking 
simulations were performed using the Surflex-Dock module [302]. CB2 ligands CP-55,940, 
SR144528 and XIE95-26 were docked into the putative pocket. During the flexible docking, the 
receptor structure was fixed while ligands were allowed to rotate on single bonds and move 
flexibly within the tentative binding pocket. The docking mode was GeomX and other default 
docking parameters defined in the Surflex-Dock module [302] were  as follows: additional starting 
conformations per molecule and angstroms to expand the search grid were set to 6, the maximum 
conformations per fragment were set to 20, maximum number of routable bonds per molecule was 
100, the maximum number of poses per ligand was set to 20, and the minimum RMSD between 
final poses was 0.50. Pre-dock minimization, post-dock minimization, molecule fragmentation, 
ring flexibility, and soft grid treatment were turned on. The binding interaction energy was 
calculated to include van der Waals, electrostatic, and torsional energy terms defined in the Tripos 
force field [302] . 
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3.2.1.2 Modeling, molecular dynamics simulation based on based on ten known 
crystal structures of GPCRs 
     The second approach for building  CB2 models was the 3D molding method developed  in 
different studies conducted in our lab [40]. This model is based on ten known GPCRs crystal 
structures (including Class A and Class B) that were used to build the new CB2 modules namely 
(bovine rhodopsin,  SMO,CXCR4, β1AR, β2AR, A2AAR,  H1R,  M2MAR, S1P,  D3R) for more 
details see (Table 16, Appendix A). The structure of the CB2 receptor was truncated from both 
N, C terminal and 3ICL before alignment with other GPCRs. Then manual alignment for the 
receptor from 2ECL to TM5 was conducted to insure that there would be no gaps within the helix 
sequences. We used Sybyl-x1.3 for generating the 3D moles and energy minimization. Then in 
order to choose the most reasonable conformation for all these CB2 models, we utilized molecular 
dynamics. The lowest energy 3D models were chosen for more energy minimization and 
validation. Using the Surflex-Dock program in SYBYL, we made a training set for the validation 
of the 3D models. 1000 compounds (17 active in house compounds, 3 known ligands and 980 
randomly chosen compounds from National Cancer Institute (NCI) Database) were used and 
docked into the receptor. The MOLCAD program was used to determine the binding pocket for 
the models. For more detailed information about the methods please see [40]. 
3.2.1.3 Amino acid numbering scheme 
     Ballesteros and Weinstein have suggested a numbering system, which was adapted in the study 
[304]. In short, each amino acid is indexed by its helix number followed by a two-digit number. 
The high conserved residues in a transmembrane domain are given the value of “0.50”. Then the 
amino acids positions are assigned relative to this reference amino acid in the helix. For example, 
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Pro7.50 (296) is the highly conserved residue in transmembrane helix7 of human cannabinoid 
receptor 2 and therefore the residues follow it is Val7.51 (297). 
3.2.1.4 Mutagenesis experiments 
   Mutations of the CB2 receptor were carried out using the QuikChange site-directed mutagenesis 
kit (QuikChange; Stratagene, CA) according to the manufacturer’s recommendations. A point 
mutation was performed individually to the human CB2 expression plasmid pcDNA3.1+3X – HA-
hCB2 (Missouri S&T cDNA Resources Center), which was used as a template. Three PCR steps 
were used to introduce the mutations. Firstly, Oligonucleotide primers encoding the desired amino 
acids were annealed to the denatured DNA template and nicks were repaired with PfuTurbo DNA 
polymerase with high fidelity. The list of the primers used in these studies are shown in Table 15. 
Secondly, the PCR products were treated with restriction enzyme DpnI endonuclease to digest 
methylated and hemi-methylated DNA (the parental DNA template). Finally, the mixture was 
transformed into XL10-Gold ultra-competent cells (QuikChange; Stratagene, CA) to convert 
ssDNA to double stranded plasmid DNA. The mutant CB2 plasmids were subsequently confirmed 
by DNA sequencing. 
3.2.1.5 Transfection and cell culture 
    Chinese hamster ovary (CHO) cells were maintained in RPMI-1640 (Gibco Laboratories, 
Grand Island, NY) containing 10% fetal bovine serum (FBS, GICBO) in a 5% CO2 humidified 
incubator at 37 °C. The transfection was performed when the CHO cells reached 90% confluence 
in 60-mm culture plates. According to manufacturer’s protocol (Invitrogen), 8.0 μg of mutated 
human CB2 receptor cDNA plasmid and 20 μL of the transfection agent lipofectamine 2000 were 
separately diluted in 0.5 mL of Opti-MEM reduced serum medium, mixed, incubated for 20 min 
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at room temperature, and then added to the cell culture for stable transfection. After 4 hours of 
incubation, the medium was refreshed and the cells were incubated for an additional 24 hrs. The 
transfected cells were selected by conditional incubation in the presence of 800 μg /mL G-418 
(Gibco) for 5 days. The selected cells were then maintained in the medium containing 220 μg /mL 
of G-418. 
3.2.1.6 Cell harvesting and membrane preparation 
     Highly confluent culture plates were placed on ice prior to harvesting. The plates were rinsed 
twice with phosphate-buffered saline (PBS). Then the cells were collected by scraping and 
centrifuged at 500 x g for 5 min at 4°C. The cell pellets were resuspended in 5 mL of membrane 
preparation buffer (50 mM Tris–HCl pH 7.4, 5 mM MgCl2, 2.5 mM EGTA and 200 mM sucrose) 
and homogenized with a Polytron PT1600E Homogenizer (Kinematica, Littau-Lucerne, 
Switzerland). The lysed cells were centrifuged at 68,000 g for 5 min at 4 °C and the supernatant 
was collected. The remaining pellets were resuspended with membrane buffer and centrifuged 
three times. All supernatants were combined and centrifuged at 13,000 x g for 90 min at 4 °C. 
Pellets were then collected and re-suspended in membrane preparation buffer for competition 
binding assays. 
3.2.1.7 Western Blot Analysis 
     Cells were lysed in Radio- immunoprecipitation assay buffer (RIPA) composed of 25 mM Tris-
HCl, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS (Thermo, NP 89901) and 
protease inhibitory cocktail  (Thermo Scientific, P1861281), and centrifuged at 13,000 x g for 15 
min at 4 °C. Supernatants were collected and protein concentrations were determined using the 
bicinchoninic acid protein assay kit (Pierce, Rockford, IL). Each sample (25 μg each) was 
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solubilized in SDS-sample buffer, separated on a 10% SDS–PAGE gel and transferred onto 
polyvinylidene difluoride membranes (PVDF). The membrane then was blocked with 0.1% Tween 
20 in PBS (PBS-T) containing 5% non-fat dried milk for 1 hour and incubated in a solution of 
primary antibody diluted 250-fold (goat polyclonal antibody; Thermo Scientific, PA5-18428) for 
1 hour at room temperature. After 3 washes with PBS-T for 10 min, the membrane was incubated 
in horseradish peroxidase-labeled secondary antibody solution (Santa Cruz Biotechnology, Santa 
Cruz, CA, and 2000 x dilute) for 1 hour at room temperature. Following 3 additional washes with 
PBS-T, the membrane was developed with using ECL Western Blotting Detection Reagents (Super 
Signal West Femto, Thermo Scientific). 
3.2.1.8 Competition binding assay 
     The protein concentration was measured using Pierce BCA Protein Assay (Rockford, IL). Three 
structurally distinct, representative cannabinoid ligands were used (Figure 3-3) in this study. CP-
55,940 (CB agonist) and SR144528 (inverse agonist) were obtained from RTI International 
(Research Triangle Park, NC) and XIE95-26 (inverse agonist) was synthesized recently in our lab 
[269]. The ligand binding was performed as previously described [305]. Briefly, non-radioactive 
(or cold) ligands were diluted in binding buffer (50 mM Tris-HCl, 5 mM MgCl2, 2.5 mM EGTA, 
0.1% (w/v) fatty acid free BSA, pH 7.4), supplemented with 10% dimethyl sulfoxide and 0.4% 
methyl cellulose. Each assay plate well contained a total of 200 μL of reaction mixture of 5 μg of 
membrane protein, 3 nM of labeled [3H]-CP-55,940 (RTI International Research Triangle Park, 
NC) and concentrations of unlabeled 3 ligands described above. Plates were incubated at 30 oC for 
1 hour with gentle shaking. The reaction was terminated by rapid filtration through Unifilter GF/C 
filter plates using a Unifilter Cell Harvester (PerkinElmer, NL). After the plate was allowed to dry 
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overnight, 30 µL of MicroScint-0 cocktail (PerkinElmer) was added to each well and the 
radioactivity was counted using PerkinElmer TopCounter. All assays were performed triplicate in 
duplicate wells and data are represented as the mean ± S.E.M. Bound radioactivity data was 
analyzed for Ki values using non-linear regression analysis via GraphPad Prism 5.0 software.  
3.2.1.9 cAMP assay 
       A LANCE® cAMP 384 kit (PerkinElmer) was used to detect cAMP as previously described 
[264]. Briefly, the assay is based on competition between a Europium-labeled cAMP trace 
complex and sample cAMP for binding sites on cAMP-specific antibodies labeled with a 
fluorescent dye. The energy emitted from the Eu-chelate is transferred to the dye on the antibodies, 
which in turn generates a time-resolved fluorescent resonant energy transfer (TR-FRET) signal at 
665 nm. The fluorescence at 665 nm will decrease in the presence of cAMP from test sample. CB2 
WT and mutant transfected CHO cells were seeded in a 384-well white ProxiPlate (Perkin Elmer, 
Bridgeville, USA) at a density of 2500 cells per well in 5 μL of RPMI-1640 medium containing 
1% dialyzed FBS, 100 μg/mL penicillin, 100 U/mL streptomycin and 200 μg/mL of G-418. After 
culture overnight, 2.5 μL of cAMP antibody and RO20-1724 (phosphodiesteras inhibitor) (50 μM 
final concentration) in stimulation buffer (DPBS 1x, containing 0.1% BSA) was added to each 
well, followed by addition of 2.5 μL CP-55,940 (various concentration) in 5 μM forskolin 
stimulation buffer for agonist-inhibited AC activity assay. After incubation for 45 min at room 
temperature, 10 μL of detection reagent was added to each well and incubated for 1 hr at room 
temperature. The fluorescence was detected with a Synergy H1 hybrid reader (BioTek) at 340nm 
excitation/665nm emission. Each cAMP determination was averaged from at least three 
independent experiments, each in triplicate. EC50 values were calculated by nonlinear regression, 
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dose–response curves (GraphPad Prism 5). 
3.2.1.10 Constitutive activation of the wild type CB2 receptors   
     We also evaluated the ability of inverse agonists SR144528 and Xie-95-26 to inhibit the 
stimulated cAMP in the absence of a cannabinoid agonist. Comparatively, we evaluated the agonist 
CP55,940 on decreasing the forskolin stimulated AC activity. The study design was briefly, 
different concentrations of forskolin (10-105 nM) incubated with wild type receptor with and 
without ligands (0.3 μM final concentration). The folds of cAMP accumulation were measured 
using LANCE cAMP kit. The cell preparation and procedure are the same as previously described 
in the agonist-induced inhibition of cAMP production. The constitutive activation has been 
investigated in previous studies [284, 288]. 
3.2.2  Results  
3.2.2.1 Homology modeling and molecular docking 
    A 3D homology model of CB2 was derived with the I-TASSER protein structure prediction 
server. As shown in (Figure 3-4 A) and (Figure 6-4 in appendix A) , a putative binding pocket 
of the minimized CB2 model was found among residues pertaining to helices II, III, V, VI and 
VII. CP-55,940, SR144528 and XIE95-26 compounds were docked into the binding pocket using 
the Surflex-Dock module [302]. (Figure 3-4 B, C and D) shows molecular docking results for 
CP-55,940, SR144528 and XIE95-26, respectively. Several important interactions were observed 
for each ligand. For example: Asn188 and Ser285 are predicted to participate in H-bonding with 
CP-55,940 and XIE95-26 respectively and Leu192, Leu201 and Val 261 exhibit a hydrophobic 
interactions with ligands. We also compared the binding modes between agonist and antagonists. 
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Hydrophilic interactions between the CB2 model and agonist (CP-55,940) were found in the top 
of the binding pocket, while hydrophilic interactions between CB2 and antagonists were found in 
the bottom (or middle) of the binding pocket (Figure 6-4 and Figure 6-5 in appendix A). His95 
and Asn188 formed hydrogen bonds with CP-55,940, while these two residues only formed 
hydrophobic interactions with antagonists, including SR-144528 and our in-house compound 
XIE95-26. Moreover, Ser285 formed hydrogen bonds both with SR144528 (3.5~4.7 Å) and 
XIE95-26 (within 3 Å). However, only hydrophobic interactions were observed between Ser285 
and CP-55,940. In addition, we found that XIE95-26 had closer interactions with Trp258   than 
SR144528. 
     In second approach utilizing MOLCAD 3D models implemented in SYBYL-X 1.3, we 
provided the second potential orthostatic ligand-binding pocket and residues involved in the 
binding pocket of CB2 as shown in (Figure 3-5 A) and (Figure 6-5 in appendix A). Consistent 
with the I-TASSER models and residues previously reported in the literature, the CB2 receptor 
pocket is located between helices III, V, VI, and VII Figure 3-5 B. Beside the orthosteric ligand-
binding pocket, we found a small binding pocket, which was close to the orthosteric one. 
Moreover, a channel connecting these two pockets together can be observed in our model, as 
shown in (Figure 3-6 ). This allosteric pocket was formed by conserved residues including Asn51, 
Val54, Leu76, Ala77, Ala79, Asp80, Ser120, Leu124, Trp258, Asn291, Ser292, Asn295, 
Asn296,Tyr299 present in A2AA receptor [306] and the δ-opioid receptor [75] . this pocket using 
highlighted some residue including Phe87, Phe91, Phe94, Asp101, Phe106, Lys109, Ile110, 
Val113, Phe117, Glu181, Leu182, Phe183, Trp194, Phe197, Trp258, Val261, Met265, Lys278, 






Figure 3-4. Molecular docking of CB2 ligands into putative CB2 binding site using 
I-TASSER protein structure prediction. 
A 3D homology model of the CB2 seven transmembrane helices showing an amphipathic-
binding cavity. B-D Interactions between each ligand and the receptor Magnified views of the 
predicted binding pocket, which show hydrophobic residues such as L201, V261, V113, L192 
predicted to interact with CP-55,940, SR144528 and XIE95-26. In addition, N188 is predicted 





         
Figure 3-5. Potential binding pocked and residues involved in the binding pocket of 
CB2 based on ten known crystal structures of GPCRs. 
A. The potential binding pocket was highlighted in red, which was mainly formed by helices 
III, V, VI, and VII, but also can extend into helix IV. Important residues involved in the 
binding pocket were highlighted in green sticks, which included: Phe872.57, Phe912.61, 
Phe942.64 (not shown), Asp101 (ECL1), Phe1063.25 (not shown), Lys1093.28 (not shown), 
Ile1103.29, Val1133.32, Phe1173.36 (not shown), Glu181 (ECL2), Leu182 (ECL2), Phe183 
(ECL2), Trp1945.43, Phe1975.46, Trp2586.48, Val2616.51 (not shown), Met2656.55, Phe2817.35, 
and Ser2857.39. 
B.  The common residues predicted in both models some of which have been conformed from 



















Figure 3-6. Potential allosteric binding pocket in CB2 model.  
The orthosteric ligand-binding pocket (highlighted in cyan) and the allosteric pocket (highlighted 
in magenta), which was formed by Asn511.50, Val541.53, Leu762.46, Ala772.47, Ala792.49, Asp802.50, 




Allosteric binding site                            
Orthosteric binding site                            
Connecting channel                            
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3.2.2.2 Expression of recombinant human wild type and mutant CB2 in CHO cells 
The expression of wild-type human CB2 and V113E/L, L192S/A and F183V mutants in stably 
transfected polyclonal Chinese hamster ovary (CHO) cell lines was analyzed and confirmed by 
western blot (Figure 3-7). The CB2 receptor is shown as the band corresponding to 41 kDa. 
 
 
Figure 3-7. Western Blot analysis of wild type and mutant h-CB2 receptor 
isoforms in transfected CHO cells. 
Western blot analysis of expression level of WT and mutants Hu-CB2 receptors in 
transfected CHO cells. From left to right: 1-CB2 WT (wild type), 2- V113E, 3-
V113L, 4-F183V, 5- L192S, and 6- L192A.  
 
3.2.2.3 Ligand binding of wild type and mutant CB2 receptors 
      The ligand binding affinity of wild-type and mutant CB2 receptors were determined by 
competitive binding assays using radioactive [3H]-CP-55,940 and three non-radioactive ligands: 
CP-55,940 (agonist), SR144528 (inverse agonist) and XIE95-26 (inverse agonist). Binding data 
(Figure 3-8, summarized in Table 4) indicated that the L192A substitution had no effect on the 
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affinity of CB2 for CP-55,940; whereas the binding affinities of SR144528 and XIE95-26 were 
slightly reduced compared to the wild-type. Similarly, the V113L substitution resulted in a slight 
reduction in CB2 affinity for SR144528, yet no significant effect was observed for CP-55,940 or 
XIE95-26 binding. Substitutions at V113E, F183V/Q, L192S and F281K independently resulted 



















































































































































































































Figure 3-8. Competitive ligand displacement assay for mutant CB2 for agonist and inverse 
agonist. 
Binding profile of (A) for CP55940; (B) for SR144528; and (C) Xie95-26 for WT, V113L and 
L192A. The dynamic range of the binding is show in Table 4. Competitive displacement of the 
[3H] CP55940 was obtained by using an increased amount of unlabelled ligands. Assay was 
performed in duplicate (n = 2). Data represented as mean ± SEM. 
92 
 
Table 4. Cannabinoid receptor ligands binding affinity of wild type (WT) and 
mutant CB2 receptors stably expressed in CHO cells (Ki, nM )* 
 SR144528 CP55940 Xie95-26 










CB2 WT 19 (10-74) 837-2217 0.1 (0.05-0.4) 474-1085 96 (25-362) 752-1246 
V113E ND 975-1027 ND 897-927 ND 888-977 
V113L 2.9 (1.2-8.5) 960-1481 0.7 (0.02-3) 680-1100 411 (105-972) 914-1799 
F183Q ND 988-1007 ND 756-840 NT - 
F183V ND 527-578 ND 527-582 NT - 
L192A 4.8 (2.9-12.5) 1018-1374 2.8 (0.7-7.1) 739-1170 252 (109-580) 762-1101 
L192S ND 888-915 ND 817-1031 ND 756-780 
F281K ND 954-1159 ND 988-1038 NT - 
* Data are the means and corresponding 95% confidence intervals of two independent experiments each 
performed in duplicate. ND: binding not detected, NT not tested.  
3.2.2.4 Agonist-induced inhibition of cAMP production 
      A LANCE cAMP time-resolved fluorescence resonance energy transfer (TR-FRET) 
immunoassay was used to detect the signal from CHO cells stably expressing wild type CB2 and 
four mutant receptors. CP-55,940 was used as an agonist to induce inhibition of cAMP 
production in the presence of 5 μM forskolin and the phosphodiesterase inhibitor RO20-1724 (50 
μM). When the agonist concentration was increased, the inhibition on the forskolin-induced 
cAMP production also increased, resulting in an enhancement of the LANCE signal, which is 
inversely proportional to the concentration of cAMP. These results were congruent with the 
ligand-receptor binding affinity data. EC50 values were 32 nM, 9.7 nM and 0.14 nM for wild-
CB2, V113L and L192A, respectively. Further, V113E and L192S substitutions resulted in a 
complete loss of signal transduction (Figure 3-9). 
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Reading/Receptor WT V113L V113E L192S L192A 
Cells (FK+CP55940) 141.7 to 97.4 132.12-106.7 102.6-91.9 100.9 - 94.1 133.1-96.5 
* The base cAMP was measured in the present of forskolin.
Figure 3-9. Agonist-induced inhibition of forskolin-stimulated cAMP accumulation. 
Agonist-induced inhibition of forskolin-stimulated cAMP accumulation of CB2 WT and all 
mutants’ receptors. (▼) WT- CB2, (▲) V113L, (■) V113E (●) L192A and ( ) L192S. All 
receptors were stably expressed in CHO cells. Data are mean ± S.E.M. of at least two independent 
experiments in triplicate. 






































3.2.2.5  FSK-stimulated 
    The effects of the agonist and inverse agonist (SR144528 and Xie95-26) have been tested on 
the FSK-stimulated of the CB2 receptor (wild type). This effect was assessed by decreasing or 
increasing the levels of forskolin-stimulated cAMP accumulation (shifting on the EC50 value) 
before and after incubation of the cells with 0.3 μM of ligands. In the absent of the ligands the 
forskolin will stimulate the adenylyl cyclase leads to stimulate the cAMP levels. Treatment of the 
CHO cells stably expressing human CB2 WT receptor with CB2 inverse agonists (0.3 μM) led to 
a reduction of the EC50 to 0.2 (0.16–0.25) μM and to 0.18 (0.14-2.4) μM for SR144528 and Xie95-
26 respectively. Whereas treatment with 0.3 μM of CP55940 decreased the forskolin stimulated 
AC activity, with a higher EC50=13.4 (8.5-15.1) μM compared to the no cannabinoid ligand treated 
control (forskolin alone) with EC50=1.38 (1.0–1.8) μM as shown in (Figure 3-10) and Table 5. 















Table 5. Effects of CB2 inverse agonists SR144528, Xie95-26 and agonist CP55,940 on 
constitutive activation of CB2 WT. (EC50, µM). 
Receptor Forskoline alone + SR144528 + Xie95-26 + CP55,940 
Wild Type 1.38 (1.0-1.8) 0.2 (0.16-0.25) 0.18 (0.14-2.4) 13.4 (8.5-15.1) 
 
Figure 3-10. The FSK-stimulated of the wild type CB2 receptor. 
CHO cells expressing CB2 wild type receptor were assayed for cAMP accumulation in the 
presence of a gradient concentration forskolin (10–105 nM) with or without the presence of 0.3 
μM ligands (CP55940, SR144528 and Xie95-26). The results were expressed as percentage of the 
LANCE signal representing forskolin- stimulation cAMP accumulation. The base cAMP 
accumulation was measured in the absence of forskolin. Data shown represent the means and 




    In this study, molecular modeling and mutagenesis experiments were applied to gain valuable 
insights into the effect of certain CB2 residues on receptor binding with agonists and antagonists. 
A 3D homology model of CB2 was first constructed and then further minimized using a conjugate 
gradient method. The minimized model served as the basis for molecular docking studies (see 
Materials and Methods). A putative binding pocket was first predicted via the MOLCAD analysis, 
which suggested the importance of several residues such as SER112, TRP172, TYR190, TRP194, 
PHE197, TRP258, and SER285 that have previously been validated experimentally [261-268]. As 
shown in (Figure 3-4 and Figure 3-5), the putative binding pocket was amphipathic and 
composed of hydrophilic and electrically charged residues, such as Asn188 and His95 near the 
upper part of the pocket facing the extracellular loop 2 (ECL-2) and hydrophobic residues such as 
Val113, Leu201, Val261 and Trp258 near the bottom of the pocket. These results were found to 
be congruent with previously reported studies, which also suggested a hydrophobic binding pocket 
[307, 308]. Receptor chimera studies by Shire et al [279] showed that ECL2 is important for the 
binding of CP55940 to CB2. Replacing ECL2 of CB2 with ECL2 of CB1 resulted in a loss of 
binding of CP55940. A prior report affirmed that this loop dipped down toward the binding site of 
SR144528 to make a π-sulfur interaction with the Cys17 [283]. Therefore, we investigated the 
effect of the aromatic side chain of Phe183 in ECL2 for SR144528 binding. Mutation of Phe183 
in silico, indicated that CB2 did not form strong hydrophobic interactions with SR144528 and 
CP55940. Mutation of Phe183 to the polar uncharged amino acid such as glutamine (F183Q) or to 
a hydrophobic side chain such as valine (F183V) abolished the binding of SR144528 to CB2 and 
CP55940 binding affinity to Phe183 mutated CB2 were also tested, and the similar results can be 
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found in Table 4. Phe183 did not form a π−π interaction with CP55940 and maybe did not form a 
hydrophobic interaction (or a very weak hydrophobic interaction), but the mutations of Phe183 
showed a significant effect for CP55940 binding. We therefore suggested that the mutations of 
Phe183 significantly affected both SR144528 and CP55940 binding affinity. Moreover, some 
residues in ECL2 may have similar effects, including Glu181 (ECL2) and Leu182 (ECL2) [279]. 
     In addition, Phe281 formed a strong π−π interaction with SR144528, but it formed a 
hydrophobic interaction with CP55940. We therefore mutated it to a charged chain such as lysine 
(F281K) to study its influence on CB2 ligand binding. As shown in Table 4, our results showed 
that this kind of mutation led to the complete loss of CB2 ligand binding. Phe281 also had an 
important role in the binding of SR144528 and CP55940 to CB2 through a π−π interaction or a 
hydrophobic interaction. In our model, we found that Phe183 in ECL2, Met265, and Phe281 
formed a strong hydrophobic pocket in the extracellular side of CB2. Mutations of F183Q and 
F281K will change the charge environment, while the mutation of F183V will affect the 
hydrophobic pocket. We suggest that these three mutations will reduce the affinities of ligands on 
CB2. Further, results of molecular docking with the CP-55,940, SR144528 and XIE95-26 ligands 
are shown in (Figure 3-4 B, C and D), revealing other important ligand-receptor interactions for 
each ligand. Specifically, five hydrophobic residues were found to be in close contact with all three 
ligands during docking simulations: Val113, Leu192, Leu201, Val261 and Trp258. Indeed, 
Leu201, Val261 and Trp258 have previously been implicated in the formation of the ligand-
binding pocket [267, 283].  A prior report affirms that residue 3.32 is occupied by a negatively 
charged amino acid in biogenic amine receptors (D2 Dopamine, ß2 Adrenergic and m3 
Muscarinic) and that it is essential for recognition and binding of endogenous amines [309] [310]. 
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In an attempt to resemble the functionality of this residue in amine receptors, Jiang et al. substituted 
endogenous V83 (position 3.32) with aspartic acid (D) in the A2a adenosine receptor. The V83D 
mutant A2a was unable to bind to any ligand tested. Interestingly, substitution of the same valine 
residue with leucine (V83L) did not significantly affect biding with any ligand with respect to the 
wild-type A2a. Using a similar approach, in the present study with the CB2, the V113E substitution 
led to the complete loss of binding for CB2 ligands and the elimination of receptor downstream 
signaling activities. Whereas, the V113L isoform displayed specific binding activity that was 
comparable to wild-type CB2. Molecular docking analyses showed that V113 maintains 
hydrophobic interactions with the alkyl chain of CP-55,940, the fenchyl (bulky) group of 
SR144528 and an aromatic ring of XIE95-26 at distances of 3.27 Å, 3.33 Å and 3.04 Å, 
respectively. Similarly, Leu192 interacted hydrophobically with CP-55,940, SR144528 and 
XIE95-26. In order to validate the modeling studies, these two residues were subjected to 
mutagenesis experiments. Mutation of Val113 to Glu and Leu192 to Ser interrupted the 
hydrophobic interactions with all three ligands leading to loss the binding affinity (Table 4). 
However, the hydrophobic feature of L192A and V113L mutants restored the binding with 
minimal effect on binding for CP-55,940, SR144528 and XIE95-26 compared to the CB2 receptor. 
In fact, L192A and V113L mutants showed only 5-fold and 6-fold reduction for SR144528 binding 
and almost no significant change for CP-55,940 and XIE95-26 binding (Table 4). These results 
confirmed that our predicted residues play an important role in CB2 ligand binding.  
     The following functional experiment further proved the importance of the predicted residues: 
V113 and L192. In a cell-based cyclase assay, an agonist will activate CB2 receptor, cause the 
dissociation of Gαi and inhibit forskolin-induced AC activity, [311] resulting in a decreased cAMP 
and an increased LANCE signal. As shown in (Figure 3-9), there is no inhibition of cAMP 
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accumulation mediated by CP-55,940 in the V113E and L192S mutant cells. However, mutating 
to different hydrophobic residues restored the functionality of the receptor as shown by the mutants 
V113L and L192A. The EC50 values of CP-55,940 on the WT, V113L and L192A were 32 nM, 
9.7 nM and 0.14 nM, respectively. These results indicated that hydrophobic residues at positions 
3.32 (V113) and 5.41 (L192) are important for both ligand-receptor interaction and function of the 
receptor.  For the testing the constitutive activation effect of the ligands on the CB2 receptor (WT), 
we conducted the assay to measure the change in EC50 value of the CB2 receptor with or without 
the ligands. The results showed significant inhibitory effects (p < 0.05, two-tailed t-test) for the 
agonist on the EC50 (increase) comparing to the enhancement effect of SR144528 and Xie95-26 
which represented as decreased in the EC50 as illustrated in  (Figure 3-10 and Table 5). These 
changes in FSK-stimulated for both agonist and invers agonists were comparing to the cells that 
treated with forskolin alone as shown in (Figure 3-10). The EC50 values of WT CB2 receptor 
stimulated by forskolin alone was 1.3 µM for CP-55,940 was 11.3 µM and for SR144528 and 
Xie95-26 were 0.2 µM and 0.18 µM. Other CB2 mutant receptors have not tested for the 
constitutive activation.  
3.2.4  Conclusion 
In this study, molecular modeling studies were first performed to derive a homology model of CB2 
receptor and predict a putative binding site for CB2 ligands. During molecular docking simulations 
consisting of three different CB2 ligands (CP-55,940, SR144528 and XIE95-26) and the CB2 
model, several important ligand-receptor interactions were observed. To validate our in silico 
findings, we performed site-directed mutagenesis experiments and functional assays for four 
residues, namely V3.32 (V113), F183, L5.41 (L192), and F7.35 (F281) that had hydrophobic and 
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π−π interaction with all ligands during the simulation. Mutating such hydrophobic residues to non-
hydrophobic residues such as V113E, F183Q/V, L192S and F281K eliminated the binding for all 
ligands as well as the functional activity of the CB2 receptor. However, mutating to different 
hydrophobic residues such as V113L and L192A had minimal effect the binding of CB2 ligands 
and functional activity of the receptor. To the best of our knowledge, these four residues have not 
previously been reported and our findings provide the first insights into the importance of these 
residues for the binding of CB2 ligands as well as the functional activity of the CB2 receptor. 
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4.0 GENERATION AND CHARACTERIZATION OF CONSTRUCTS OF CANNABINOID 



















        With the exception of rhodopsin, which has been crystalized without modification, different 
strategies for expression, purification and crystallization of chimeric GPCRs have been performed. 
These approaches include the combination of a variety of modification steps including: 1: 
Refolding proteins from E.coli,   2: Detergent solubilization and stabilization with different ligands 
in different crystal forms. 3: Increasing the protein expression by using different 
thermostabilization point mutations, 4: Removing the glycosylation position and truncating the N- 
and/or C-terminals, and 5-: Insertion of a fusion counterpart or antibodies in the N-terminal, second 
or third intracellular loops.  
     Understanding the residuals interaction involved in the activation mechanisms of GPCRs 
during binding and downstream signaling events is crucial for solving the structure of common 
GPCRs. Locking in conformational states and removing unstructured regions are essential for 
producing proteins suitable for co-crystallization [51]. In addition, combinations of the baculovirus 
expression system and epitope-tagged proteins have allowed for facilitating GPCRs purification. 
Previous studies provided guidance in two methods of fusion protein insertion [51][17]. The first 
study used highly stable soluble proteins to replace the structurally variable third intracellular loop 
region of either ICL2 or ICL3. This conformed to the lattice-forming contacts needed for 
crystallization. For example, in β2-adrenergic receptors (β2AR), various constructs with the T4L 
fusion protein were generated in order to determine the optimal length and position of fusion 
proteins for crystallization studies [43]. Truncation of both β2AR N- and C-terminus were also 
essential to remove the glycosylation sites. In an additional set of receptor stabilization constructs, 
monoclonal antibody Fab fragments were used against a synthetic polypeptide mimicking the N- 
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and C-terminal domains [43]. This is a second study demonstrated fusion of the T4L protein into 
the N-terminus of β2AR was also suitable for crystallization studies. The T4L C-terminus was 
fused to the first amino acid of the β2AR transmembrane helix 1. Subsequently, the flexible region 
of the β2AR C-terminus was removed to generate a rigid interaction. These data indicated insertion 
of alanine-like and mutations in the extracellular loops (M for receptors highly homologous to the 
CB2 receptor, M96T and M98T) were essential to improve GPCRs expression levels.  
Additionally, residues of the third intracellular loop were deleted to prevent proteolysis during 
purification [312]. 
    Overall, the GPCR co-crystal structures published to-date have experienced rigorous 
optimization including chimeric receptor truncation, introduction of thermostabilization point 
mutations, selecting the proper fusion proteins for insertion, cell culture optimization, and 
determination of ideal conditions for X-ray diffraction, and structure determination.      
CB1 and CB2 belong to the rhodopsin family of GPCRs. Only 44% of the amino acid 
sequence of CB2 is homologous to the CB1 receptor, though the percentage increases to 68% in 
the transmembrane domains [250]. Upon ligand binding and activation of the cannabinoid 
receptor, the third intracellular loop and C-terminus couples to Gi, leading to inhibition of adenylyl 
cyclase (a reduction in cAMP levels), activation of the MAPK cascade, and inhibition of PKA 
phosphorylation. Each of these cascade steps is critical in maintaining cell function integrity [259, 
313].  
CB1 is generally expressed in CNS and is less abundant in peripheral organs and tissues, 
such as the heart and lungs [171, 250]. In contrast, CB2 is expressed throughout the peripheral 
immune system, including the spleen, lymph nodes, tonsils, thymus, and immune cells (T cells, B 
cells, macrophages, and monocytes)[250]. The tissue distribution pattern of CB2  implies the 
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receptor plays a crucial role in the immune system and thus, may be a target in the treatment of 
autoimmune and immunological disorders similar to multiple sclerosis [314]. Additionally, 
research supporting modulation of CB2 signaling has demonstrated potential for the treatment of 
various cancers such as lung, bladder [255], pancreas [256], breast [257] and prostate [230]. The 
CB2 agonist HU-910/308 has been shown to attenuate oxidative stress markers, inflammation, and 
cell death following hepatic ischemia reperfusion injury in mouse models [217, 218]. Therapeutic 
intervention through targeting the CB2 receptor is a feasible proposal. However, specific details 
of receptor structure, as well as molecular-level interactions among ligands and G-proteins, have 
not yet been confirmed to design effective CB2-specific therapies.  
  CB2 has shown to be expressed in insect cells [315, 316]. The heterologous expressed 
receptor was purified as tagged or untagged protein. Both the N-terminus Flag tagged and C-
terminus 6xHis tagged CB2 constructs revealed high binding affinities when compared to other 
constructs. Western blot analysis indicated acceptable levels of the receptor as well, the 
glycosylated region of the receptor was removed due to the presence of the double-tag. This was 
shown by anti-His and anti-CB2 antibodies. Mass spectroscopic analysis indicated adequate 
protein expression levels. [316]. Functional expression of the wild type and mutant cannabinoid 
receptor was evaluated in sf9 cells. In this study, the irreversible affinity properties of AM-841, as 
well as the use of ligand-assisted protein structure (LAPS), allow for the study of residual and 
direct identification by mass spectrometry (MS). Cysteine at TMH 6 (257) in hCB2R has shown 
an important role of the binding and function of the receptor.    
    To begin to study these ideas for expression and purification of functional CB2 constructs in 
insect cells, we have collaborated with Dr. Kobilka and his colleagues. We will insert fusion 
protein T4 Lysozyme or apocytochrome b562RIL (BRIL) into the third intracellular loop and N-
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terminus and evaluate the changes on the structured integrity of the cannabinoid receptor CB2.  
Previously, it has been shown that the distance between the N- and C-terminus of the fusion protein 
needs to be within 6-14 Å [51]. Therefore, we have designed our constructs to fulfill this 
requirement. In collaboration with the Kobilka lab, a variety of constructs of CB2 expressed in Sf9 
cells using the Bac-to-Bac system (Invitrogen, Carlsbad, CA), were constructed. These constructs 
feature dual Flag and His-6 tags at the N- and C-termini, respectively. One area of concern is the 
precise placement of the T4L either at the N termini or between helices V and VI.  
      Therefore, the position of the T4L was adjusted by a determinate number of residues in order 
guarantee adequate stability during protein expression and lattice-forming contacts in pre-
crystallization trials. Moreover, receptor truncations, de-glycosylation and proteolytic cleavage 
were also considered during construct design and purification to create a stabilized receptor that 
also retains complete functional activity. Among the many constructs assessed, few revealed 
sufficient expression levels and binding activity in small-scale purifications.  
      The goal of this study is to screen and understand the effects of chimeric receptor modifications 
in order to provide the best constructs for large-scale purification. This will be further discussed 




4.2 MATERIAL AND METHODS 
4.2.1 Insect cells expression system and reagents  
    The insect cells and E. coli (strain DH10) BAC to BAC baculovirus expression system was 
purchased from Invitrogen (Carlsbad, CA). Bac-to-Bac contains site-specific transpositioning of 
Tn7 to generate recombinant bacmid DNA. DH10Bac™ E. coli was utilized to host the 
pFastBac™ constructs which contain a shuttle vector (bacmid) and a helper plasmid. All restriction 
and DNA modifying enzymes were purchased from New England Biolabs (Ipswich, MA). The 
sf900 II SFM was purchased from Life Technology (Pittsburgh, PA) and the fetal bovine serum 
from Thermo Scientific (Pittsburgh, PA). 3H-CP55,940 (specific activity: 88.3 Ci/mmol), 
CP55,940 and SR144,528 were obtained from RTI International (Research Triangle Park, NC). 
Xie 2-64 was synthesized as described previously [317]. Protease inhibitor cocktail was purchased 
from Sigma (St. Louis, MO). Dodecyl- β-D-maltoside (DDM), n-tetradecylphosphocholine (FC14), 
Lauryl Maltose Neopentyl Glycol (MNG) and cholesteryl hemisuccinate (CHS) were purchased from 
Affymetrix (Alabaster, AL). CHAPS detergent and other chemicals, unless otherwise mentioned, 
were obtained from Fisher Scientific (Pittsburgh, PA). 
4.2.2 Vector design of various CB2 constructs  
    Nineteen different recombinant CB2 constructs expression were generated in vector of pFastBac 
dual form BAC to BAC (California, LA). Truncation of these constructs at N and/or C terminal 
were obtained to remove the amino acids not involved in binding and could hamper crystal 
formation. Moreover, two different fusion proteins used for the insertion namely: 
107 
 
thermostabilized apocytochrome b562RIL: 
(ADLEDNWETLNDNLKVIEKADNAAQVKDALTKMRAAALDAQKATPPKLEDKSPDSPE
MKDFRHGFDILVGQIDDALKLANEGKVKEAQAAAEQLKTTRNAYIQKYL) [51] . T4 
lysozyme have been amplified from DNA obtained from Addgene (Cambridge, MA) and used 
for ligation into either N or C terminal of the CB2 constructs.   
(NIFEMLRIDEGLRLKIYKDTEGYYTIGIGHLLTKSPSLNAAKSELDKAIGRNTNGVITKDE
AEKLFNQDVDAAVRGILRNAKLKPVYDSLDAVRRAALINMVFQMGETGVAGFTNSLR
MLQQKRWDEAAVNLAKSRWYNQTPNRAKRVITTFRTGTWDAY) [51] . 
     Wild CB2 was amplified from pcDNA3.1 + 3X – HA-hCB2, obtained from Missouri S&T 
cDNA Resources Center and was designed to separate the N-terminal of CB2 from the Flag epitope 
(DYKKDDDDK) and HA signal peptide (MKTIIALSYIFCLVFA) by Tobacco Etch Virus (TEV) 
at the enzymatic cleavage site. TEV was also used to separate the C-terminal of CB2 from the 6 X 
His, as shown in (Figure 4-1). The receptor design was adapted from [318]. Similar modifications 
were previously used for the β 2 adrenergic receptor expressed in insect cell membranes and were 
shown to have no effect on the ligand binding profile.  We used the overlapping gene segments by 
PCR in which we used template DNA for another PCR to create a full-length gene of the receptor 
[319] as following condition for all of the CB2 constructs. 
3 step PCR Method for 30 cycles 
98°C      for         10 sec. 
55°C      for         10 sec. 
        72°C      for         1 minute /kb 
        Recombinant CB2 DNAs were subcloned into the pFastBac vector between the 5′ BamHI or 




Figure 4-1. Two-dimensional structure of the wild type cannabinoid receptor CB2. 
The wild type CB2 receptor design showing Flag at N-terminal and 6X His at C-terminal 
to facilitate the purification. TEV cleavage sites designed to separate the CB2 protein 







4.2.3 Receptor truncation  
       To ligate the HA signaling peptide, Flag tag and TEV protease cleavage site to the N terminal 
regions of cannabinoid receptor (wild type), we have used the primers as shown in Table 6. 
Moreover, we ligate the TEV protease cleavage site and 6XHis to different positions at the 
carboxylic terminus of cannabinoid receptor using the primers as shown in Table 6. Finlay, we 
have used high fidelity PrimeSTAR HS DNA polymerase for all processes of the PCR, including 
the overlapping PRC and sub-cloning process (Takara Clontech). To verify insertion into the 
vector, we carried out double digestion of the parent gene with HindIII and BamHI or EcoRI to 
release the CB2 gene fragment. The released product was gel purified and sequence verified as 
CB2 receptor cDNA. All sequences were verified by automated DNA sequencing at the University 













Table 6. Primers used for truncation and tags ligation for both N and C terminals.  
Position of 
insertion/truncation 
Sequence of insertion and 




Position 1 amino acid 






start at (MEEEC……) 
5’ - ATC GAA GAA TTC AAG 
ACG ATC ATC GCC CTG AGC 
TAC ATC TTC TGC CTG GTG 
TTC GCC ATG GAT TAC AAG 
GAT GAC GAT GAC AAG GAG 
AAC CTG TAC TTC CAG GGT 
ATG GAG GAA TGC TGG GTG 
ACA GAG –’3 . 
 
 
Position 18 amino 






start at (DSNPM……) 
5’ - ATC GAA AAG ACG ATC 
ATC GCC CTG AGC TAC ATC 
TTC TGC CTG GTG TTC GCC 
ATG GAT TAC AAG GAT GAC 
GAT GAC AAG GAG AAC CTG 
TAC TTC CAG GGT GAT TCC 
AAC CCT ATG AAG GAT –’3 
 
 
Position 26 amino 






start at (MILSG……) 
5’ – ATC GAA TTC AAG ACG 
ATC ATC GCC CTG AGC TAC 
ATC TTC TGC CTG GTG TTC 
GCC ATG GAT TAC AAG GAT 
GAC GAT GAC AAG GAG AAC 
CTG TAC TTC CAG GGT ATG 
ATC CTG AGT GGT CCC CAG –
’3 
 
Position 360 amino 
acid (Cys) of CB2 (C 
–terminal) 
 
CB2 end at (DLSDC)------- 
ENLYFQGHHHHHH 
5’ – C AAG CTT CTA TTA ATG 
GTG ATG GTG ATG GTG ACC 
CTG GAA GTA CAG GTT CTC 
GCA ATC AGA GAG GTC TAG 
TC –’3. 
 
Position 340 amino 
acid (Thr) of CB2 (C 
–terminal) 
 
CB2  end at (SVTET)------- 
ENLYFQGHHHHHH 
5’ – C AAG CTT CTA TTA ATG 
GTG ATG GTG ATG GTG ACC 
CTG GAA GTA CAG GTT CTC 
TGT CTC GGT GAC TGA GGA 
TCT –’3. 
 
Position 322 amino 




CB2 end at  (KCVRG)------- 
ENLYFQGHHHHHH 
5’ – GAA TTC CTA ATG GTG 
ATG GTG ATG GTG ACC CTG 
GAA GTA CAG GTT GCC CCT 







4.2.4 The fusion insertion position  
   Two different fusion partners (T4L and apocytochrome b562RIL) and two attachment sites (the 
N- and third intracellular loop) were used in our study. 
4.2.4.1 N- Terminal fusion insertion  
   We used T4L and apocytochrome b562RIL as fusion proteins at the N-terminal of the CB2 
receptor. Two constructs were generated based on previously published data on β2-adrenoceptor 
[312]. The first construct was generated and annotated by pFastBac: HA -Flag-TEV-APO (N-
terminal) CB2 ICL3 (220-234) (340 C-terminal). In this construct, we removed CB2’s N 
terminals and replaced it by a TEV cleavage site followed by apocytochrome b562RIL. In addition, 
a portion of the third intracellular loop was removed between amino acids 220 and 234 to diminish 
the flexibility. The C-termini also truncated and ligated to TEV cleavage site followed by 6XHis 
to facilitate the purification. The second construct generated was annotated by pFastBac: HA-Flag-
TEV-AA-T4 (N-terminal) CB2 ICL3 (220-234) (340 C terminal). Similar modifications were 
introduced, however, one difference, the fusion protein (T4 lysozyme) was inserted after two 
alanine to facilitate the protease cleavage. The multiple primers used in this study are presented in 












Table 7. Primers used for N-terminal fusion protein insertion. 



































5’ –  ATC GAA GAA TTC 
AAG ACG ATC ATC GCC 
CTG AGC TAC ATC TTC 
TGC CTG GTG TTC GCC 
ATG GAT TAC AAG GAT 
GAC GAT GAC AAG GAG 
AAC CTG TAC TTC CAG 
GGT GCT GAT CTG GAA 













L  CB2 start at 18 
(DSNPM……) 
5’ –  GGA ATG CAT ACA 5’ 
–  GGA ATG CAT ACA TTC 
AGA AGT ACC TGA TGA 
TCC TGA GTG GTC CCC 
AGA AG –’3 
5’ – CTT CTG GGG ACC 
ACT CAG GAT CAT CAG 
GTA CTT CTG AAT GTA 







CB2  end at 340 (SVTET)------
ENLYFQGHHHHHH 
5’ – C AAG CTT CTA TTA 
ATG GTG ATG GTG ATG 
GTG ACC CTG GAA GTA 
CAG GTT CTC TGT CTC 





























ITTFRTGTWDAYAA            
5’ –  ATC GAA GAA TTC 
AAG ACG ATC ATC GCC 
CTG AGC TAC ATC TTC 
TGC CTG GTG TTC GCC 
ATG GAT TAC AAG GAT 
GAC GAT GAC AAG GAG 
AAC CTG TAC TTC CAG 
GGT ATT ATA TTT GAA 















CB2 start at 18 (DSNPM……) 
5’ –  ACT GGC ACT TGG 
GAC GCG TAT GCG GCG 
TAC ATG ATC CTG AGT 
GGT CCC –’3  
5’ – GGG ACC ACT CAG 
GAT CAT GAT CGC CGC 
ATA CGC GTC CCA AGT 









CB2 start at  340 (SVTET) 
ENLYFQGHHHHHH 
5’ – C AAG CTT CTA TTA 
ATG GTG ATG GTG ATG 
GTG ACC CTG GAA GTA 
CAG GTT CTC TGT CTC 























CB2 ICL3 (V220 to A235) 
5’ – CTC TGG AAG GCC 
CAT CAG CAT GTG GCC 
CGA ATG AGG CTG GAT 
GTG AAG-’3 and 5’ – CCT 
CAC ATC CAG CCT CAT 
TCG GGC CAC ATG CTG 
ATG GGC CTT CCA GAG -
’3 
5’ – C AAG CTT CTA TTA 
ATG GTG ATG GTG ATG 
GTG ACC CTG GAA GTA 
CAG GTT CTC TGT CTC 

























4.2.4.2  3ICL fusion insertion 
    For the third extracellular loop, we considered fusion insertion based on the previously 
successful co-crystal structure fusion location. We selected the sequences of CB2 (UniProtID: 
P34972) and other GPCRs belongs to same rhodopsin family. These receptors are beta-2 
adrenergic receptor (UniProtID: P07550), adenosine receptor A2a (UniProtID: P29274), C-X-C 
chemokine receptor type 4 (UniProtID: P61073), D3 dopamine receptor (UniProtID: P35462), 
muscarinic acetylcholine receptor M2 sphingosine 1-phosphate receptor 1 (UniProtID: P08172), 
and HRH1 (UniProtID: P35367) to carry out the sequence alignments on UniProt online server 
(http://www.uniprot.org) based on their sequence identities and using the Clustalo program. 
Default parameters are as follows: The default transition matrix is Gonnet, gap opening penalty is 
6 bits, and gap extension is 1 bit. Clustal-Omega uses the HHalign algorithm, and its default 
settings were the core alignment engine. The algorithm is described in [320]. Moreover, we have 
used different primers for insertion– either T4L or apocytochrome b562RIL–in 3ILC, combined 
with or without N- and/or C-terminal truncations as listed in Table 17 of Appendix B. 
4.2.5 Optimization of the wild type and truncated receptor production 
4.2.5.1 Culturing of Spodoptera frugiperda for virus and protein production 
      Healthy Sf9 cells of less than 25 generations were grown in Sf-900 II SFM (Serum-Free Media) 
in both forms–a monolayer attached to the bottom of the plates or as suspension culture in a vented 
flask. 2% of serum is added to the culture at the time of shaking to reduce the shared forces and 
aggregation of the cells in .Usually, the cell double within 24-30 hours when cultured at 27 C. 
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The culture media and LB agar plates were supplemented with antibiotics: 50 µg/ml kanamycin, 
7 µg/ml gentamicin, 10 µg/ml tetracycline, and 10 µg/ml gentamicin. 
4.2.5.2 Producing the Virus  
   All CB2 constructs go through the same process of producing the virus. Briefly, 1-5 µl of 
recombinant pFastBac DNA was transform used to DH10Bac E. coli and cells were incubated on 
ice for 30 minutes. The competent cells were heat-shocked for 45 seconds at 42°C. The cells then 
chilled on ice for 5 minutes. In order to increase transformation efficiency, 0.5 ml of S.O.C. 
medium was added to the competent cells and cultures were shaken at 250 rpm in 37°C for 4 hours. 
Serials dilutions of the media were added to LB agar plates that contained 50 µg/ml kanamycin, 7 
µg/ml gentamicin, 10 µg/ml tetracycline, 100 µg/ml Bluo-gal, and 40 µg/ml IPTG. The plates were 
incubated for 48 hours at 37°C or until white and blue colonies appeared. Colonies were picked 
up and re-streaked on fresh LB agar plates containing 50 µg/ml kanamycin, 7 µg/ml gentamicin, 
10 µg/ml tetracycline, 100 µg/ml Bluo-gal, and 40 µg/ml IPTG and incubated for 24 hours at 37°C. 
The process was done twice to insure that the colonies were well isolated. These colonies were 
used for producing the recombinant bacmid DNA using PureLink™ HiPure Plasmid kit. Bacmids 
were prepared according to manufacturer’s protocols. All DNA was stored in -20°C until further 
use. Moreover, to ensure insertion and transposition of the DNA into the bacmid had been 
successful, we did a PCR analysis using pUC/M13 primers:  
pUC/M13 forward 5’ -CCCAGTCACGACGTTGTAAAACG-3’ and  
pUC/M13 reverse 5’ -AGCGGATAACAATTTCACACAGG-3’.  
    The PCR conditions are described in Table 18 of Appendix B. Based on the concentration of 
the bacmid, transfection took place using Cellfectin II reagent (Invitrogen). Different 
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concentrations of the bacmid and Cellfectin were used to transfect 6-well (35 mm) plates according 
to the Bac-to-Bac expression system manual. Briefly, a mixture of DNA and Cellfectin in Grace’s 
Insect Medium, Un-supplemented (Invitrogen) were added to the cells and incubated at 27°C for 
four hours. After four hours, the transfection media was exchanged for 2ml of fresh Sf-900 II 
(2%FBS) medium and incubated again in a humidified environment at 27°C. After 5-7 days, the 
media was collected and spun down at 500 x g for 5 minutes to remove dead cells and large debris. 
The supernatant is considered P1 virus stock that was either stored at 4°C for the short term or at 
-20°C for long-term storage. In addition, 2% FBS was added to the virus stock as substrate for 
proteases. 
4.2.5.3  Amplification of the virus (P2) 
    Using first generation virus (P1 stock), 0.4 to 0.5 ml was added to 20 ml of the Sf9 cells at 2.5 
x 106 cells/ml in a vented flask for 4 days. The virus was collected by centrifugation of the cells at 
speed 500x g for 10 minutes in a JA 30,50 rotor in the Beckman Avanti J-30I centrifuge. The viral 
supernatant (P2) was either stored at 4°C for short term or at -20°C for long term in 2% FBS. In 
order to determine the titer of viral stock to be used in the infection, we used the viral plaque assay 
to measure the plaque forming units, pfu/ml for P1.  
    We seeded 2 ml of sf9 cell suspension containing 5 × 105 cells/mL into six-well plates followed 
by one-hour incubation in an incubator to allow the cells to settle on the bottom. The medium was 
then replaced with 1 ml that contained an 8-logs of serial dilution (10–1 to 10–8) of baculoviral 
stock, and one well of the plate was used as control where the medium contained no virus. The 
cells were incubated with virus for 1 hour at room temperature. The medium was removed, 
replaced with 2 mL of plaque medium (30 mL of Sf-900 II (1.3X) and 10 mL of melted 4% agarose 
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gel) and incubated for one hour at room temperature. The plate was then incubated at 27C in a 
humidified incubator for 7-10 days until plaques were visible and ready to count. The final step 
was to visualize the plaques using tetrasodium thiazolal blue bromide (MTT). Two milliliters of 
0.1 mg/mL MTT solution in 1x PBS was overlaid on the agarose medium, and the plates were kept 
at room temperature in the dark for 3-5 hours. The yellowish medium turns purple color due to the 
reduction of MTT formazan, and the number of plaque formed are counted. To calculate the viral 
titer, we counted the number of plaques present at each dilution and used the following equation: 
 
Titer (pfu/ml) = number of plaques × dilution factor × 
1
 𝑚𝑙 𝑜𝑓 𝑖𝑛𝑜𝑐𝑢𝑙𝑢𝑚/𝑤𝑒𝑙𝑙
 
4.2.6 Preparation of insect cell membrane fractions 
      The viral stock, P2, was then used to infect the Sf9 cells. Different ratios of the virus: cells 
were used to determine the best time and ratio for cell harvesting. Pellets from 1.5 x 106 to 2.5 x 
106 cells/ml were harvested and pelleted down by centrifugation at 6000× g for 5 minutes. The 
pellets were then washed twice with 0.1 M Tris-HCI pH 8.0 buffer and re-suspended in lysis buffer: 
(40mM Tris-HCl pH 7.8, 1mM EDTA, and protease inhibitors (400X, 64mg/ml benzamidine and 
1mg/ml leupeptin). The suspended pellet was incubated on ice and homogenized using a glass 
dounce homogenizer stroked for approximately 20 times. The supernatant was subjected to 
centrifugation (500× g, 10 minutes) at 4°C using an Eppendorf centrifuge 5702 R. The obtained 
membrane pellet was washed in 10 mM HEPES, pH 7.4, three times and homogenized using a 
using a glass dounce homogenizer stroked for approximately 20 times followed by centrifugation 
at 100,000 × g for 30 minutes. The washed membrane pellets were then re-suspended in the storage 
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buffer: (20 mM HEPES + 150 mM NaCl + 20% glycerol). Then aliquots were stored at -80°C for 
subsequent use. The protein concentration was estimated using the Bio-Rad Bradford or BCA 
assays.  
4.2.7 Western blotting 
    Western blotting analysis for the expression of parental and truncated CB2 was done using 
protein obtained from membrane preparations or from small samples of cells that were lysed with 
400 µl of 1X SDS-PAGE buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS). The supernatant was 
isolated from the cell debris by centrifugation at 13,000x g for 10 min at 4°C. Each sample (25 µg 
protein each) mixed with 3X sample buffer before the load into the SDS page well. The sample 
separated by electrophoresis on a 12% SDS–PAGE gel and transferred onto polyvinylidene 
difluoride membranes (PVDF) using 130 volts. PVDF membranes were incubated at blotted 
1:1000 with either with anti-Flag M2 (Cell Signaling) or anti-His, cannabinoid receptor CB2 
(Santa cruze) in 0.1% Tween 20 in PBS (PBS-T) containing 5% non-fat dried milk. The PVDF 
membranes were washed three time with PBS-T for 10 min followed by incubation with secondary 
antibodies 1:2000. Following three rinses the bands on the membrane were detected using ECL 
detection kit (Super Signal West Femto, Thermo Scientific). 
4.2.8 3H-Radioactive saturation and binding assay 
Membrane proteins obtained from infected Sf9 cells were evaluated in displacement binding 
and saturation binding assays. Saturation and binding experiments were used to characterize the 
CB2 receptor by measuring the total and non-specific binding at various concentrations of 
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radiolabeled ligand. Two values were derived, Kd (equilibrium dissociation constant) and Bmax 
(receptor density). Briefly, the previously prepared membrane fractions (20 μg) were incubated 
with increasing concentrations of [3H]-CP55,940 (0.01–5 nM) in 96-well plates at 30°C with gentle 
shaking for 1 hr. The incubation buffer was composed of 50 mM Tris–HCl (pH 7.4), 5 mM MgCl2, 
2.5 mM EGTA, and 0.1% (w/v) fatty acid free BSA. The radiolabel ligand was diluted in 
incubation buffer supplemented with 10% dimethyl sulfoxide (less than 1% per each well) and 
0.4% methylcellulose. Non-specific binding determined in the presence of unlabeled CP55,940 
(5000 nM) in excess. The reaction was terminated by rapid filtration through Unifilter GF/C filter 
plates using a Unifilter Cell Harvester (PerkinElmer). The plate was left to dry overnight, then 35 
μl of MicroScint-20 cocktail (PerkinElmer) was added to each well. The count per minute (CPM) 
were measured with a PerkinElmer Top Count instrument.  
For the competitive displacement binding assay, ligand binding was performed as previously 
described [321]. Briefly, non-radioactive (or cold) ligands diluted in binding buffer (50 mM Tris-
HCl, 5 mM MgCl2, 2.5 mM EGTA, 0.1% (w/v) fatty acid free BSA, pH 7.4), supplemented with 
10% dimethyl sulfoxide and 0.4% methyl cellulose. Each well contained a total of 200 μL reaction 
mixture consisting of 10 μg membrane protein, 3 nM labeled [3H]-CP-55,940 (RTI International 
Research Triangle Park, NC) and different concentrations of  the unlabeled agonists. Plates were 
incubated at 30°C for 1 hour with gentle shaking. The reaction was terminated by rapid filtration 
through Unifilter GF/B filter plates using a Unifilter Cell Harvester (PerkinElmer). The plate was 
left to dry overnight, then 40 μL MicroScint-0 cocktail, (PerkinElmer) was added to each well and 
the (CPM) was counted by PerkinElmer TopCount instrument. All assays were performed in 
duplicate and data represented, as the mean ± S.E.M. Bound radioactivity data analyzed for Ki 
values using non-linear regression analysis via GraphPad Prism 5.0 software 
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4.3 RESULTS AND DISCUSSION 
4.3.1 Expression of CB2 wild type and truncated variant of the receptor 
    It is noteworthy that the flexible portions of unstructured extracellular and/or intracellular 
domains of Class B, C, and F GPCRs participant in protein–protein interactions, ligand 
recognition, and signal transduction [7], [13]. However, these parts of these regions need to be 
deleted to facilitate the crystal formation. Thus, the truncation of the GPCRs needs to done in order 
to obtain less flexible receptors and maintain the overall receptor integrity and expression levels 
with no significant change in the GPCRs structure. Figure 4-2 show the overall methodology 
involved in the expression and screening of best CB2-fusion constructs to select the best construct for 
the large scale purification from insect cell.  In an attempt to achieve this structural engineering in 
the cannabinoid receptor CB2, 3 different constructs and wild type CB2 receptors were generated. 
First truncated at the (Threonine) located at 340 of the CB2 amino acid sequence in the C terminal 
(construct #3). This position has been tested previously in beta 2 adrenergic GPCRs. The result 












   Second, we generated two different N terminal truncation constructs that were more cautious 
because the N-terminus and second extracellular loop of CB2 receptor were previously shown in 
report to be involved in the ligand binding site recognition [322]. These truncations were based on 
the S1P1 receptor crystal structure [65]. In the first (construct#11), seventeen amino acids removed 
before aspartic acid. Notably this removal of 17 amino acids did not affect the receptor expression 
and incorporate one of the N- linked glycosylation positions. Generally, the presence of the 
glycosylation is required for expression and folding of some GPCRs. However, the 
deglycosylation facilitates crystal formation. Further, there are some examples of glycosylated 
GPCRs that have been crystalized including rhodopsin, SMO [155], mGlu5 [154] and A2A [306] 
receptors. In our case, deglycosylation of CB2 at position 11 does not seem to affect expression 
levels and also produces functional receptor (will discuss later). We also made other constructs 
(#6) to remove both glycosylation positions (at 11 and 20). The N -Terminus completely removed 
to the first amino acid of the TMH (Methionine). The results indicate that removal of all N-
terminus completely reduces expression levels, decrease binding affinity and disrupts in the overall 













Figure 4-3. Diagram of modification and truncation position and expression levels. 
2 diminution diagram for the truncation modification of CB2 receptor showing the 
position for the amino acids deletion. Construct #1 (wild type), #3 (C – terminus truncated 
CB2 receptor), and #6, 11 (N–terminus truncated CB2 receptor) expressed in Sf9 and 
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4.3.2 Expression of CB2 with fusion partner  
    There are different advantages of utilizing soluble fusion protein partners which tend to be 
insert into the GPCRs. For example it helps to solve the lack of hydrophilic surface needed for 
crystallization and also to lend receptor rigidity to solve the flexibility problems that are inherent 
in GPCRs [63]. Thus, extensive screening must be done in order to find positions for insertion of 
the fusion proteins within the GPCRs. There are different characteristics required for successful 
protein insertion into the chimeric receptor including: 1- The ligand binding affinities of the 
GPCRs after insertion are similar or close to wild type receptor; 2) The expression levels of 
chimeric receptors are close or comparable to wild type; 3) The protein is functional after 
purification; and 4) the Chimeric receptor needs to be stable in the presence of all detergents, 
ligands, and lipid material. Thus, two approaches were considered in our protein engineering for 
fusion insertion: The N-terminal and 3ICL fusion insertion. 
4.3.2.1 N-terminal fusion protein expression 
     An N-terminal fusion insertion has been successfully implemented to obtain many GPCRs co-
crystal structures. For example, using T4L in β2-adrenoceptor, Zou, Y et al., made extensive 
modifications to the β2-adrenoceptor at different position in the N-terminus, 3ICL and C- 
terminus. Not only did this modification enable them to obtain receptor crystals but also the 
downstream signaling was maintained similar to the wild type.  Inserting the fusion protein at the 
N-terminus of the GPCRs causing no disruption of the downstream signaling [312]. Thus, the 
receptor maintained the coupling to the G protein at intracellular site .This is considered one of 
the major advantages of using the N-terminus fusion protein over the 3ICL insertion approach. 
On the other hand, the receptor chimeric modifications including 3ICL modifications (deletion or 
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fusion insertion) and /or C-terminal truncation leads to disrupt the coupling of the GPCRs with 
intracellular effector proteins in most cases [312]. Utilizing a T4L insertion at the N-terminal, the 
Rasmussen group was able to produce a crystal structure for the β2-adrenoceptor binding to Gs 
protein. This structure was the first and unique example demonstrating G-protein coupling to the 
receptor [60]. The β2-adrenergic receptor has also been crystalized in complexes with agonist and 
antibody [323, 324]. Apocytochrome BRIL has also been used previously as an N-terminal fusion 
protein for the determination of GPCR crystal structures, including, nociceptin/orphanin FQ, 
glucagon, smoothened receptor, metabotropic glutamate receptor 1 and human δ receptors [51, 
75, 153, 155].  
      Two different fusion proteins were used in our study to generate two CB2 constructs. Briefly, 
we considered similar approaches to the β2-adrenoceptor [312]. For the T4L protein, the N-
terminus of the cannabinoid receptor was truncated at the first amino acid in the TMH and replaced 
with T4 lysozyme. Part of 3ICL was also removed between V220 (5.69) and A235 (6.25) since 
this removal was necessary for the case of β2-adrenoceptor to reduce the flexibility of the third 
loop and to reduce proteolysis [62]. In addition, part of the C terminal (last 20 amino acids) was 
removed based on our preliminary data of the truncation effect (section 4.3.1). The plasmid for 
this construct annotated by PfastBac: (HA tag-Flag-TEV-T4L A-A N terminal) CB2 ICL3 (220-
234) (340 C-terminal). The second fusion protein insertion used apocytochrome b562RIL that been 
generated the same way as T4L but missing the Ala linker. The plasmid for this construct was 
annotated by PfastBac: (HA tag-Flag-TEV-Apo N- terminal) CB2 ICL3 (220-234) (340 C-
terminal). The expression levels results show that both constructs are significantly reduced and the 
function of the receptor was also disrupted (Figure 4-4) and (Section 4.3.2.3). Although this 
approach has been successfully used for the β2-adrenergic receptor, the removal of the N terminus 
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of CB2 and replacement with a fusion partner did not work for either expression or functional 
activity. 
 
Figure 4-4. Expression and function of both N-terminal constructs. 
A. Schematic diagram of human CB2 fusion protein inserted at N-terminus and western 
blot analysis showing the expression levels comparing to WT CB2 receptor. 
B. The competitive binding assay for the corresponding construct (1 and 2) and for the 
wild type (3). The relative CPMs are shown in Table 9. The binding was only the 
detected for the wild type. the competitive displacement of the 3H-CP55,940 was 
obtained by using an increased amount of cold ligands of SR 144528 and assay was 
performed in duplicate (n = 2). Data represented as mean ± S EM.  
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4.3.2.2  Intracellular loop (3ICL) fusion protein expression 
        Unlike the N-terminus approach, insertion the fusion protein partner into third intracellular 
(IC3) loop of GPCRs is the best chose to provide most common GPCRs co-crystals up to date. It 
has been shown previously for the purpose of crystallization that removal of this region in receptors 
is generally preferable to control the relative motion of surrounding helices. In addition, the 
removal provides a hydrophilic core for forming crystal lattice contacts [62]. However, the overall 
structural integrity needs to be maintained during the fusion protein insertion and not affect protein 
topology [51]. Generally, there is no criteria established yet for determining the best position to 
insert of fusion protein in GPCRs [51]. In an attempt to gain insight into some positions to begint 
with for the CB2 receptor, we and our collaborator  (Dr. Brian Kobilka) performed multiple amino 
acids sequence alignments with 7 crystal structures of GPCRs as shown in (Figure 4-5) and Table 
8. The result of the multiple sequence alignment analysis of these GPCRs revealed about 40% TM 
similarity between CB2 and other GPCRs, but overall the sequence identities are far less similar 
due to the diversity observed within the extracellular and transmembrane-intracellular (TM-IC) 
regions. However, the results of the alignment revealed potential truncation sites, highlighted in 
(Figure 4-5) based on the nature of the amino acids. For example,  an insertion between postion 
5.69 and 6.25 is considered to be the most popular postion for T4L insertion based on the previous 
studies of the β2AR. In addition, the CB2 N-terminus truncation at Asp18 and the C-terminus 
truncation at Thr340 are similar to S1P1R and β2AR, respectively. Thirteen different constructs 
shown in (Figure 4-6) and Table 9 have been generated based on this sequence homology analysis 
(Figure 4-5) as well as the effects of truncations that have been mentioned previously. The receptor 
expression levels and the ligands binding affinity profiles of the protein each constructs for fusion 
insertions with or without truncations were assessed (Figure 4-6) and Table 9. The results showed 
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that different constructs were shown to be comparable to the wild type. Modifications in three of 
these constructs significantly reduced either receptor expression or radio-ligand binding affinity 
for constructs 12 and 15, 19 respectively. In construct #12 the receptor was subjected to the 
maximum truncation in both the N – and C- terminus which potentially accounts for the decrease 
in receptor expression as well as the loss of binding affinity. In contrast, constructs 15 and 19, the 
effect of the truncation modifications to the receptor was not in receptor expression levels. Rather, 
the effect of the fusion insertion was loss of structural integrity and radio-ligand binding affinity 







  A.                                                                               N-terminus          Helix I                                        1ICL                          Helix II 
|CNR2_HUMAN    -----------------------MEECWVTEIANGSKDGLDSNPMKDYMILSGPQKTAVAVLCTLLGLLSALENVAVLYLILSSHQLRRKPSYLFIGSLAGADFLASVVFACSFVNFHVF     97 
|ADRB2_HUMAN   -----------------MGQPGNGSAFLLAPNGSHAPDHDVTQERDEVW------VVGMGIVMSLIVLAIVFGNVLVITAIAKFERLQT-VTNYFITSLACADLVMGLAVVPFGAAHI-L     95 
|HRH1_HUMAN    -----------------MSLPN-SS-CLLEDKMCEGNKTTMASP----Q------LMPLVVVLSTICLVTVGLNLLVLYAVRSERKLHT-VGNLYIVSLSVADLIVGAVVMPMNILYL-L     89 
|AA2AR_HUMAN   ------------------------------------------MPI--MG------SSVYITVELAIAVLAILGNVLVCWAVWLNSNLQN-VTNYFVVSLAAADIAVGVLAIPFAITIS--     67 
|CXCR4_HUMAN   -----------MEGISIYTSDNYTEEMGSGDYDSMKEPCFREE-------NANFNKIFLPTIYSIIFLTGIVGNGLVILVMGYQKKLRS-MTDKYRLHLSVADLLFVITLPFWA-VD--A     98 
|DRD3_HUMAN    MA---------S-LSQLSSHLN-YT-CGA--ENSTGASQ--ARPHAYY-----------ALSYCALILAIVFGNGLVCMAVLKERALQT-TTNYLVVSLAVADLLVATLVMPWVVYLEVT     92 
|M2MAR_HUMAN   -------------------MNN--------STNSSNNSLALTSPYKTFE------VVFIVLVAGSLSLVTIIGNILVMVSIKVNRHLQT-VNNYFLFSLACADLIIGVFSMNLYTLYT-V     85  
|S1PR1_HUMAN   MGPTSVPLVKAH-RSSVSDYVN-YD-IIVRHYNYTGKLN--ISADKENS------IKLTSVVFILICCFIILENIFVLLTIWKTKKFHR-PMYYFIGNLALSDLLAGVAYTANLLLS--G     106  
               1ECL            Helix III                                    2ICL                                            Helix IV  2ECL                                                             
|CNR2_HUMAN    HGVD--SKAVFLLKIGSVTMTFTASVGSLLLTAIDRYLCLRYPPSYKALL---TRGRALVTLGIMWVLSALVSYLPLMGWTC---------------CPRPCSELFPLIPND-------Y     190  
|ADRB2_HUMAN   MKMWTFGNFWCEFWTSIDVLCVTASIETLCVIAVDRYFAITSPFKYQSLL---TKNKARVIILMVWIVSGLTSFLPIQMHWYRATHQEAI-----NCYANETCC--DFFTNQ-------A     198  
|HRH1_HUMAN    MSKWSLGRPLCLFWLSMDYVASTASIFSVFILCIDRYRSVQQPLRYLKYR---TKTRASATILGAWFLSFLWV-IPILGWN-HFMQQT-S-----VRREDKCET--DFYDVT-------W     189  
|AA2AR_HUMAN   -TGFCAACHGCLFIACFVLVLTQSSIFSLLAIAIDRYIAIRIPLRYNGLV---TGTRAKGIIAICWVLSFAIGLTPMLGWN-NCGQPKEGKNHSQGCGEGQVAC--LFEDVVPM----NY     176  
|CXCR4_HUMAN   VANWYFGNFLCKAVHVIYTVNLYSSVLILAFISLDRYLAIVHATNSQRPR---KLLAEKVVYVGVWIPALLLT-IPDFIFAN-------------VSEADDRYICDRFYPND---LWVVV     198 
|DRD3_HUMAN    GGVWNFSRICCDVFVTLDVMMCTASILNLCAISIDRYTAVVMPVHYQHGTGQSSCRRVALMITAVWVLAFAVS-CPLLFGF-NTT-----------GDPTVC-----SISNP-------D     187  
|M2MAR_HUMAN   IGYWPLGPVVCDLWLALDYVVSNASVMNLLIISFDRYFCVTKPLTYPVKR---TTKMAGMMIAAAWVLSFILW-APAILFW-QFIVGV-R-----TVEDGECYI--QFFSNA-------A     185 
|S1PR1_HUMAN   ATTYKLTPAQWFLREGSMFVALSASVFSLLAIAIERYITMLKMK----LHNGSNNFRLFLLISACWVISLILGGLPIMGWNC--ISAL-----------SSCSTVLPLYHKH-------Y     202  
                                         Helix V                                                                                                             3ICL 
|CNR2_HUMAN    LLSWLLFIAFLFSGI--IYTYGHVLWKAHQHVASLS------------------------------------------------------------------------------------     224 
|ADRB2_HUMAN   YAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKIDKSE-----------------GRFH------------------------------------------------------------     241 
|HRH1_HUMAN    FKVMTAIINFYLPTLLMLWFYAKIYKAVRQHCQHRELINRSLPSFSEIKLRPENPKGDAKKPGKESPWEVLKRKPKDAGGGSVLKSPSQTPKEMKSPVVFSQEDDREVDKLYCFPLDIVH     309  
|AA2AR_HUMAN   MVYFNFFACVLVPLLLMLGVYLRIFLAARRQLKQMESQ----PL------------------------------P---------------------------------------------     217 
|CXCR4_HUMAN   FQFQHIMVGLILPGIVILSCYCIIISKLSHSK---G------------------------------------------------------------------------------------     231 
|DRD3_HUMAN    FVIYSSVVSFYLPFGVTVLVYARIYVVLKQRRRKRILTRQNSQC---NSVRPGFPQQTLSPD------------P----------------------AH------LELKRYYSIC-----     259  
|M2MAR_HUMAN   VTFGTAIAAFYLPVIIMTVLYWHISRASKSRIKKDK----KEPVANQDPVSPSLVQGRIVKPNNNNM-------PSSDDGL--EHNKIQNGKAPRDPVTE-----------NCV------     275  
|S1PR1_HUMAN   ILFCT--TVFTLLLLSIVILYCRIYSLVRTRSRRLTFRKNIS------------------------------------------------------------------------------     242 
                                                                                                
|CNR2_HUMAN    --------------------------------------GHQ---------------------------------------------------------DRQVPGMARMRLDVRLAKTLGL     249  
|ADRB2_HUMAN   VQN-----------L---------SQVEQD--GR-----------------------------------T-----------GH----------------GLRRSSKFCLKEHKALKTLGI     277  
|HRH1_HUMAN    MQAAAEGSSRDY-----VAVNRSHGQLKTDEQGLNTH---GASEISEDQMLGDSQSFSRTDSDTTTETAPGKGKLRSGSNTGLDYIKFTWKRL--RSHSRQYVSGLHMNRERKAAKQLGF     419  
|AA2AR_HUMAN   -----------------------------G-----------------------------------------------------------------------ERARSTLQKEVHAAKSLAI     237  
|CXCR4_HUMAN   -------------------------------------------------------------------------------------------------------HQKR-----KALKTTVI     243 
|DRD3_HUMAN    -Q---------DTALGGPGFQERGGELKREEKTRNSLS--------------------------PTI-APKL---------SLEVRKLSNGRLSTSLKLGPLQPRGVPLREKKATQMVAI     333  
|M2MAR_HUMAN   QGEEKESSNDSTSVSAVASNMRDDEITQDENTVSTSLGHSKDENSKQTCIRIGTKTPKS DSCTPTN--TTVEVVGSSGQNGDEKQNIVARKIV-KMTKQPAKKKPPPSREKKVTRTILA     391  
|S1PR1_HUMAN   ------------------------------------------------------------------------------------------------------KASRSSEKSLALLKTVII     260 
                       Helix VI          3ECL              Helix VII                                             C-Terminus   
|CNR2_HUMAN    VLAVLLICWFPVLALMAHSLATTLS------D--QVK-KAFAFCSMLCLINSMVNPVIYALRSGEIRSSAHHCLAHWKKCV----RG-LGSEAKEEAPRSSVTETEADGK----------    345  
|ADRB2_HUMAN   IMGTFTLCWLPFFIVNIVHVIQDNL------IR-KEV-YIL--LNWIGYVNSGFNPLIYCR-SPDFRIAFQELLCLRRSSL----K----------AYGNGYSSNGNTGEQSGYHVEQEK    372  
|HRH1_HUMAN    IMAAFILCWIPYFIFFMVIAFCKNC------CN-EHL-HMF--TIWLGYINSTLNPLIYPLCNENFKKTFKRILHIRS------------------------------------------    487  
|AA2AR_HUMAN   IVGLFALCWLPLHIINCFTFFCPDC------SH-APL-WLMYLAIVLSHTNSVVNPFIYAYRIREFRQTFRKIIRSHVLRQ----QEPF---KAAGTSARVLAAHGSDGEQVSLRLNGHP    342  
|CXCR4_HUMAN   LILAFFACWLPYYIGISIDSFILLEIIKQGCEFENTVHKWISITEALAFFHCCLNPILYAFLGAKFKTSAQHALTSVSRGS---SLKILSKGKRGGHS---SVSTESESSSFHSS-----    352  
|DRD3_HUMAN    VLGAFIVCWLPFFLTHVLNTHCQTC------HVSPEL-YSA--TTWLGYVNSALNPVIYTTFNIEFRKAFLKILSC--------------------------------------------    400 
|M2MAR_HUMAN   ILLAFIITWAPYNVMVLINTFCAPC------IP-NTV-WTI--GYWLCYINSTINPACYALCNATFKKTFKHLLMCHYKNI----G----------ATR---------------------    466 
|S1PR1_HUMAN   VLSVFIACWAPLFILLLLDVGCKVK------TC-DIL-FRAEYFLVLAVLNSGTNPIIYTLTNKEMRRAFIRIMSCCKCPS----GDSAGKFKRPIIAGMEFSRSKSDNS----------    358  
                                           
|CNR2_HUMAN    I-------TPWPDSRDLDLSDC----------------------------------------------------------------    360 
|ADRB2_HUMAN   ----------------------------------------------ENKLLCEDLPGTEDFVGHQGTVPSDNIDSQGRNCSTNDSLL   413  
|HRH1_HUMAN    --------------------------------------------------------------------------------------    487   
|AA2AR_HUMAN   PGVWANGSAPHPERRPNGYALGLVSGGSAQESQGNTGLPDVELLSHELKGVCPEPPGLDDPLAQDGAGVS-----------------   412  
|CXCR4_HUMAN   ---------------------------------------------------------------------------------------   352 











 N- Terminal of fusion protein  
C -Terminal for fustian protein 
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Table 8.  Comparison table between CB2 and other GPCRs. 
 CXCR4 M2MAR DRD3 ADRB2 AA2AR2 HRH1 S1PR1 
PDB entry 3OEO 3UON 3PBL 2RH1 3EML 3RZE 3V2W 
Resolution (Å) 2.9 3 2.9 2.4 2.6 3.1 3.3 
CB2 to GPCR whole 
sequence identity (%) 
17.1 13.1 15.5 18.6 18.8 12.8 22.2 
CB2 to GPCR sequence 
identity in TM (%) 
19 25 26 26 27 28 32 
CB2 to GPCR sequence 
similarity in TM (%) 
38 43 43 47 44 49 50 
Deletion of amino acid for 
fusion insertion 
S229-K230 K218-K375 R222-R319 I233-L266 Q210-A221 Q222-G404 Q222-G404 
 
Figure 4-5. Multiple sequence alignment and homology study of CB2 and eight GPCRs. 
A. Sequence alignment of CB2 receptor with most recently revealed GPCR crystal structures. Colored regions represent the 
helices and deletion regions of intercellular loops for T4L or APO fusion insertion by UniProt analysis.  
B. Comparison of seven GPCRs with CB2 sequences in terms of identity, similarity for whole sequence, and within TM by 
UniProt analysis. CXCR4: chemokine (C-X-C motif) receptor 4; M2MAR: muscarinic acetylcholine receptor M2; 
DRD3: D (3) dopamine receptor; ADRB2: beta-2 adrenergic receptor; AA2AR2: adenosine receptor A2a; HRH1: 


























Figure 4-6. Expression levels of CB2 constructs (3ICL fusion insertion). 
Thirteen different construct and wild type CB2 receptor expressed in sf9 and tested for expression levels using western blot 
probed against (anti Flag antibodies). All WB results for expression were adapted from (Dr. Brian Kobilka lab) with exception 





Table 9. Expression and binding affinity results of cannabinoid receptor CB2 constructs (3ICL fusion insertion). 
 
Constructs with loss of protein expression relative to WT – 5, 6, 12, 23 and 24.  Constructs with diminished binding activity relative to 
WT – 5, 6, 12, 13, 14-1, 14-2, 15, 16, 17, 18, 19, 20, 21 & 22.
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4.3.2.1 Competitive ligand binding assay for measuring CB2 structural integrity  
    As we assessed the effect of the receptor modification on the expression levels, the binding 
affinity was tested. Ligand binding at the active site confirms the native structure of the receptor. 
We performed competitive ligand displacement binding assays to ensure that proper folding 
occurred and expression and to verify that fusion protein insertion did not compromise the 
structural integrity of the receptor. In these assays, different ligands including SR144528 as inverse 
agonist (unlabeled) were used to displace a radioactively ligand. In this case, there is no ambiguity 
of the unlabeled ligand occupying a different site other than the radiolabeled ligand. We have 
tested wild type (construct # 1) and truncated variants of CB2 (construct # 3, 6 and 11) for ligand 
binding capability. All receptors were expressed in Sf9 and the membrane fraction was used for 
the binding assay. The results indicated that the modifications (i.e., N- and C-terminus truncations) 
led to diminished binding activity relative to WT – in constructs 5, 6, 12, 13, 14-1, 14-2, 15, 16 , 
17, 18, 19, 20, 21 & 22 as illustrated in (Figure 4-3) and (Figure 4-7) . In construct 6, we have 
completely removed the N-terminal of cannabinoid receptor and the loos of the binding affinity 
was consistent with the decrease the expression levels (Figure 4-6). The fusion proteins junction 
position also has been tested for their ability to maintain the structure of the receptor after insertion. 
Unfortunately, none of the N-terminus fusion insertion constructs have maintained comparable 
competitive ligand binding activity compared to wild type. These results are consistence with the 
receptor expression levels as shown in (Figure 4-3). However, the 3ILC fusion protein constructs 
have shown promising results. All Thirteen constructs were tested for the binding and some of 
them for the saturation-binding assay as well and showed positive for binding. Only three 
constructs out of thirteen exhibited no binding after the insertion positions or due to the decrease 
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in expression levels (12, 15 and 19). Despite the fact that the truncations have shown a diminished 
in binding profile with the WT, relative CPM counting (CPM of total, specific, and non-specific 
binding) for the binding of 3H-labeled ligands is significantly lower in some truncation. However 
in construct # 20, we notice the CPM is higher comparing to other constructs as shown in 
(Figure 4-7) and Table 9. The non-specific background CPM’s window was only 5-fold instead 
of 10-fold as in WT. This fact suggests that further optimization may be needed to improve the 




















Figure 4-7. Competitive binding assay of SR144528 for all CB2 construction. 
Competitive binding experiments were performed on membrane proteins harvested from sf9 cells expressing CB2 receptors of various 
constructs. Competitive displacement of [3H]-CP55, 940 was obtained by using an increased amount of SR144528. Constructs #1, 3, 6 
and 11 represent the wild type and N- and or C- terminals truncation receptor binding affinity. All other receptor constructs have fusion 
protein, with or without truncation. The position for insertion is indicated in the table below each binding. Assay was performed in 





      Overall, the cannabinoid receptor CB2 appears to be amenable to the fusion protein insertion, 
similar to the family A class of GPCRs for both expression and ligands binding properties. In the 
first approach using N-terminal fusion protein -CB2, we were not able to produce large amounts of 
the protein as well as the receptor integrity was disrupted, which was confirmed by ligand binding 
assay. However, if we wanted to study the effect of the N-terminal fusion strategies in more detail, 
a few steps could be explored. For example, determining which N-terminus junction positions is 
suitable for protein insertion, also how many amino acids need to be removed for both 3ICL and 
C-terminus. We have demonstrated that the truncated receptors at Asp 18 have no effect on the 
binding and expression of the receptor. Despite our observation that the N-terminus is not suitable 
for the fusion protein insertion, the CB2 receptor has showed some tolerance for fusion protein 
insertion at the 3ICL sites. In this study, we observed the effect of two fusion partners in several 
constructs. Some of these constructs # (14-B, 20 and 21) could be tested for large-scale purification 
in Chapter 5. 
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5.0  PURIFICATION OF FUNCTIONAL CHARACTERIZATION CANNABINOID 

















5.1.1 Fusion protein for the functional expression and purification of GPCRs  
    High-affinity tags are considered efficient tools for expression and purification of proteins. This 
method is now widespread in biological, structural, and functional proteomics research [325-327]. 
Variability in heterologous expression, solubility, stability, and functionality of GPCRs, presents 
a great challenge in purification of large functional quantitates of the protein. The presence of tags 
is essential for the expression and purification of GPCRs. Tags are divided into two categories, 
affinity tags, which aid in purification, and solubility tags, which enhance the function and 
solubility of the protein as shown in Table 10  [326, 327]. Generally, a combination of these tags 
are present in most GPCR gene constructs, especially when they are expressed as heterologous 
proteins in E. coli [94]. However, the presence of some of these tags in the proteins after 
purification may affect the protein conformation, potentially altering the function of the receptor 
and becoming toxic to the host cell. Native proteins need to be removed by inserting protease 
susceptible peptide sequences that are amenable to removal of the tag from the protein. Examples 
of these proteases are shown in Table 11 . HA signaling peptides and other helpers, such as β-
galactosidase in the N-terminal, are essential for the inner membrane targeting of β2-adrenoceptor 
in mammalian cell [108]. The presence of maltose-binding protein (MBP) and thioredoxin A 
(TRX) at both N- and C-terminals, respectively, contribute to an enhanced 40-fold increase of 
expression and purification of neurotensin NTS1 [48, 113] and CB2 receptors [110]. In addition, 
MBP is also used as an N-terminal fusion partner for the A2A receptor [112].  
       To ensure greater implementation of the inner membrane of mammalian or sf9 cell lines, 
studies of fusion-related methodologies on extensive receptor modification and truncation need to 
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be performed [94]. A biotin–protein ligase recognition site (BRS) has been used as support in 
receptor detection and purification. This has previously been implemented the functional 
expression and purification of CB2 in E. coli [328].  BRS was introduced into the C-terminus, 
upstream of deca-histidine and in the N-terminus. The ligand-binding affinity of these constructs 
was fully retained, and they were able to generate approximately 1mg of CB2 protein per liter. 
These methodologies, not only helped in the purification of the protein, but also provided 
homogeneous support in immobilization. Likewise, Rho-tag at the C-terminal of the CB2/1D4 
antibody system has been utilized for functional production, purification, and analysis of the 
receptor using surface plasmon resonance (SPR). This study was the first to demonstrate the use 
of a Rho-tag in producing GPCRs in E. coli. [328]. The tag was sufficient for immobilization and 
characterization of the CB2 on a 1D4-coated SPR sensor surface [329].  
    In our lab, we have previously demonstrated that Mistic and TarCF, as novel fusion partners, 
have successfully enabled us to express and produce a functional CB2 receptor [110]. Mistic was 
derived from B. subtilis integral membrane protein [330], and TarCF is the carboxylic terminal 
fragment of a chemotactic response transducer [331]. Our study is the first study to elucidate the 
effects of introducing both partners in the production of GPCRs. More importantly, the 
combination Mistic and TarCF fusion proteins led to localization of the receptor in the inner 
bacterial membrane, which assists in maintaining the function of the receptor. Different 






Table 10. All current recombinant affinity and solubility tags. 









Flag 8 aa 
Can be used for the purification of either Ca2+-
dependent (M1) or Ca2+-independent (M2) and 
mAB protein. It is introduced in C- or N-
terminals.  
[332] 
Strep tag II 8 aa 
Can be used for streptavidin-modified protein, 
eluted with biotin analog.  
[333] 
Poly His 
6 up to 
12 aa 
Most commonly used tag for N- and C-terminal, 
native and denatured protein purification. 
[334] 
HA tag 9 aa 
For hemagglutinin, antibody-based purification. 
Can be tagged both for N- and C-terminal of the 





The purification is antibody based. This tag can be 
used in N-terminal and internal tagging.    
[335] 
S tag 15 aa N- or C-terminal purification using s resin.  [336] 
c-myc tag 10 aa 






Bound to chitin. Used for tagging the protein at 





Used for both N- and C-terminal tagged protein 






Can be tagged in different positions, at N- or C-
terminal, or internally. The protein can be eluted 
by guanidine HCl or urea > 4 M or ethylene 
glycol. 
[338] 
DHFR 25 kda Can be used as N-terminal fusion protein.  [327] 
Poly Arg 5-6 aa 
Can be used for C-terminal tagged protein. The 




















It has been used for many GPCR crystal 





Can be introduced at both N- and C-terminals. It 






Used previously in many GPCR protein 
solubilities from E.coli such as CB2. Usually 






It is fused to the N-terminal of the protein. It is 






A small ubiquitin-modifying protein. It has been 
used for N-terminal protein fusion to increase 
folding and increase solubility. The fusion 






It has been used to increase the solubility of 
human β (2)-adrenergic and human A (2A) 
adenosine receptors for crystallization trials. 
[51] 




Most used fusion protein for solubilization of 
GPCR junction to N-terminal and internal 









Table 11. Proteases commonly used for tagging and fusion removal. 
  Adapted from [18] and [326, 327].
Name of protease Cleavage site Comment Reference 
TEV protease EQLYFQ*G It is highly specific and suitable for low temperatures.  [343] 
Thrombin LVPR*GS 
It performs some non-specific cleavage due to impurities. It is less 
sensitive to detergent compared to other proteases. 
[344] 
Factor Xa IDGR* 
Factor Xa has two disulfide links, which may be sensitive for reduction 
in the buffer.  
[345, 346] 
Enterokinase DDDDK* Cleavage efficiency is 61 - 88%. May have unintended cleavage site. [345] 
SUMO 
SUMO proteases S. 
cerevisiae Ulp1 
It is preferable in wide pH ranges and temperatures; a good choice in 
inclusion body purification.   
[347] 
PreScission LEVLFQ*GP The advantage over others is maintenance of optimal activity at 4°C for 
cleaving many fusion proteins. 
[348, 349] 
3C protease ETLFQ*GP 
Aminopeptidase 
M 




It used for cleaving His tag at N-terminal with 75–90% cleavage 
recovery. 
[352] 
Granzyme B D*X, N*X, M*N, S*X Serine proteases show highly specific and efficient processing. [353] 
Sortase A LPET*G 
Recognizes and cleaves the Thr–Gly bond in LPXTG sequence in 




Exopeptidase Cleaves C-terminal. No cleavage at X-R, P. [350, 351] 
Carboxypeptidase 
B 
Exopeptidase Cleaves C-terminal R, K. [350, 351] 
Intein Self-cleavable Self-splicing catalyzation by post-translational process. [355] 
Aeromonas 
aminopeptidase 
Exopeptidase Cleaves N-terminal, effective on M, L. Requires Zn. [351] 
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5.1.2 Current methodologies for purification of GPCRs and cannabinoid receptor CB2  
The native environment where a membrane protein is inserted and expressed is altered after 
the extraction and purification of the protein. The thermal stability of GPCRs is significantly lower 
after solubilization and cell disruption [94], [356]. Therefore, exaggerated and overheated forces 
should be avoided during the entire purification process. The process of membrane protein 
purification begins with lysing or breaking the cell membrane. There is considerable variability in 
cell membrane composition of different host cells, and bacterial membranes are considered rigid 
and not easy to break [94]. Consequently, alternative lysis agents, such as lysozymes are added. 
Conversely, mammalian and insect cell biological membranes are susceptible to easy breakage. 
Each method requires a different buffer be used for cell disruption before solubilization.  In 
mammalian and insect cells, a hypotonic buffer (low salt) flow to a hypertonic buffer (up to 1.0 M 
NaCl ) in a freeze-thaw or mechanical process (e.g. dounce homogenization), is the most common 
way to achieve cell disruption and remove  cytoplasmic proteins [357]. Notably, the entire process 
requires ice and protease inhibitors (e.g. PMSF, benzamidine, leupeptin or protease cocktails) to 
minimize proteolytic degradation. Several studies have been performed to identify a family of 
structurally related detergents for GPCR extraction from mammalian cells [358]. It has been shown 
that many GPCRs are not stable in certain types of detergents due to their inherent structural 
flexibility [48]. These detergents are used alone or in combination for testing the extraction of the 
membrane proteins after cell lysis. Table 12 provides the most commonly used detergents for 
crystallography. In order to remove the N- and C-termini tags after purification, the detergents 
must be compatible with protease cleavage. In addition, the thiol group of the cysteine residues 
within the receptor need to be blocked to reduce the aggregation. This is commonly achieved by 
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incorporation of either an alkylating agent, such as iodoacetamide, or a reducing agent, such as 
tris2-carboxyethylphosphine (TCEP) or dithiothreitol (DTT). Although the extent of detergent 
solubilization varies from receptor to receptor, the purpose behind the use of detergent is a key 
selection criteria. For example, different studies have shown that mixtures of NG, HPTO, HTG, 
DDM, LDAO and OG have been successful in solubilizing the bovine Rhodopsin [140, 359-362]. 
However, from the crystallization standpoint for other GPCRs there are other preferable 
detergents. DDM and DM at concentrations of (0.5–1.0%, w/v) and (1.5–2% w/v) respectively are 
the most common detergents [356]. Compared to the widely used conventional detergents such as 
n-dodecyl β-D-maltoside (DDM) and tetradecylphosphocholine (FC14), certain kinds of maltose-
neopentyl glycol (MGN) detergents have been successfully used to solubilize many GPCRs [60, 
363]. In some cases, the use of MGN rather than DDM was necessary to obtain high-resolution 
GPCR crystal structures [363]. A mixture of sodium cholate with digitonin or LMNG or DDM 
have also been used at (0.2-0.35%) to determine the structure of the human M2 muscarinic 
receptor, human protease-activated receptor 1, human OX2 orexin and δ-opioid receptor [66, 67, 
69, 151]. The addition of a cholesterol derivative to the solubilization process at concentrations in 
the range (0.1–0.3%) w/v was necessary [356]. Cholesterol is known to stabilize GPCR structures 








Table 12. List of detergents with corresponding CMC values tested for GPCR 










 Detergents CMC (mM) Ref 
1 n-octyl-b-D-glucopyranoside 23.4 [365] 
2 n-decyl-b-D-maltoside 1.8 [366] 
3 n-dodecyl-b-D-maltoside (DDM) 0.17 [367] 
4 Cyclohexyl-butyl-b-D-maltoside (Cymal-4) 4.76 [368] 
5 Cyclohexyl-pentyl-b-D-maltoside (Cymal-5) 2.4 [368] 
6 Cyclohexyl-hexyl-b-D-maltoside (Cymal-6) 0.56 [368] 
7 Cholic Acid, Sodium Salt 9.5-14 [369] 
8 Cyclohexyl-heptyl-b-D-maltoside (Cymal-7) 0.19 [368] 
9 n-octylphosphocholine (Fos-choline-8) 114 [370] 
10 n-decylphosphocholine (Fos-choline-10) 11 [371] 
11 
3[(3cholamidopropyl)dimethylammonio]-1-
propanesulfonate hydrate (CHAPS) 
8 
[372] 
12 Diheptanoyl-phosphocholine (DHPC) 1.4 [373] 
13 n-tetradecylphosphocholine (Fos-Choline-14) 0.12 [374] 
14 Lauryl Maltose Neopentyl Glycol (MNG) 0.01 [363] 
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 The solubilization of the CB2 receptor from bacterial membranes has been evaluated. At least 
40 detergents from different classes were screened for solubilization. It was evident that only a 
few detergents were able to maintain receptor binding during the solubilization [375]. Mixtures of 
relatively high concentrations of dodecyl maltoside (DDM) (1% w/v) and CHAPS (0.5% w/v), in 
combination with cholesterol was among the more efficient detergents identified [375]. Similarly, 
the combination of DDM, CHAPS and CHS for the stabilization of GPCRs was also reported for 
the neurotensin receptor with an efficiency of 85% [50]. These high concentrations of detergents 
are only required for the solubilization process. After the solubilization process, the subsequent 
amount of the detergents in the purification buffer can be reduced 10-30 times according to the 
critical micelle concentration (CMC). This decrease in detergents allows the protein to remain in 
the folded, soluble, functional form [364] . In the case of CB2 receptor, the detergent was reduced 
to 0.1%, 0.5% and 0.1% for DDM, CHAPS and CHS respectively [375].  
In chapter 4.0 we discussed a couple of CB2 candidate constructs for large-scale purification. 
We evaluated the fusion protein junction position for the various CB2 constructs. Construct # 20 
was the most ideal in regards to the expression, and binding of the receptor.  
Throughout this chapter, we assessed the stability profiles of membrane proteins within 
different detergents in the presence and absence of ligands before executing the entire process of 
purification. Multistep purifications that were conducted using immobilized metal affinity 
chromatography (IMAC), M2 Flag, and other separation techniques were performed. During the 
purification process, optimization of various conditions of additives, buffer components, and 
cleavage processes were assessed in an attempt to maintain the structural and functional integrity 
of expressed CB2 proteins. The purified protein obtained from this this study will be tested in pre-
crystallization trials in the future. 
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5.2 MATERIAL AND METHODS 
5.2.1 Optimized large scale productionCB2 pellets for detergent extraction and 
purification 
     Pellets of CB2–fusion constructs #20, 21 and 22 in Table 9 were produced by infecting the P2 
of the corresponding virus at ration of 1:50 to 3 L of Sf9 at 2.5 x 106 cells/ml. The cells were grown 
and maintained in sf 900 II SFM (life technology) throughout the process. We have determined 
the viral titer for all construct using plaque assay as mention in 4.2.5.3 .The MOI was 0.75. The 
cells were kept in the shaker for 50 hours at 27C. Cell pellets were collected by centrifugation the 
cell at 4500 RPM for 15 minutes in JA 10 rotor using The Beckman Avanti J-30I centrifuge. The 
pellet was washed using sf900 media and centrifuged again. Cell pellets stored at -20C until 
further use. 
5.2.2 Detergent extraction analysis to carry out purifications 
     To optimize detergent solubilization, we tested the solubility of constructs # 20 and 14 in three 
different detergents namely (n-dodecyl-b-D-maltoside (DDM), n-tetradecylphosphocholine (Fos-
Choline-14) and Lauryl Maltose Neopentyl Glycol (MNG) with or without 0.2% of sodium 
cholate. All detergents were purchased from Anatrace (Maumee, OH). The membrane fractions 
from sf9 expressing the CB2- fusion proteins were lysed in 10mM Tris (pH 7.6), 1 mM EDTA 
(pH 8.0), 2mg/ml of iodoacetamide and protease inhibitors in the presence of the inverse agonist 
(SR144528 10mM) and stirred at 4C for 30 minutes. Then, resulting mixture was centrifugation 
at 18,000 RPM for 15 minutes. All CB2 containing pellets were re-suspended in basic buffer then 
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split into ten parts in to which corresponding detergents were added. The concentrations of 
detergents used was 1% and 0.5% for DDM and CHAPS respectively. The buffer containing 
detergents and membrane protein homogenized 20 times in the dounce homogenizer and incubated 
at 4C and stirred for four hours. Samples were collected after four hours by centrifugation at 
20,000 RPM for 90 minutes and both the soluble fraction and pellet were evaluated by western 
blotting (more details in Table 19  in Appendix B). 
5.2.3 Large-scale preparatory purification of pFastBac-Flag-TEV-1-CB (T4L 224-
231) 340-TEV-6His 
5.2.3.1  Immobilized metal affinity purification 
       Insect cell membranes were disrupted by thawing frozen cell pellets in lysis buffer containing 
10 mM Tris (pH 7.6), 1mM EDTA (pH 8.0), 2mg/ml IA powder,10 mM SR144528, and protease 
inhibitor cocktail (Roche) with brief dounce homogenization 30 times. The insoluble materials 
resulting from centrifugation of the pellets (18,000 rpm for 15 minutes at 4°C) were solubilized in 
buffer containing 1% DDM, 0.3% CHS, 0.5% CHAPS, 30mM HEPES (pH 7.8), 750 mM NaCl, 
30% glycerol, 2mg/ml IA powder, 2uM mM SR144528, and protease inhibitor cocktail (Roche). 
After four hours of stirring in solubilization buffer at 4°C, the supernatant was isolated by 
centrifugation at 20,000 rpm for 90 minutes. The supernatant was then loaded into an IMAC 
column (GE Healthcare His trap HP), which had been pre-equilibrated with column buffer. The 
pre-equilibration buffer consisted of 0.1% DDM, 0.1% CHS, 0.5% CHAPS, 30 mM HEPES (pH 
7.8), 750 mM NaCl, 30% glycerol, 2uM SR144528, and 40 mM imidazole to removal of non-
specifically bound proteins. The column was then washed with the same buffer, but the imidazole 
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concentration was raised to 70 mM. The protein was eluted with four column volumes of 0.1% 
DDM, 0.1% CHS, 0.5% CHAPS, 30 mM HEPES (pH 7.8), 750 mM NaCl, 30% glycerol, and 2 
uM SR14528 supplemented with 400 mM imidazole. The eluted protein was concentrated using 
an Amicon concentrator (Millipore, MWCO-~30 kDa), and the protein concentration of the 
solution was determined using the Bradford assay. We added 5 mM (1mg/ml) IA before the final 
concentration was stored at -80°C. The protein purity and expression was evaluated in 12% SDS-
page gels. 
5.2.3.2 Flag purification 
       Typically, the appearance of purified CB2 protein (IMAC) on Coomassie brilliant blue gel 
determines the need for Flag purification. Briefly, Flag resin (A2220, sigma), 3 ml/L of pellet, was 
used for more purifying steps of CB2 protein. The beads had been equilibrated in advance with 
Flag wash buffer (0.1% DDM, 0.1% CHS, 0.5% CHAPS, 30 mM HEPES, 500 mM NaCl, 2 uM 
SR144528) before used. The beads were then mixed with CB2 elution samples (IMAC elution 
from previous steps) and incubated at 4C and stirred for four hours. The beads were then washed 
twice (~15 ml each) with buffer contains 10 -fold reduced in detergents (0.05% DDM, 0.01% CHS, 
0.05% CHAPS, 30 mM HEPES, 500 mM NaCl, 2 uM SR144528. Then the CB2 eluted from the 
beads using 10 ml of buffer (0.05% DDM, 0.01% CHS, 0.05% CHAPS, 30 mM HEPES, 500 mM 
NaCl, 2 uM SR144528) containing 100 μL of Flag peptide (final conc. ~200 uM, 0.2 mg/ml) and 
200 μL of EDTA (0.25 M). The Flag eluents was tested for the amount of the protein and 
concentrated to small volume of 0.4 ml using a 10 kDa molecular weight cut off concentrator. 
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5.2.3.3 Cleavage and deglycosylation 
          It has been shown previously that non-glycosylated and glycosylated versions of CB2 
receptor can form specifically when using His-tag at the C-terminus [316]. Thus, it may be 
necessary to treat the purified receptor with glycosylation. The concentrated CB2 protein was 
deglycosylated by incubation with N-glycosidase F (PNGase F) overnight at 4°C. To remove the 
Flag and 6x His tags from the deglycosylated protein, incubation samples with TEV protease was 
carried out for three hours at 30°C then overnight at 4°C to ensure cleavage efficiency. The 
cleaved, purified protein was then subjected to size exclusion chromatography (SEC). 
5.2.3.4 Size exclusion chromatography 
 
          Size exclusion chromatography (SEC) purification was conducted on a column (Superdex 
200 10/300 GL) equilibrated with SEC washing buffer (0.1% DDM, 0.1% CHS, 0.5% CHAPS, 
30 mM HEPES, 500 mM NaCl, 2 uM SR144528) for three column volume. Then, each of the 
eluents loaded into the column at a rate of 0.5 ml/min. The proteins elations were monitored by 
UV absorbance using an AKTA purifier machine. The eluted proteins fractionations by volume 
were analyzed using SDS-PAGE. 
5.2.4 Protein titration assay for the ligand binding 
        The eluted CB2 proteins were tested for their ability to bind radioactive ligands. In order to 
use the protein efficiently and determine the amount of proteins required for the saturation binding 
assay, we performed a protein titration assay by fixing the amount of radioactive ligands (3H-
SR144528 and 3H -CP44,940) to be 2 nM per well. The total reaction volume was 200 μL/well. 
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Each well was filled with 50 mM Tris-HCl (pH 7.4), 5 mM MgCl2, 2.5 mM EGTA, and 0.1% 
(w/v) fatty acid-free BSA and supplemented with 10% dimethyl sulfoxide and 0.4% 
methylcellulose. The protein concentration varied between 0.1 and 10 μg. We also mimicked the 
purification buffer by adding 0.1 to 1% DDM to the reaction buffer. Assays were performed in 
duplicate and data points were analyzed in (Prism 5, GraphPad). We used the Unifilter GF/C filter 
plates to harvest and terminate the reaction. MicroScint-20 Scintillators (PerkinElmer) were used 
to detect CPMs using the TopCount NXT machine.   
5.2.5 3H-CP55940 saturation and binding assay for purified protein 
     The competitive radiolabeled ligand binding assays for CB2 receptors after purification were 
performed using a Perkin Elmer 96-well Top Counter to determine the cannabinoid receptor 
binding affinity (Ki) for CB2 inverse agonist by displacing [3H]-CP55,940 (specific activity: 88.3 
Ci/mmol) [376]. In short, the inverse agonist ( SR144528) was diluted in binding buffer (50 mM 
Tris-HCl (pH 7.4), 5 mM MgCl2, 2.5 mM EGTA, and 0.1% (w/v) fatty acid-free BSA) and 
supplemented with 1% dimethyl sulfoxide and 0.4% methylcellulose. We also included the 
detergents and lipid to mimic the elution buffer and maintain structure. Each assay plate well 
contained a total of 200 μL of reaction mixture comprising 5 μg of purified CB2, labeled [3H]-
CP55,940 at a final concentration of 3 nM, with the unlabeled ligand at varying dilutions. Plates 
were incubated at 30°C for one hour with gentle shaking. The reaction was terminated by rapid 
filtration through Unifilter GF/B filter plates using a UniFilter cell harvester (PerkinElmer). After 
the plate was allowed to dry overnight, 40 μL of MicroScint-0 cocktail (PerkinElmer) was added 
to each well, and radioactivity was counted with a PerkinElmer TopCount. All assays were 
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performed in duplicate and data points were represented as mean ± range. The Ki was calculated 
using nonlinear regression analysis (Cheng-Prusoff equation). 
     Saturation binding experiments were performed in order to characterize receptor expression 
and the quality of the receptor after purification. The experiments were carried out as previously 
described [376]. The method measures the total and non-specific binding at various concentrations 
of the radioligand. Two values are calculated from data: Kd (equilibrium dissociation constant) and 
Bmax (receptor density). Briefly, the purified receptor (10 μg) was incubated with increasing 
concentrations of [3H] (CP55,940) (0.01–5nM) in 96-well plates at 30°C with slow shaking for 
one hour. The incubation buffer was composed of 50 mM Tris–HCl (pH 7.4), 5 mM MgCl2, 2.5 
mM EGTA, and 0.1% (w/v) fatty acid-free BSA and supplemented with detergents and lipid. 
Radiolabeled ligand was diluted in incubation buffer and supplemented with 10% dimethyl 
sulfoxide and 0.4% methylcellulose. Non-specific binding was determined in the presence of 
1:1000 unlabeled SR144528 (5000 nM) in excess. The reaction was terminated by rapid filtration 
through Unifilter GF/C filter plates using a Unifilter Cell Harvester (PerkinElmer). After the plate 
was allowed to dry overnight, 40μL of MicroScint-20 cocktail (PerkinElmer) was added to each 
well, and radioactivity was counted using a PerkinElmer TopCount.  
5.2.6 In gel trypsin digestion 
     The gel trypsin digestion method was carried out as previously described [377]. Excised gel 
bands were washed with HPLC water and destained with 50% acetonitrile (ACN)/25mM 
ammonium bicarbonate until there was no visible staining. Gel pieces were dehydrated with 100% 
ACN, reduced with 10mM dithiothreitol (DTT) at 56°C for 1 hour, followed by alkylation with 
55mM iodoacetamide (IAA) at room temperature for 45min in the dark. Gel pieces were then again 
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dehydrated with 100% ACN to remove excess DTT and IAA, and rehydrated with 20ng/μl 
trypsin/25mM ammonium bicarbonate and digested overnight at 37°C. The resultant tryptic 
peptides were extracted with 70% CAN 5% / formic acid, vacuum dried and re-constituted in 18μl 
0.1% formic acid. 
5.2.7 Tandem mass spectrometry 
     Proteolytic peptides from in gel trypsin digestion were analyzed by a nanoflow reverse-phased 
liquid chromatography tandem mass spectrometry (LC-MS/MS). Tryptic peptides were loaded 
onto a C18 column (PicoChip™column packed with 10.5cm Reprosil C18 3μm120Å 
chromatography media with a 75μm ID column and a 15μm tip, New Objective, Inc., Woburn, 
MA) using a Dionex HPLC system (Dionex Ultimate 3000, ThermoFisher Scientific, San Jose, 
CA) operated with a double-split system (Personal communication with Dr. Steve Gygi from 
Department of Cell Biology, Harvard Medical School) to provide an in-column nano-flow rate 
(~300nl/min). Mobile phases used were 0.1% formic acid for A and 0.1% formic acid in 
acetonitrile. Peptides were eluted off the column using a 52 minute gradient (2-40% in 42 min, 40-
95% in 1min, 95% for 1 min, 2% for 8 min) and injected into a linear ion trap MS (LTQ-XL, 
Thermo Fisher Scientific) through electrospray. 
     The LTQ XL was operated in a date-dependent MS/MS mode in which each full MS spectrum 
[acquired at 30000 automatic gain control (AGC) target, 50 ms maximum ion accumulation time, 
precursor ion selection range of m/z 300 to 1800] was followed by MS/MS scans of the 5 most 
abundant molecular ions determined from full MS scan (acquired based on the setting of 1000 
signal threshold, 10000 AGC target, 100ms maximum accumulation time, 2.0 Da isolation width, 
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30 ms activation time and 35% normalized collision energy). Dynamic exclusion was enabled to 
minimize redundant selection of peptides previously selected for CID. 
5.2.8 Peptide identification by database search  
      MS/MS spectra were searched using MASCOT search engine (Version 2.4.0, Matrix Science 
Ltd) against the UniProt human proteome database. The following modifications were used: static 
modification of cysteine (carboxyamidomethylation, +57.05 Da), variable modification of 
methionine (oxidation, +15.99Da). The mass tolerance was set at 1.4 Da for the precursor ions and 
0.8 Da for the fragment ions. Peptide identifications were filtered using PeptideProphet™ and 
ProteinProphet® algorithms with a protein threshold cutoff of 99% and peptide threshold cutoff 
of 90% implemented in Scaffold™ (Proteome Software, Portland, Oregon, USA). 
5.2.9 Circular dichroism spectroscopy 
     Circular dichroism spectra were recorded on the CD (Spectroscopy JASCO J-810) at 20 C in 
a path length 1 mm quartz over the wavelength range of 190nm to 300 nm with average time of 5 
seconds. Spectrum for purified CB2-T4L monomers (construct #21) were blanked to CD buffer 
(30mM phosphate buffer (pH7.8), 0.1% DDM, 150 mM NaCl and 10% glycerol). After baseline 
(buffer) subtraction, the mean residue molar ellipticity was calculated to all ranges and it is present 
in  MRM (deg X cm2 X dmol-1). The percentage of α-helix was calculated using the following 
equation:  (-[θ222] + 3000)/39000 [378]. Moreover, we used K2D2 software to conform the result 
of the secondary structure of the purified receptor CB2-T4L and SOPMA calculations to predict 
the wild type  and  β strand  percentage content [379]. 
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5.3 RESULTS AND DISCUSSION 
5.3.1 Detergent screening  
              In an effort to determine the class of detergents that can effectively solubilize the CB2 –
fusion from the extracted membrane fraction, numerous detergents were screened. These 
detergents were considered mild enough to not degrade protein structure and functionality. We 
used a set of three detergents known for having the highest solubility in GPCRs [60, 363], 
supplemented in buffers to identify the detergent with the highest membrane protein solubilizing 
capability. DDM and CHS have been widely utilized, among other detergents for pursuing lipid 
cubic phase (LCP) [356]. Cholesterol was required to support the receptor during extraction and 
to reduce conformational changes [356]. Since solubilization of GPCRs is dependent upon the 
formation of micelles in solution, it is important to increase the detergent concentration at this 
specific step to facilitate the membrane protein extraction for cell membrane [94]. The critical 
micelle concentration (CMC) for each detergent is the key factor for efficient solubilization. It is 
vital to keep the detergent at least 2-3 times higher than the CMC. Lowering this concentration 
may cause the protein to dissociate from the micelles and lead to aggregation. DDM, Fos-Choline-
14, and MNG are known for their lower CMCs. Thus, in our lab and our collaborator’s lab, we 
compared the solubilization and extraction effect in the presence of 0.2% sodium cholate as shown 
in (Figure 5-1). The results clearly demonstrate that all three detergents in both concentrations, 
1% and 0.5%, were efficient at extracting the protein with almost identical efficiency. 
Crystallization using LCP is a common method, thus, we decided to use a concentration of 1% and 
0.5% from DDM for solubilization and immobilized metal affinity purification, respectively. 
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Figure 5-1 B also clearly shows that the pellets were extracted completely from the receptor for 

















Figure 5-1. CB2- fusion protein detergents screening analysis by western blot. 
A. Construct #8 carries T4 lysozyme expressed in Sf9 lysate, subjected to three different 
detergents in different concentrations, with or without 0.2% sodium cholate. All 
detergents can extract CB2 receptor efficiently. The receptor was detected by anti-Flag 
antibody (provided by our collaborator). 
B. Construct #14-2 carries different fusion protein (apocytochrome b526), also tested with 
the same detergents. Equal protein amounts of soluble fractions and pellets were 
analyzed. The western blot shows complete extraction of the receptor and no trace in 




5.3.2 Purification the CB-fusion pFastBAC: CB2 1 – T4 (224-231) ∆ C terminal  
     Fifteen grams of cell pellets infected with third-generation recombinant virus for 50 hours 
(construct#21) was used as the starting material for the purification. Pellets were lysed and the 
receptor extracted in the presence of 1%, 0.5%, and 0.3% DDM, CHS, and CHAPS, respectively. 
Although CHAPS is not necessary in the purification of many other GPCRs, using a zwitterionic 
detergent, such as CHAPS, for cannabinoid receptor CB2 purification was necessary for both 
solubilization and maintaining the function of CB2 in micelles [380]. Moreover, CHAPS is also 
required to increase solubility of cholesterol in aqueous media. The presence of CHS and the 
inverse agonist, SR144528, maintain the receptor in its correctly folded state and mimics the 
receptor’s natural state. Figure 5-2 illustrates a schematic diagram of the overall steps involved in 
the extraction and purification of CB2 receptor from infected insect cells. In the first step of 
purification, a simple imidazole IMAC chromatography was conducted as presented in (Figure 5-3 
A). Briefly, CB2 1 – T4 (224-231) ∆ C terminal was eluted from the IMAC column at pH 8, with 
400 mM imidazole as a double band, ~57 kDa. Noticeably, contaminating proteins were less than 
~30 kDa as determined by SDS PAGE CBB staining (Figure 5-3 B). Meanwhile, the N-terminal 
of the cannabinoid receptor CB2 has two positions of asparagine, making it susceptible to 
glycosylation. Although we have used PNGase F to eliminate glycosylation in non-denaturing 
conditions, a small trace of the glycosylated protein is still present. The double band typically 
represents the glycosylated version of the receptor. In addition, the amount of protein extracted 
from the pellet was significantly lower, indicating that increased time and solubilizing buffer are 
required. Due to the presence of the Flag tag at the N-terminal of the CB2-fusion protein, further 
purification was conducted using Flag resin to rectify the protein impurities. 
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Figure 5-2. Schematic flow diagram for the processes required for the purification 






Figure 5-3. Scaled–up purification steps for CB2 1 – T4 (224-231) ∆ C-terminal. 
A. Multi-step purification on-column chromatography process using Äkta 
purifier. Two peaks appear in the washing and elution steps. 
B. SDS-page and WB for CB2 1 – T4 (224-231) ∆ C-terminal extracted by 
detergents DDM, CHS and CHAPS and purified by affinity chromatography 
(Ni2+) column.    
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   The IMAC eluent was incubated with Flag resin and eluted using the conventional method (i.e. 
Flag peptide and EDTA to chelate Ca+2 required for Flag–protein binding). Afterwards, CB2-
fusion flag eluent protein was subjected to size exclusion chromatography using a Superdex 
column (10/300 GL GE Healthcare) to improve protein purity (Figure 5-4 A). Moreover, SEC 
was used to separate the monomeric protein from other polymeric proteins that tend to aggregate 
at high molecular weights. As illustrated in (Figure 5-4 B), the concentrated eluent of protein was 
loaded onto the SEC column and produced two separate peaks. The first peak is the monomeric 
peak, while the second one represents the flag peptide in the elution buffer. The amount of protein 
was considerably low for SDS-PAGE determination. All protein analyses were confirmed and 
tracked using western blotting. 
      In conclusion, we carried out the purification of CB2 by subjecting construct #21 to anti-Flag 
and 6 histidine (His6) tags and analyzed SR144528 as an inverse agonist. The protein was purified 
by a Ni-column followed by anti-Flag resins as shown in (Figure 5-3) and (Figure 5-4). We were 
able to successfully purify ~0.6 mg CB2-T4L of fusion protein (construct # 21) from each liter of 
Sf9 cells, which was sufficient for proceeding with more biophysical studies. We also performed 
the complete purification analysis total protein, specific binding activity, and percent yield–after 
each step of the purification. This data allowed us to directly compare and evaluate the expression 
and purification strategies as presented in (Figure 5-4 C) and Table 13. We observed that specific 
activity is significantly increased 4-fold from 2039 CPM/10 µg of protein at the first step of 




Table 13. C. Protein analysis throughout the construct #21 purification.  
Figure 5-4. Flag purification and gel filtration for 1 – T4 (224-231) ∆ C-terminal. 
A. The chromatography step of the Flag eluent for construct #21  
B.  SDS page and western blot for Flag and SEC purification  
C. Analysis table for purification.  











Whole lysate 2.25 150 337.5 100 
Bmax = 2039 CPM/10 µg 
KD :  11.68 nM 








Soluble material 1.3 145 188.5 55.8 - 
Flow through 0.545 145 79.025 23.4 - 
Wash (non-
specific peak) 
0.4 15 6 1.7 
- 
Elution 0.6 12 7.2 2.1 
Bmax  =8706 CPM/10 µg 
KD :  12.68 nM 
Ki =30 nM 
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5.3.3  Purification of CB2-fusion CB2 18 – T4 (224-231) ∆ C-terminal  
      To avoid the glycosylation removal step, which was not efficient in previous purifications, we 
selected a construct with a truncated amino acid 18. Construct #22 is similar to #20 with the 
exception of the N-terminus truncation. To remain consistent and eliminate variability in the 
purification, we have performed the same conditions for expression, receptor extraction, and 
purification. Throughout previous purifications, solubilization was not optimal (Figure 5-3). Thus, 
increased the time for solubilization up to six hours at 4°C. Approximately nine grams of 
supernatant were collected from one liter and solubilized to CB2 protein. Treatment with DNA 
breaking enzymes (Pierce Universal Nuclease) was added at a concentration of 10U/L of culture. 
This incubation step was carried out at 4°C for half an hour. The sample was subsequently 
centrifuged for 1.5 hours at 29,000 rpm at 4°C. Following elution from the IMAC column, the 
eluted fractions were tested for purity, and total protein yield is depicted in (Figure 5-5).  
      The protein analysis results demonstrate that the majority of CB2 protein was solubilized and 
the pellet was clear of any traces of protein. In addition, the purity of the protein appears higher 
with no evidence of double bands. In addition, the contaminant is smaller in this purification, ~30 
kDa (Figure 5-5 B).  The amount of imidazole was 70 mM, enough to remove most of the non-
specific contaminating proteins. We also used up to 100 mM of imidazole in the washing step, 
which did not affect the yield of the protein (data not shown). The final protein concentration 














Table 14.  Protein analysis for construct # 22. 







Specific activity binding 
and inhibition constants 
Whole lysate 3.23 120 387.6 100 
Bmax = 3083 CPM /10 µg 
 
KD = 7.9 nM 
Ki = 0.19 nM 
Soluble material 1.8 115 207 53.4 - 
Flow through 1.3 110 143 36.9 - 
Elution 1.09 11 11.9 3 
Bmax = 11400 CPM/10 µg 
KD =  14.4 nM 
Ki = 3.4 nM 
 
Figure 5-5 . Comparison purification process for CB2 18 – T4 (224-231) ∆ C-terminal. 
 
A. Chromatography profile for IMAC purification (load, flow though, wash1 and 
elution. 
B. SDS-page and western blot analysis for entire purification process. 
C. Comparison table for the percentage yield of the protein and specific activity 











     Moreover, we performed the protein titration assay to assess the binding activity of the receptor, 
as well as, to gain an estimation of protein amount needed for the displacement, saturation and 
binding assays as shown in (Figure 5-6). We have used a concentration of 2 mM/well of the 
radioactive ligands, CP55940 (CB2 agonist) and SR144528 (inverse agonist). The protein 


















Figure 5-6. Protein-ligand titration assay for CB-fusion protein. 
In this assay, we fixed the amount of the radioactive ligand (2 nM) in each well and titrated 
the protein amount. Two different, known ligands were used: CP55940 (agonist) and 
SR144528 (inverse agonist). 
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    The maximum binding CPM has increased significantly from 3083 CPM to 11400 CPM, 
indicative of maintenance of binding activity. The competition-binding assay also preserved 
binding activity of the receptor as shown in (Figure 5-7). Moreover, we used the SEC (Superdex 
10/300 GL) to separate monomeric protein. In this construct, we observed CB2 protein elution at 
a high molecular weight (8 ml fraction) and trace amounts of protein eluted at 15 ml, which is 
representative of the monomeric version of the receptor as illustrated in (Figure 5-8 A). In order 
to investigate the binding affinity pattern of a high molecular weight protein, we subjected the 
protein to titration, saturation, and binding assays. Interestingly, the protein provided, to some 
extent, binding activity as shown in (Figure 5-8 B). This variation in the elution pattern is due to 
the effect of the detergent on the receptor complex in the gel filtration column.  We speculate that 
the cause is instability of the protein in the detergent, or misfolding/unfolding of the protein. This 
phenomena has been observed in human mu opioid receptor [379]. To study the detergent’s effect, 
we desalted the IMAC elution using a zipa column and replaced the buffer with 500mM NaCl, 
20mM KCl, 10mM MgCl2, 50mM HEPES (pH 7.5), 5% glycerol, 25mM imidazole, 0.05% (w/v) 
DDM, and 0.01% (w/v) CH, supplemented with SR144528. This buffer lacked the CHAPS 
detergent. Next, this was loaded onto a new IMAC column, 1 ml equilibrated with 500mM NaCl, 
20mM KCl, 50 mM HEPES (pH 7.5), 10% (v/v) glycerol, 50 mM imidazole, 0.025% (w/v) DDM, 
and 0.005% (w/v) CHS. The column was then washed with 10 CV of  500mM NaCl, 20mM KCl, 
50mM HEPES (pH 7.5), 10% (v/v) glycerol, 50 mM imidazole, 0.025% (w/v) DDM, and 0.005% 
(w/v) CHS. Finally, the column was eluted with 500mM NaCl, 20mM KCl, 50mM HEPES (pH 
7.5), 10% (v/v) glycerol, 400 mM imidazole, 0.025% (w/v) DDM, 0.005% (w/v) CHS, and 
SR144528 (Figure 5-9) . Fractions corresponding to the elution protein were concentrated and 
loaded to Superdex 200 at a rate of 0.5 ml/min. The buffer was used at 500mM NaCl, 20mM KCl, 
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50mM HEPES (pH 7.5), 10% (v/v) glycerol, 0.025% (w/v) DDM, 0.005% (w/v) CHS, and 
SR144528) to run the gel filtration. We elucidated that the majority of the protein was eluted as a 





Figure 5-7 . Displacement and saturation binding assay for CB2-fusion. 
In these assay, both membrane protein and purified protein expressing construct #22 test 
for the binding and saturation assays. CPM’s, Kd, and Ki for the membrane protein are 3083 
CPM’s/10 µg protein, 7.9 nM, and 0.19 nm, respectively. Additionally, CPM’s, Kd, and Ki 




Figure 5-8.  Gel filtration for pFastBAC: CB2 1 – T4 (224-231) 340 C-terminal. 
A. Chromatography profile for the gel filtration of CB2-fusion protein showing two 
major peaks. SDS-page and western blot for each corresponding fraction. CB-fusion 
was pure in the B5 fraction, which represent the monomeric peak. 
B.   Binding activity of the higher molecular weight protein; 1. Protein titration; 2. 



























Figure 5-9. Gel filtration optimization for the nickel column. 
The Nickle elution from previous purification was subjected to buffer exchange and new IMAC column purification. All fractions 
obtained were then loaded onto SEC and analyses done using SDS-page for each corresponding fraction.      
173 
 
    To examine the effect of using different ligands in the purification and SEC profile of 
pFastBAC: CB2 18 – T4 (224-231) 340 C- terminus, we have added other inverse agonists 
throughout the purification process. Unlike previous purification in which we used SR144528, the 
new purification process included different in-house inverse agonists, Xie2-64 and a triaryl 
sulfonamide derivative, throughout the entire purification [381]. Xie2-64 has shown selectivity to 
CB2, with a Ki = 0.5 nM, which is increased over CB1 [381]. Similarly, pellets obtained from 
pFastBAC: CB2 18 – T4 (224-231) 340 C-terminal (construct #22) was purified using previous 
methods mentioned in 5.3.2 and 5.3.3. Total protein yield and the purity of the final elution protein 
was comparable to previous purifications, as presented in chromatography profile (Figure 5-10 
A). Moreover, the monomeric separation of the protein on the size exclusion chromatograph was 

















Figure 5-10. CB2 purification using different ligands, Xie2-64. 
A. Chromatography profile, SDS-page and western blot for IMAC of CB2-fusion 
protein for construct #21 using different inverse agonist (Xie2-64). 
B. Chromatography profile and SDS-page for Flag and SEC purification of CB2-fusion 





    We extended the experiment further to study the effect of using different fusion proteins. To 
examine this, we replaced T4L with apocytochrome b562RIL. This fusion protein was used 
previously for the successful GPCRs co-crystal structure determination in both 3ICL and N-
terminal insertion [51, 75, 153, 155]. We used construct #22, harboring apocytochrome b562RIL 
at a position between amino acid 224 and 231 in the third intracellular loop. Figure 5-11 clearly 
displays the expression levels comparable to those in previous T4L-fusion protein. It also 
demonstrates that purity was maintained throughout the purification. However, a significant 
portion of the protein was eluted at a high molecular weight, indicating aggregation, which 

















Figure 5-11. Scaled–up purification steps for the DDM - solubilized apocytochrome 
b562RIL -CB2 fusion construct. 
A. Step-wise purification process for construct # 22 using Ni+2 column attached to 
AKTA purified (1).  Flag and Gel filtration purification chromatography (2). 
B. Purification analysis using SDS-page and western blot for the each IMAC, Flag and 
SEC corresponding step.    
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5.3.4 Protease cleavage for CB2-fusion protein  
          The eluted protein for CB2-fusion protein construct #21 and was concentrated using 30 kDa 
molecular weight cut-offs (MWCO) to increase the protein concentration and remove 
contaminants and salts of lower molecular weights. We performed the cleavage process using pro 
TEV plus obtained from Promega (1000IU) before the SEC. Multiple conditions were analyzed 
for cleavage according to the manufacturer’s protocol. The protein was incubated with TEV 
protease at a concentration of 10 units per 20 μg total protein in non-denaturing conditions. The 
mixtures were incubated for 1, 5 hours and overnight at 4 C°. The cleavage efficiency was 
measured and analyzed using western blot. The data provide evidence that with increasing 
incubation time and protease units 100% cleavage efficiency for both tags (His and Flag) was 
achieved (Figure 5-12). The western blot signals were clearly diminished after 1 hour, 5 hours and 
overnight when the protein samples were probed against anti-Flag and anti-His antibodies. This 
was not the case against anti-CB2 antibodies, indicating that the tags were no longer attached to 
the construct. The presence of the CB2 receptor was detected using a polyclonal antibody against 















Figure 5-12. TEV protease cleavage of CB2-fusion protein. 
Time point for cleavage efficiency of His, Flag tags attached to CB2 receptors. Increase contact time of the TEV protease to CB2 
protein lead to cleave more tag form the construct. The TEV protease were add to all samples. Products yielded after the cleavage 
were verified by western blotting and was probed against Anti-Histidine, Anti-CB2 and Anti-CB2 antibodies. A. showed the loaded 
of the protein for each time point. B. represent the western blot for the cleavage efficiency for each time point. 
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5.4 SAMPLES ANALYSIS AND STUCTURAL CHARICTRIZATION  
5.4.1 Proteomic analysis of SDS-Page samples and description of identified proteins 
   Concentrated protein samples were prepared for proteomic analysis by digestion of the gel bands 
for the SDS-Page with trypsin (Figure 5-13 A). Digested samples were and analyzed by nano-LC-
MS/MS and individual peptides were identified from the collision-induced dissociation (CID) 
spectra and are then queried against proteome database. The obtained list of identified peptides 
was correlated to identify specific proteins using MASCOT search engine. Using the Scaffold 
program, six unique peptide sequences corresponding to human cannabinoid receptor CB2 were 
























































Figure 5-13. Sample purification for mass spectroscopy analysis. 
A. Cleaved monomeric purified protein using for the MS/MS analysis 





5.4.2  Characterization of secondary structure of CB2 fusion protein  
    Receptor of construct #21 was purified in buffer contains (0.1% of DDM and 0.1%CHS) and 
were separated by SEC (Superdex 200) that equilibrated by buffer lacking the cholesterol 





Figure 5-14. Purification of CB2-T4L for Circular dichroism. 
A. SEC for the purified cleaved receptor (construct#21) 
B. Corresponding SDS-page analysis for the protein purification 
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    We performed the circular dichroism for the protein (0.1 mg/ml) in 30mM phosphate buffer 
(pH7.8), 0.1% DDM, 150 mM NaCl and 10% glycerol. As shown (Figure 5-15 A) the result shows 
double minima in the spectrum at about 208 and 222 nm characteristic for -helical proteins. The 
helical content derived from the mean residue molar ellipticity was 45.9% using the equation: 
-helical % = (-[θ222] + 3000)/39000). 
     In addition, the K2D2 results (web server to estimate the α helix and β strand content of a 
protein from its circular dichroism spectrum) was slightly larger in helical percentage with 48.5% 
and 9.74% for β strand as shown in (Figure 5-15 B). Moreover, by comparing the CD spectrum 
result for the fusion-CB2 with the wild type receptor CD spectrum obtained from previous 
literature report [382], the result for wild type receptor show comparable result about 49% alpha 






















Figure 5-15. Circular dichroism spectra for purified CB2 - T4L monomer. 
A. Mean residue ellipticity for each spectrum shown is the average of 5 replicate scans at 25 
C. The spectrum shows typical a-helical profile switch minima at 208 nm and 222 nm. 
The helical contents for CB2-T4L is 45.9%.  
B. Predicted and fusion -CB2 CD result spectra using K2D2 software show 48.5% and and 
9.74% for  helix and β strand respectively.  These results suggest that CB2-T4L and 





5.5 SCREENING CB2 CONSTRUCTS TOWARD CRYSTALLIZATION TRIALS 
   Similar to pervious GPCR purifications, our data demonstrated that purification of CB2 can 
also be obtained by using detergents including 1% DDM and 0.5% CHAPS and CHS [383, 384]. 
We have started an extensive screening for the optimal combination of ligands and constructs to 
produce large quantities of the functional monomeric fusion CB2 receptor. We used CP55,940 
(agonist), SR144528, and Xie2-62 (inverse agonists). Constructs # 8, 13, 16, 18, 20, and 21 were 
subjected to IMAC, Flag purification, and SEC. As shown in (Figure 5-16 A), the SEC for the 
wild type CB2 receptor, using two ligands (CP55940 and SR144528), demonstrated that the 
agonist was able to stabilize the CB2 receptor in a monomeric form. Thus, we have screened the 
fusion CB2 receptor in combination with ligands. When evaluating constructs # 8, 13, and 16, 
construct #16 had a small amount of the receptor in monomeric phase, using CP55940 (agonist) 
in the presence of iodoacetamide as an alkylating reagent used to block reduced cysteine residues 
(Figure 5-16 A). Constructs # 20 and 18 showed significant improvement in producing the 
monomeric peak in the presence of an agonist (Figure 5-16 B). Moreover, constructs # 20 and 21 
were the only ones that produced the expected monomeric peak using an inverse agonist 
(SR144528). Thus, we attempted a change to a different inverse agonist (Xie2-64). In a previous 
study, with a refolded CB2 receptor from an inclusion body using DMPC, Xie2-64 displayed 
advantages over other ligands in high affinity binding with the CB2 receptor (data not published). 
Figure 5-16 C indicates that the protein was more stable and produced a significant amount in 
monomeric phase after complete purification using IMAC, Flag, and size-exclusion 
chromatography with Xie2-64. This protein was in enough quantity to move forward with 








Figure 5-16.  Ligand screening for production of monomeric protein. 
SEC chromatography profiles for different constructs with different ligands. (A)  Chromatogram 
for monomer CB2 protein for constructs WT, 8, 13 and 16 using either the inverse agonist 
SR144528 or the agonist CP55940. (B). Constructs #18, 20, and 21 were the only ones that 
produced monomeric protein more significantly with the agonist. Changing the inverse agonist to 
Xie2-64 led to higher amounts of the monomeric protein for construct #21, as shown in C. This 




       Studies involving GPCR structural biology often face significant technical obstacles. 
However, findings from these studies could contribute significantly to innovation in the field. 
Nevertheless, we anticipated that the successive rounds of affinity purification would maximize 
protein purity. Utilizing the Flag and 6xHis tags at the two termini of the recombinant protein 
would ensure that highly purified recombinant CB2 proteins could be isolated. Size eclusion 
chromatography (SEC) is the key step for determining the construct for crystallization. Due to 
variability in ligand structure, detergent characterization, and different candidate insertion 
positions for the fusion protein in CB2, screening different CB2 constructs was necessary to 
confirm that the binding of the receptor was preserved (chapter 4). Moreover, the conformation 
stability and using the best ligands and constructs to produce more monomer CB2 protein was our 
goal. Development of a good diffraction quality, membrane protein crystal presents a formidable 
challenge, and trial-and-error optimization may be necessary to achieve success. Optimization may 
involve altering phase composition, time, or temperature. 
    In our portion of experiments, we were able to overcome some of these challenges. We began 
by using the most optimal construct with highest binding activity and screened for the best 
combination of detergents for solubilization. We also tested the effects of structural modifications 
that assisted in reducing conformation changes, such as N- and C-terminal truncations in the 
overall production of active protein. Moreover, the position of the fusion insertion was also 
validated by using different fusion proteins (apocytochrome b562RIL), confirming the best 
construct to carry over to crystallization trials. Notably, the conformational changes of the CB2 
receptor were monitored using saturation binding throughout the purification process.  
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6.0 SUMMARY AND FUTURE DIRECETION 
6.1 PROCESS CONCLUSIONS 
       The study of the CB2 receptor structure, like other GPCRs, has recently increased. Due to 
structural instability, low expression profile, and optimal purification conditions the use of insect 
cells and bacterial systems is ideal for many scientists. The results presented in this dissertation 
provide insights and open multiple avenues for future studies relating to CB2 structure for the 
purpose of drug design. 
     Throughout the initial portion of this research, we mainly focused on the structural and 
functional requirements for binding and function of the CB2 receptor. This type of work will need 
to be advanced over several years however, in the interim, homology modeling is a powerful tool 
and a new strategy for generating models of GPCRs for drug discovery and functional studies. 
When provided an experimental crystal structure of GPCR (template), models can be generated 
for a homologous sequence (target) that possesses sequence similarity or identity. Models built 
with over 50% sequence identities are accurate enough for drug discovery. The models built 
between 25% and 50% sequence identities can be used for designing mutagenesis experiments and 
assess target potential [385]. Homology and pharmacophore models based on previous GPCR 
crystal structures have been successfully used for drug discovery in the past decade. Evers et al. 
[386] described homology modeling of the alpha 1A adrenergic receptor based on the X-ray
structure of bovine rhodopsin and successfully found antagonists using virtual screening [140]. 
Likewise, Chin et al. generated a homology model of the human M1 muscarinic acetylcholine 
receptor (mAChR) based on the crystal structure of an M3 mAChR [142]. Virtual screening 
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experiments show that refined models can efficiently differentiate agonists from decoy molecules, 
with the TM5-modified models also providing good agonist/antagonist selectivity [387]. 
Homology models have proven to be an invaluable resource to rationalize SAR data and predict 
binding modes of experimental compounds for the cannabinoid receptor 2 [40], the human 
adenosine A2A receptor, and the alpha-1-adrenoreceptors [388]. Several repositories like Modbase 
(http://modbase.compbio.ucsf.edu), I-TASSER (http://zhanglab.ccmb.med.umich.edu/I-
TASSER/), Protein Model Portal (http://proteinmodelportal.org), and SWISS-MODEL 
(http://swissmodel.expasy.org/SWISS-MODEL.html) contain protein models generated using 
various automated methods.  
        Our group also built homology and pharmacophore model for CB2 and screened for a new 
ligands (agonist, inverse agonists) based on their 3D CB2 homology structure and pharmacophore 
models [291] [40]. These models led to the discovery of a selective inverse agonists used as 
osteoclast inhibitors [317, 381]. Moreover, we reported on comprehensive studies of amino acids 
required for ligand binding and recognition. We have tested mutations of amino acids and their 
effects in the binding pockets of the CB2 receptor by utilizing the homology modeling of the CB2 
receptor. Unlike other GPCRs, which have hydrophilic endogenous ligands, cannabinoid receptors 
are known for their neutral and highly lipophilic endogenous ligands [181]. Thus, we believe that 
some hydrophobic residues are involved in the ligand-binding pocket. Disruption of these 
interactions by mutations to polar or charged side chain amino acid residues leads to loss of the 
binding and downstream signaling [291]. These studies also highlighted the importance of the 2EL 
for ligand recognition, especially for inverse agonist binding. Although, homology and 
pharmacophore modeling provides a cost-effective alternative in the absence of experimental 
structures, generating models with sufficient accuracy remains a large challenge.  
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     Throughout the second part of this research, our lab had previously investigated the expression 
purification and refolding process for fusion CB2 protein from E. coli to produce a fully functional 
protein (unpublished data). We attempted multiple different strategies, such as Mistic-CB2-TarCF, 
TrpΔLE-CB2-His6, and GST-CB2-His6 constructs for producing the binding receptors. However, 
among these constructs, only GST-CB2-His6 showed the sufficient results for binding 
(unpublished data). The need for refolding the CB2 receptor and insufficient amounts of protein 
for crystallography of the CB2 receptor was a limitation. To overcome this, we decided to pursue 
a different system that is known for maintaining post-translational modification. Likewise, in other 
GPCRs, the CB2 receptor was subjected to chimeric modification (i.e. truncation, fusion protein, 
and tags insertion), leading to different constructs. All constructs were tested for expression and 
conformed in a binding assay. This intensive work ultimately leads to fewer optimal CB2 
constructs susceptible for large-scale purification.  
       In the final section of this dissertation, we tested various purification conditions, time courses 
for expression, titers of virus, and detergent solubilization.  Purification tags in the receptor for the 
subsequent purification process were largely used. In spite of the hydrophobicity of the receptor 
causing impurities, the multi-step purification produced a highly purified protein. The protein also 
required cleavage by a protease that was highly efficient. We also tested the effect of different 
fusion proteins, ligands in expression, and obtaining high amounts of pure protein in monomeric 
phase. These steps are integral for producing active proteins that can be amenable to the lipidic 
cubic phase (LCP). In parallel, our collaborator analyzed multiple crystallization trials. Further 
studies will need to be performed to increase the success of crystallization. Overall, we have 
provided robust and dependable methods for the functional expression and purification of other 
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GPCRs that share structural homology to CB2, such as cannabinoid receptor (CB1) from insect 
cells. 
6.2 LIMITATIONS AND FUTURE DIRECTION 
       The scope of CB2 functional expression is enormous and involves many levels of expertise in 
various areas, such as protein pharmacology, protein chemistry, molecular biology, and structural 
function determination. However, due to the cost of expression, purification, crystallization, and 
data inconsistency, tremendous effort must be made in order to provide scant amounts of the 
functional protein. In the future, we will need to improve the protein expression levels in order to 
reduce cost. Increased insertion position optimization and different fusion proteins need to be 
investigated to improve homogeneity of the receptor during the purification process. This 
challenge may lead to large decreases in quantity as they will appear as aggregated or non-
functional protein for binding. We may also use a different protease that is known for its stability 
in many detergents as well as introduce a linker to increase cleavage efficiency. Thus, we provided 
construction modification to the current working construct (#21). Construct #21 was the best in 
terms of homogeneity before the crystallization trials (Figure 5-16). In addition, we included 19 
amino acid drivers from β2AR in the N-terminus of the CB2 receptor followed by a linker, Flag 
tag peptide sequences, and C3 protease and linker as shown in (Figure 6-1 B and C). Including 
the first nineteen amino acids of β2AR shown previously in our collaborator’s lab, it boosted the 
expression for many GPCRs. Moreover, we introduced two linkers at both sites just before the C3 
cleavage site to expose the C3 cleavage sequence and increased cleavage efficiency.     
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      The preliminary data proved encouraging results regarding receptor over-expression. 
Moreover, as shown in (Figure 6-2), we have tested construct # 21 and a new construct in a side 
by side comparison for their expression and binding. The binding capacity for the new construct 
was increased significantly using the same amount of protein for testing. The nineteen amino acids 
drivers from β2AR and the linker that attached to the CB2 N- terminus maintained structural 
integrity of the CB2 receptor and did not influence the expression and binding. We are currently 
in the process of purifying large-scale pellets for new constructs to obtain insight into its behavior 
for crystallization as well as cleavage efficiency. Functional CB2 receptor obtained in these steps 










CB2 1 T4 lysozyme (224-231) -340’) 
TEV TEV 
6HIS Singling peptide 
Flag 
C3 
CB2 2’ T4 lysozyme (224-231) -340’) 
C3 












Figure 6-1. Schematic diagram of human CB2 fusion protein for constructs 21 and future work. 
All expression plasmid vectors were constructed on the pFastBac vector backbone under the control of the polyhedrin (PH) 
promoter. A) Current working plasmid (construct # 21). HA signaling peptide and Flag tags in the N-terminal and His, C-
terminal fusion tag were separated from the CB2 receptor by the TEV sequence. B) Nineteen amino acids of β2AR were 
inserted after HA and Flag tags in the N-terminal to boost expression. Here, we replaced TEV by a C3 cleavage sequence 
which was separated by two linkers at both termini to increase cleavage efficiency. C) Details of amino acid sequence 







































































































Figure 6-2. Comparison of the binding profiles between construct #21 and the future 
suggested construct. 
A. Saturation and binding assay and expression profile of construct # 21. Bmax = 1539 CPM. 
B. Saturation binding assay and expression profile for newly suggested construct showing 
significant increase in Bmax to 72327 CPM and receptor expression levels. 
Assay was performed in duplicate (n = 2). Data represented as mean. We used 10 µg total 





Lastly, optimization will be performed during the entire purification process with different 
detergents other than DDM, such as amphiphiles, mainly lauryl maltose neopentyl glycol (MNG). 
Multiple examples in previous GPCR purifications demonstrated dependable and native-like 
environments after refolding using amphipols, such as in cannabinoid receptor CB1, serotonin 
receptors, and vasopressin [389]. Our small-scale purification and preliminary data obtained 
showed encouraging results. As evidenced in (Figure 6-3 A), protein was eluted with high purity 
results and highlighted the glycosylation pattern. Moreover, the functionality assay was performed 
on the purified protein obtained from the SEC. 
    In conclusion, purifying CB2-fusion protein in homogenous form with large amounts will 
provide a platform for crystallization trails. Such trials can ultimately provide, for the first time, 

















Figure 6-3. Purification of the CB2 fusion protein using MNG instead of DDM. 
        Half liter used for the purification of construct #21.  
A.  Represents the overall purification process in each step. Notably, the elution showed 
high protein purity.  
B. Size exclusion chromatography for the protein, showing low aggregation and two 







































































Table 15. List of the primers used for the site directed mutagenesis.  
Amino acids Mutated amino acid Primers used 
Val113  V113L 5’- GCT GAA GAT TGG CAG CTT GAC TAT GAC 
CTT CAC -3’ 
’3- GTG AAG GTC ATA GTC AAG CTG CCA ATC 
TTC AGC -’5 
Val113 V113E 5’- GCT GAA GAG AAG CAG CGA AAC TAT 
GAC CTT CAC -3’ 
’3- GTG AAG GTC ATA GTT TCG CTG CTT CTC 
TTC AGC -’5 
 Phe183 F183Q 5’- GGC CCT GCT CTG AGC TTC AGC CAC TGA 
TCC CCA ATG A-3’ 
’3-T CAT TGG GGA TCA GTG GCT GAA GCT 
CAG AGC AGG GCC -’5 
Phe183 F183V 5’- GCC CCT GCT CTG AGC TTG TCC CAC TGA 
TCC CCA ATG A -3’ 
’3- T CAT TGG GGA TCA GTG GGA CAA GCT 
CAG AGC AGG GGC -’5 
Leu192 L192A 5’- CCC AAT GAC TAC CTG GCG AGC TGG CTC 
CTG TT-3’ 
’3-AA CAG GAG CCA GCT CGC CAG GTA GTC 
ATT GGG -’5 
Leu192 L192S 5’- CCC AAT GAC TAC CTG TCG AGC TGG CTC 
CTG TT-3’ 
’3-AA CAG GAG CCA GCT CGA CAG GTA GTC 
ATT GGG -’5 
Phe281 F281K 5’- ACC AGG TCA AGA AGG CCA AGG CTT 
TCT GCT CCA TGC T -3’ 
’3- A GCA TGG AGC AGA AAG CCT TGG CCT 





































































































































































*We listed the information of 10 GPCRs used in the present work, including PDB entry, 



















Figure 6-4 . Residuals interaction details between cannabinoid ligands and CB2 receptor model (I-TASSER). 
Figures A and C represent the CB2 receptor- inverse agonist (SR144528 and Xie95-26 respectively) interaction with residues 
in the binding pocket. B interaction with agonist (CP55, 940). All details residuals mapping performed in models obtained 
from (I-TASSER). 







Figure 6-5. Residuals interaction details between cannabinoid ligands and CB2 receptor model. (ten known crystal 
structures of GPCRs). 
Figures A represent the CB2 receptor- inverse agonist SR144528 interaction with residues in the binding pocket. B. Interaction with 















5’ – TGG AAG GCC CAT CAG CAT GTG AAT AAT TTT GAA ATG TTA CGT –’3  , 
5’ –  ACG TAA CAT TTC AAA TAT ATT CAC ATG CTG ATG GGC CTT CCA  –’3,   
5’ – ACT GGC ACT TGG GAC GCG TAT GCC CGA ATG AGG CTG GAT GTT–’3 






5’ –  TTC CGG AAT CAT CAT CAC CTA TGG GAA TAT ATT TGA AAT GTT ACG 
TAT AGA TG  –’3, 5’ –CAT CTA TAC GTA ACA TTT CAA ATA TAT TCC CAT 
AGG TGT AGA TGA TTC CGG AA  –’3, 5’ – GTT TAG AAC TGG CAC TTG GGA 
CGC GTA TCT GGA TGT GAG GTT GGC CAA GAC  –’3  and 5’ – GTC TTG GCC 




5’ – GTT CTC TGG AAG GCC CAT CAG AAT ATA TTT GAA ATG TTA CGT ATA 
G –’3, 5’ –CTA TAC GTA ACA TTT CAA ATA TAT TCT GAT GGG CCT TCC AGA 
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 GAA –’3, 5’ –GAA CTG GCA CTT GGG ACG CGT ATA TGA GGC TGG ATG TGA 
GGT TG –’3 and 5’ – CAA CCT CAC ATC CAG CCT CAT ATA CGC GTC CCA AGT 





5’ –GCC CAT CAG CAT GTG GCC AGC AAT ATA TTT GAA ATG TTA CGT ATA–
’3, 5’ – CTA TAC GTA ACA TTT CAA ATA TAT TGC TGG CCA CAT GCT GAT 
GGG  –’3, 5’ – ACT GGC ACT TGG GAC GCG TAT GCC CGA ATG AGG CTG GAT 
GTT–’3 and   5’ –  CAC ATC CAG CCT CAT TCG GGC ATA CGC GTC CCA AGT 





5’ –GCC AGC TTG TCT GGC CAC CAG AAT ATA TTT GAA ATG TTA CGT ATA –
’3 ,5’ – TAT ACG TAA CAT TTC AAA TAT ATT CTG GTG GCC AGA CAA GCT 
GGC –’3 ,5’ – ACT GGC ACT TGG GAC GCG TAT GAC AAG CAG GTG CCA GGA 
ATG –’3 and 5’ –CAT TCC TGG CAC CTG CCT GTC ATA CGC GTC CCA AGT 




5’ –  TGG AAG GCC CAT CAG CAT GTG AAT AAT TTT GAA ATG TTA CGT  –’3  
, 5’ –  ACG TAA CAT TTC AAA TAT ATT CAC ATG CTG ATG GGC CTT CCA  –’3, 
,5’ –ACT GGC ACT TGG GAC GCG TAT GCC AGC TTG TCT GGC CAC CAG –’3 
and 5’ – CTG GTG GCC AGA CAA GCT GGC ATA CGC GTC CCA AGT GCC AGT–







5’ –  CAG CAT GTG GCC AGC TTG TCT AAT ATA TTT GAA ATG TTA CGT 
ATA–’3  , 5’ –  TAT ACG TAA CAT TTC AAA TAT ATT AGA CAA GCT GGC CAC 
ATG CTG –’3, ,5’ – ACT GGC ACT TGG GAC GCG TAT GTG CCA GGA ATG GCC 
CGA ATG   –’3 and 5’ –CAT TCG GGC CAT TCC TGG CAC ATA CGC GTC CCA 





5’ – TCT CTG GAA GGC CCA TCA GCA TGC TGA TCT GGA AGA CAA TTG GG –
’3 ,5’ – CCC AAT TGT CTT CCA GAT CAG CAT GCT GAT GGG CCT TCC AGA 
GA–’3, 5’ –TGC ATA CAT TCA GAA GTA CCT GCG AAT GAG GCT GGA TGT 
GAG GTT GG –’3 and 5’ –CCA ACC TCA CAT CCA GCC TCA TTC GCA GGT ACT 





5’ –CAT CAG CAT GTG GCC AGC TTG TCT GCT GAT CTG GAA GAA AAT TGG 
GAA –’3 ,5’ – TTC CCA ATT GTC TTC CAG ATC AGC AGA CAA GCT GGC CAC 
ATG CTG ATG–’3 ,5’ – AAT GCA TAC ATT CAG AAG TAC CTG GTG CCA GGA 
ATG GCC CGA ATG AGG–’3 and 5’ – CCT CAT TCG GGC CAT TCC TGG CAC 
CAG GTA GTT CTG AAT GTA TGC ATT –’3 
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Table 18. The PCR condition to conform the recombinant protein insertion. 
 
Recombinant bacmid DNA          100 ng 
10X PCR Buffer (thermoPol)  2.5 µl  
10 mM dNTP Mix 0.5 µl 
PCR Primers 0.5 µl each 10 M stock 
Taq polymerase thermoPol 0.125 µl 
Sterile Water Add to 25 µl 
                                                                    
                                                        
Using the following condition: 
3 step PCR Method for 30 cycles: 
Initial denaturing 
95C for 30 sec 
30 cycles: 
    95°C             15-30 sec. 
55°C              45 sec. 
  68°C              1min/kb 
68°C              5 min
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Table 19. Details procedure protocol for the detergent solubilization of membrane protein.  
Take pellet out of -80C and let it be thawing 
Prepare the Lysis buffer 
Lysis buffer 100ml: 
Stock buffer Volume Final concentration 
1M Tris pH 7.6 1ml 10mM 
0.25M EDTA pH 8.0 0.4ml 1mM 
*IA powder 0.2g 2mg/ml 
*400X Protease inhibitors 0.25ml 1X 
*SR144528 or 10mM 2ul 200nM 
Add water to 50ml 
*Add freshly right before use 
 
Transfer the half thawed pellet into Lysis buffer. Stir at 4C for 30mins. Split them into 9 
parts with equal amount.  
Spin down at 18,000 rpm for 15mins. Discard the supernatant. 
Prepare solubilization buffers. 
First make a basic composition without detergent and CHS. 
 
Solubilization buffer Basic 100 ml:   
Stock buffer Volume Final concentration 
1M HEPES pH 7.8 3ml 30mM 
5M NaCl 15ml 750mM 
50%Glycerol 60ml 30% 
*IA powder 0.2g 2mg/ml 
*400X Protease inhibitors 0.25ml 1X 
*SR144528 10mM 2ul 200nM 
Add water to 100ml.  




Split them into 10 parts with 10 ml each.  
Then add detergent and CHS in.  
Solubilization buffer (DDM-0.5) 10 ml:   
Stock buffer Volume Final concentration 
DDM powder 0.05g 0.5% 
CHS powder 0.003g 0.03% 
 
Solubilization buffer (DDM-1) 10 ml:   
Stock buffer Volume Final concentration 
DDM powder 0.1g 1% 
CHS powder 0.003g 0.03% 
 
Solubilization buffer (DDM-1+NaCholate 0.2) 10 ml:   
Stock buffer Volume Final concentration 
DDM powder 0.1g 1% 
NaCholate powder 0.02g 0.2% 
CHS powder 0.003g 0.03% 
 
Solubilization buffer (MNG-0.5) 10 ml:   
Stock buffer Volume Final concentration 
MNG powder 0.05g 0.5% 
CHS powder 0.003g 0.03% 
   
 
Solubilization buffer (MNG-1) 10 ml:   
Stock buffer Volume Final concentration 
MNG powder 0.1g 1% 





Solubilization buffer (MNG-1+NaCholate 0.2) 10 ml:   
Stock buffer Volume Final concentration 
DDM powder 0.1g 1% 
NaCholate powder 0.02g 0.2% 
CHS powder 0.003g 0.03% 
 
Solubilization buffer (FC14-0.5) 10 ml:   
Stock buffer Volume Final concentration 
FC14 powder 0.05g 0.5% 
CHS powder 0.003g 0.03% 
 
Solubilization buffer (FC14-1) 10 ml:   
Stock buffer Volume Final concentration 
FC14 powder 0.1g 1% 
CHS powder 0.003g 0.03% 
 
Solubilization buffer (FC14-1+NaCholate 0.2) 10 ml:   
Stock buffer Volume Final concentration 
FC14 powder 0.1g 1% 
NaCholate powder 0.02g 0.2% 
CHS powder 0.003g 0.03% 
 
Dissolve them by vortexing and mix under room temperature.  
Add each of the 10ml solubilization buffer to each membranes and dounce for 20-30 times. 
(Take 20ul out from each sample for western) 
Then mixing them for 2 hours at 4 degrees. 
Centrifuge at 18,000 rpm (or maximum speed) at 4 degree for 30 minutes. 
Take out 20ul out from each sample for western. Western Blot: add 20ul protein loading 
buffer into 10ul sample. Mix at room temperature for 5min before loading onto SDS-







Figure 6-6. Details mass spectrometry of CB-T4L. 
Sequence coverage of trypsin digested peptide fragments identified by MS/MS (A). Details 
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